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Abstract 
Breast cancer (BCa) is the most prevalent cancer among women in the UK. The 
majority of BCas are endocrine sensitive and develop through the action of oestrogens, 
facilitated through the transcription factor Oestrogen Receptor alpha (ERα). Treatment 
for these patients usually involves endocrine therapies (Aromatase Inhibitors and anti-
oestrogens), which are successful in many patients, but therapy resistance represents a 
major clinical issue. The Androgen Receptor (AR) is a transcription factor that is more 
highly expressed than ERα in BCa, and mediates the functions of androgens. In early 
forms of ERα-positive disease, AR is a positive indicator of prognostic outcome and 
suppresses ERα signalling. However, in ERα-negative disease AR has been 
demonstrated to drive cancer progression and recent evidence has suggested that AR 
can drive endocrine resistance.  
Reporter assays, gene expression analysis and Chromatin Immunoprecipitation 
assays demonstrated that AR and ERα inhibit each other’s activity and that anti-
oestrogens can reverse this inhibition, resulting in an active AR. Importantly, long term 
colony formation assays demonstrated that androgen could induce anti-oestrogen 
resistant growth, but anti-androgens prevented this from developing. Co-treatment of 
tumours with anti-oestrogens and anti-androgens could therefore be a viable option to 
block this mechanism of resistance.  Cell line models of endocrine resistant disease were 
used to investigate AR signalling in therapy resistance. The results demonstrated that AR 
levels were enhanced in several lines and that all cell lines were sensitive to androgen 
for growth. Importantly, anti-androgens could inhibit androgen-induced growth in all 
models. Anti-androgens could therefore also be a viable option for the treatment of 
tumours that have become resistant to endocrine therapies. This study therefore furthers 
our understanding of the role of the AR in BCa progression and suggests that it is a valid 
therapeutic target to prevent and/or treat endocrine resistant disease.  
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Chapter 1: Introduction 
1.1 Normal breast  
1.1.1 Mammary gland function  
The mammary gland is an organ that exclusively develops fully in female 
mammals, which functions in the production and secretion of milk to provide nutrition for 
their progeny (Inman et al., 2015, Rezaei et al., 2016). Mouse models have been 
instrumental in our understanding of the function, structure and development of the 
human mammary gland (Macias and Hinck, 2012, Inman et al., 2015, Yeh et al., 2003). 
The mammary gland is a compound, branched, tubulo-alveolar gland, which can be 
described as both apocrine and merocrine (Rezaei et al., 2016). Its main structure 
consists of epithelial cells that stem from the nipple, branching out into ducts within a fat 
pad comprised of a large number of adipocytes packed tightly together (Macias and 
Hinck, 2012) (Figure 1.1.1). This fat pad also contains vascular endothelial cells, 
fibroblasts and immune cells (Macias and Hinck, 2012). Once the gland is fully developed 
at puberty, it undergoes cyclical patterns of growth and involution, due to hormone 
changes during the menstrual cycle triggering proliferation, differentiation or apoptosis of 
cells (Inman et al., 2015). The ability of the mammary gland to repeatedly undergo 
proliferation, differentiation and apoptosis can be explained via the presence of Mammary 
Stem Cells (MaSCs), which can self-renew and differentiate into the variety of cells 
required (Macias and Hinck, 2012, Yang et al., 2016). Oestrogen and progesterone and 
their relevant receptors, Oestrogen Receptor alpha (ERα) and Progesterone Receptor 
(PR), are highly important for normal gland function, however the receptors are only  
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Figure 1.1.1 The general structure of the human mammary gland 
 
The breast is a secretory gland, comprising of 15 – 20 lobes that stem from 
the nipple, branching out into ducts within a fat pad comprised of adipose 
tissue. A tissue section to display the ductal regions in more detail is included. 
A duct contains initially a layer of epithelial cells, followed by a further layer of 
myoepithelial cells, which function together to result in milk production and 
secretion. 
 
(Figure is adapted from Ali and Coombes, 2002). 
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expressed by a small proportion of mammary epithelial cells (Margan et al., 2016, Macias 
and Hinck, 2012). 
During pregnancy, ductal branching vastly increases and epithelial end-bud 
structures are developed into alveoli, from which milk can be synthesised, mainly 
regulated by the action of progesterone and prolactin (Macias and Hinck, 2012). These 
luminal epithelial cells are the basis of the ductal structure bedded within fibroblast 
stroma, surrounded by an outer layer of contractible basal myoepithelial cells, which force 
milk out from the luminal cells (Macias and Hinck, 2012, Rezaei et al., 2016). Additionally, 
during pregnancy adipose tissue within the fat pad decreases and vascularisation 
increases (Macias and Hinck, 2012, Rezaei et al., 2016). Oxytocin release from the 
pituitary gland is triggered via stimulation of mechanoreceptors during nursing, initiating 
milk secretion via the nipple for lactation (Yang et al., 2016, Rezaei et al., 2016). Milk is 
comprised of water, proteins, lipids and carbohydrates as well as a variety of minerals 
and vitamins, and is required for the development and health of the new-born (Rezaei et 
al., 2016). Prior to this ‘mature’ milk, in the initial days after birth the mammary gland 
produces colostrum, consisting of vast quantities of immunoglobulins, which is important 
in providing passive immunity for the baby (Rezaei et al., 2016). Once milk production is 
no longer required, mass apoptosis occurs to allow the gland to regress back close to its 
original form (Macias and Hinck, 2012) . 
1.1.2 Mammary gland development  
Initial human mammary gland development occurs in both male and female 
embryogenesis (Inman et al., 2015, Macias and Hinck, 2012). The embryo develops 
mammary lines within the first pregnancy trimester. This produces two placodes, which 
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develop through stages such as mammary bud and nipple sheath formation, to result in 
the rudimentary mammary gland structure that remains present at birth (Macias and 
Hinck, 2012). The Parathyroid Hormone-Related Protein (PTHLH) is highly important 
during this initial development to produce the rudimentary ductal system, and mutations 
to the gene encoding this protein (Parathyroid Hormone 1 Receptor, PTH1R) which impair 
its correct functioning lead to a condition termed Blomstrand Lethal Chondrodysplasia 
(BLC). BLC is a highly uncommon classification of dwarfism, where the embryo is unable 
to develop fully, including in the production of intact nipples, rudimentary mammary ducts 
or correct bone structure, and results in death prenatally or closely following birth (Macias 
and Hinck, 2012). 
Breast development resumes in women during puberty, regulated through the 
action of hormones including Growth Hormone (GH), oestrogen, androgen, Insulin-Like 
Growth Factor-1 (IGF1) and progesterone (Ali and Coombes, 2002, Macias and Hinck, 
2012). Hormone regulation, particularly oestrogen and androgen levels, is key for this 
developmental stage, demonstrated by the occurrence of gynecomastia in men when 
these levels are abnormal (Macias and Hinck, 2012). Normal pubertal mammary gland 
development involves the resumed growth of the rudimentary ductal epithelial cells into 
the surrounding fat pad to produce the fully developed organ (Figure 1.1.1), termed 
branching morphogenesis. This process is led by epithelial cells known as Terminal End 
Bud (TEB) structures that are strongly proliferative and resemble mesenchymal cells, 
which indicates that some Epithelial-to-Mesenchymal Transition (EMT) occurs (Inman et 
al., 2015, Macias and Hinck, 2012, Yang et al., 2016). 
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1.2 Breast Cancer 
1.2.1 Epidemiology  
Breast cancer (BCa) is currently recorded as the most highly prevalent cancer 
among women in the UK, constituting approximately 30 % of female cancer cases 
diagnosed (Cancer Research UK, 2014a, Siegel et al., 2018), with 1,735,350 new cases 
predicted to be diagnosed in 2018 in the USA alone (Siegel et al., 2018). Although BCa 
survival rates have significantly increased in the last 10 years, Breast Cancer has been 
described as currently the second most common cause of cancer-related mortality in 
women in the UK (Cancer Research UK, 2014b) and USA (Siegel et al., 2018). In 2014 
in the UK alone, there were 55,222 BCa diagnoses (Wu et al., 2015), and this disease 
resulted in the deaths of 11,360 women and 73 men (Cancer Research UK, 2014b). 
1.2.2 Molecular subtypes and grading 
BCa is a highly heterogeneous disease, both within and between patients, 
therefore for the purposes of disease management, the identification of similarities 
between patients is highly important (Barnard et al., 2015). Historically, BCas have been 
classified into four main molecular subtypes: Luminal A, Luminal B, HER-2 Enriched and 
Basal-Like. Tumours are classified according to the expression of Oestrogen Receptor 
alpha (ERα), Progesterone Receptor (PR) and Human Epidermal Growth Factor 
Receptor 2 (HER-2, or Erb-B2 Receptor Tyrosine Kinase 2, ERBB2) (Yersal and Barutca, 
2014, Rakha and Green, 2016) (Table 1.2.1). These classifications can be used in 
combination with other factors to guide treatment options and to predict a patient’s 
subsequent clinical response and prognosis (Prat et al., 2015). However, at least three  
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Subtype ERα PR HER-2 
Luminal A + + - 
Luminal B + +/- + 
HER-2-enriched - - + 
Basal-like/TNBC - - - 
Table 1.2.1 The four main classifications of Breast Cancer   
Breast Cancer is classified according to the expression (+) or lack of 
expression (-) of Oestrogen Receptor Alpha (ERα), Progesterone Receptor 
(PR) and Human Epidermal Growth Factor Receptor 2 (HER-2). TNBC 
indicates Triple Negative Breast Cancer.  
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additional subtypes have been recently identified: Claudin-Low, Molecular Apocrine and 
Normal Breast-Like (Prat et al., 2015, Badve et al., 2011). In this section, the main 
features associated with each of these subtypes will be summarised, however these 
characteristics are not conclusive, and there is overlap between subtypes (Prat et al., 
2015). 
1.2.2.1 Luminal A and B Breast Cancers 
Luminal cancers are mainly identified by the expression of ERα encoded by the 
Oestrogen Receptor 1 (ESR1) gene. Therefore these cancers are otherwise known as 
ERα-positive disease, and most BCas (approximately 70 %) are categorised into this 
subtype (Rakha and Green, 2016, Ali and Coombes, 2002). Cancers grouped into these 
classifications have an increased expression of genes associated with ERα and with the 
luminal epithelium (luminal-associated genes) hence the term ‘Luminal’ being used to 
describe these subtypes (Rakha and Green, 2016). Luminal A BCas are characterised 
by having a lower expression of several genes which promote cellular proliferation and 
are involved in cell cycle progression, such as Marker of Proliferation Ki-67 (MKI67) and 
Aurora Kinase A (AURKA). Therefore, these cancers display reduced proliferation, as 
well as an elevated expression of some luminal-associated genes, notably including 
Progesterone Receptor (PR) and Forkhead Box A1 (FOXA1), compared to luminal B 
BCas (Prat et al., 2015). Luminal B cancers generally express HER-2 and express very 
little or no PR (Rakha and Green, 2016). Additionally, the Luminal A subtype contains 
fewer mutations within the genome than Luminal B (Prat et al., 2015). These factors may 
explain the identification of Luminal A BCas across many studies to show, not only a 
better prognosis than Luminal B cancers, but the most favourable prognosis across all of 
the subtypes (Prat et al., 2015, Bartmann et al., 2017, Rakha and Green, 2016). 
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1.2.2.2 HER-2 Enriched Breast Cancers 
HER-2 Enriched BCas are mainly characterised by an elevated expression of the 
ERBB2 gene encoding HER-2 (due to amplification or over-expression) and its 
associated genes (Prat et al., 2015, Rakha and Green, 2016). Additionally to this, HER-
2-enriched cancers have an increased expression of some genes involved in cellular 
proliferation for instance Growth Factor Receptor-Bound Protein 7 (GRB7), expression of 
luminal-associated genes including ESR1 (encoding ERα) and a decreased expression 
of basal-associated genes for instance Keratin 5 (KRT5) (Prat et al., 2015). Additionally, 
this subtype contains the greatest number of mutations within the genome than the others 
(Prat et al., 2015). 
1.2.2.3 Basal-Like Breast Cancers 
Basal-Like cancer is the most distinct BCa subtype (Prat et al., 2015). It has greater 
levels of proliferation due to its increased expression of cellular proliferation genes, for 
instance MKI67 (Rakha and Green, 2016, Prat et al., 2015). Additionally, these tumours 
have an elevated expression of genes which are expressed by basal skin cells and the 
Basal-Like mammary cells, including keratins such as KRT5 (Prat et al., 2015, Rakha and 
Green, 2016). Furthermore, this subtype has an intermediate expression of HER-2-
associated genes and a highly decreased expression of luminal-associated genes (Prat 
et al., 2015). These cancers contain the next greatest number of mutations within the 
genome to HER-2 Enriched BCas (Prat et al., 2015).  
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1.2.2.3.1 Triple Negative Breast Cancers (giving rise to Claudin-Low, Normal 
Breast-Like and Molecular Apocrine) 
Triple Negative Breast Cancers (TNBCs) are cancers which do not express ERα, 
PR or HER-2, and are normally classified as Basal-Like tumours, however this is not 
always the case as these tumours are a very diverse group (Alluri and Newman, 2014, 
Badve et al., 2011). TNBC has been found to be associated with Breast Cancer 1, Early 
Onset (BRCA1) mutations, patients with cancer onset at a younger age and cancers 
which are more aggressive, often with a poor prognosis (Prat et al., 2015, Alluri and 
Newman, 2014). For instance, a recent study on 886 female patients over a time period 
of 53 months following Breast Cancer diagnosis, identified those with TNBC to have the 
lowest overall survival (Bartmann et al., 2017). 
Some TNBCs can be divided into the three additional molecular subtypes: Claudin-
Low, Normal Breast-Like and Molecular Apocrine, however more alternative subtypes 
from this class have been identified (Yersal and Barutca, 2014, Badve et al., 2011, Rakha 
and Green, 2016). Claudin-low BCas are attributed to a decrease in expression of genes 
responsible for cell-cell adhesive properties and the function of tight cell junctions such 
as Claudin 3 (CLDN3) and Claudin 4 (CLDN4), an increase in EMT genes and a higher 
proportion of cells displaying stem cell characteristics (Yersal and Barutca, 2014, Badve 
et al., 2011). These cancers, like other TNBCs, tend to have a poor prognosis (Badve et 
al., 2011). 
Molecular Apocrine Breast Cancer (MABC) or Luminal Androgen Receptor is an 
additional sub-set of tumours within TNBC which express AR, and are driven by the AR 
pathway (Section 1.8.4) (Fioretti et al., 2014, Badve et al., 2011, Rakha and Green, 2016). 
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However, some MABC tumours have been reported to be HER-2-Enriched. For instance, 
Lehmann-Che et al. demonstrated that patients with this form of the disease have 
aggressive tumours with an over-expression of HER-2 and/or Gross Cystic Disease Fluid 
Protein-15 (GCDFP15) (Badve et al., 2011, Lehmann-Che et al., 2013). 
A proportion of TNBCs, which have been termed Normal-Breast Like, have been 
found to lack the Basal-Like gene expression patterns and instead contain cells that 
appear to behave as stromal and normal mammary epithelial cells (Badve et al., 2011, 
Rakha and Green, 2016). Currently, it has not been possible to clearly characterise 
Normal-Like BCas,  and therefore it is thought that diagnosis of this classification may be 
the result of tumour tissue samples containing a high level of contamination with non-
cancerous mammary tissue (Hon et al., 2016, Weigelt et al., 2010, Yersal and Barutca, 
2014). 
1.2.3 Risk factors 
There are a large number of established risk factors that are associated with BCa. 
The most significant is being female in gender, as demonstrated by the disease being 
diagnosed in approximately 140 times more women than men in 2014 (Cancer Research 
UK, 2014a). An increased risk of BCa in women has been associated with many factors, 
including: early age at menarche; nulliparity; late age of first pregnancy; shorter durations 
of breastfeeding in pregnancy; late onset of menopause; high Body Mass Index (BMI) in 
postmenopausal and low BMI in premenopausal women; familial risk; high levels of 
alcohol consumption; oral contraceptive use; geographical location; history of benign 
breast disease and use of menopausal Hormone Therapy (HRT) (Barnard et al., 2015, 
McPherson et al., 2000). 
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Familial risk has long been identified to be caused by Pathogenic Variants (PVs) 
in the BRCA1 and Breast Cancer 2, Early Onset (BRCA2) gene loci (Miki et al., 1994, 
Ford et al., 1994, Ford et al., 1998, Buys et al., 2017), with BRCA1 mutations associated 
with TNBC (Prat et al., 2015). However, the development of Next Generation Sequencing 
(NGS) techniques has led to the identification of additional hereditary PVs in genes 
associated with an elevated BCa risk. A recent study tested 35,409 female BCa patients 
with a panel of 25 of cancer genes, including BRCA1 and BRCA2 (Buys et al., 2017). 
They demonstrated that 9.3% of participants had the presence of at least one PV, and 
more than 50% of these PVs were in genes other than  BRCA1 and BRCA2, most notably 
in Ataxia Telangiectasia Mutated (ATM), Checkpoint Kinase 2 (CHK2) and Partner And 
Localiser of BRCA2 (PALB2). The authors suggest that using a panel of genes may help 
to stratify patients with a higher risk of developing BCa (Buys et al., 2017). 
Which risk factors are relevant and their degree of relevance can vary according 
to molecular subtype (Barnard et al., 2015). Bernard et al. evaluated 38 studies 
investigating the association of established BCa risk factors with the Luminal A, Luminal 
B, HER-2 Enriched and Basal-Like subtypes. They demonstrated that the majority of 
these risk factors are most relevant to Luminal A BCa and that some factors vary in 
association patterns according to the subtype (Barnard et al., 2015). A recent study 
evaluated the association of a variety of established BCa risk factors with ERα expression 
(Kerlikowske et al., 2017). They statistically evaluated information from the 
mammography results of 1,279,433 women in the United States, obtained from the 
National Cancer Institute (NCI)-funded Breast Cancer Surveillance Consortium. The 
authors reported that the strength of association of several risk factors vary according to 
ERα status. For instance, an association between increasing BMI and BCa onset in pre- 
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and perimenopausal women was reported to be more significant in ERα-positive disease 
(Kerlikowske et al., 2017). 
1.2.4 Detection and monitoring 
Different methods can be utilised for the detection and diagnosis of BCa including 
mammography, ultrasound, Magnetic Resonance Imaging (MRI) of the breast and biopsy 
of the tumour (PDQ® Adult Treatment Editorial Board, 2017). The introduction of regular 
mammography tests for women has resulted in early diagnosis to enable early 
intervention and prevent BCa-related deaths (Tilstra and McNeil, 2017), however there 
are some disadvantages associated with its use. For example, higher breast density can 
reduce its accuracy, and an increased frequency of mammography tests in women would 
be generally more useful in the identification of Ductal Carcinomas in situ (DCIS) (early 
stage BCa confined to the milk ducts) than invasive BCa (Tilstra and McNeil, 2017). Upon 
detection of BCa, ERα, PR and HER-2 expression in tumours is assessed using 
immunohistochemistry (IHC), with HER-2 testing being additionally confirmed with in situ 
Hybridisation (ISH) (Rakha and Green, 2016). This allows molecular classification of the 
tumour to determine the treatment options available. Additionally, microarray tools can 
also be used to diagnose several rare BCas, such as Mucoepidermoid Carcinoma, 
characterised by a translocation between chromosomes 11 and 19 resulting in the 
Mucoepidermoid Carcinoma Translocated 1-Mastermind-Like Transcriptional Coactivator 
2 (MECT1-MAML2) gene fusion (Rakha and Green, 2016).  
The Marker Of Proliferation ki-67 (ki67) proliferation index is an additional tool to 
predict BCa prognosis, also evaluated via IHC (Rakha and Green, 2016, Penault-Llorca 
and Radosevic-Robin, 2017). The expression of Ki67, a nuclear protein that is altered 
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during the cell cycle and is most abundant during mitosis, can be used as a marker of 
proliferation (Penault-Llorca and Radosevic-Robin, 2017). The role of ki67 is unclear, but 
it has been suggested to have a direct role in cell division and ribosomal RNA (rRNA) 
synthesis. The ki67 proliferation index represents the percentage of cells tested which 
are positive for this marker, and can be used to determine whether a cancer is Luminal A 
or B (Penault-Llorca and Radosevic-Robin, 2017) (Section 1.2.2.1). 
1.2.5 Treatment 
Treatment for BCa is complex as it is such a heterogenous disease (treatment 
options are summarised in Figure 1.2.1). The most common treatment for localised DCIS 
BCa consists of surgical removal of the tumour combined with radiation and endocrine 
therapy (if suitable) (Section 1.5). This seemingly aggressive form of treatment for DCIS 
is used as a precaution to prevent it from developing into invasive cancer (Tilstra and 
McNeil, 2017). However, recently it has been suggested that DCIS is a risk factor instead 
of a precursor for invasive BCa, so a less aggressive treatment strategy could be more 
appropriate (Tilstra and McNeil, 2017). Additionally, there is often a need for adjuvant or 
neoadjuvant therapy to account for any micrometastases, and surgery is not an option for 
cases when the cancer has spread from its primary site (Ali and Coombes, 2002, 
Vorobiof, 2016). In these cases, endocrine therapies, which aim to block ERα activity, are 
often preferred for patients with metastatic ERα-positive Luminal disease. Endocrine 
therapies include anti-oestrogens, Aromatase Inhibitors (AIs) and Gonadotropin-
Releasing Hormone agonists (GnRHas), which can be used either separately or together 
(Vorobiof, 2016, Ali and Coombes, 2002) (Section 1.5).  
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Figure 1.2.1 A summary of Breast Cancer treatment options 
 
A schematic to represent the common treatment options selected for patients 
with different classifications of Breast Cancer: Ductal Carcinomas in situ (DCIS), 
Oestrogen Receptor alpha (ERα)-positive (Luminal cancers), Human Epidermal 
Growth Factor Receptor 2 (HER-2)-Positive (HER-2-Encriched) and Basal-Like. 
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(Trastuzumab, Pertuzumab, Trastuzumab Emtansine) 
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Poly-ADP Ribose Polymerase (PARP) Inhibitor (Olaparib)
Immunotherapy (anti-PDL-1)
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The development of Trastuzumab (Herceptin), a monoclonal antibody that directly 
targets HER-2, has improved the prognosis for patients with HER-2-Enriched BCa 
(Vorobiof, 2016). This has resulted in the development of alternative monoclonal 
antibodies to target HER-2, including Pertuzumab (Perjeta) which is usually administered 
alongside chemotherapy and Trastuzumab, and antibody drug conjugates such as 
Trastuzumab Emtansine (TDM-1), which have been demonstrated to show benefits in 
many patients (Vorobiof, 2016). Currently, the irreversible HER-2/EGFR Tyrosine Kinase 
Inhibitor (TKI) drug Neratinib (HKI-272) is also being investigated and trialed as a potential 
treatment for HER-2-enriched BCa. Neratinib has shown promising results, but its use 
has been associated with negative side effects such as diarrhea and vomiting, so further 
research to reduce these complications is currently underway (Vorobiof, 2016, Ben-
Baruch et al., 2015).  
Some Basal-Like TNBC patients respond well to chemotherapy such as 
Anthracycline, however a lack of response often indicates a very poor prognosis (Badve 
et al., 2011). Basal-Like BCa patients may also benefit from drugs which target the 
Epidermal Growth Factor Receptor (EGFR) as this is normally over-expressed, and those 
with BRCA1 mutations from treatment with Poly-ADP Ribose Polymerase (PARP) 
enzyme inhibitors (Yersal and Barutca, 2014). Additionally, recent advances in treatment 
for several cancers including bladder cancer has been through the use of 
immunotherapies, such as Anti-Programmed Death-Ligand 1 (anti-PDL-1) drugs. These 
are now being demonstrated through clinical trials to have a potential benefit for TNBC 
patients (Vorobiof, 2016, Pusztai et al., 2016). Due to the heterogeneity observed in BCa 
disease, and the ongoing implementation of high-throughput genomic techniques which 
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could adjust the current disease molecular classifications, treatment is becoming 
increasingly individualised to patients (Rakha and Green, 2016).  
1.3 Nuclear Receptors 
1.3.1 The Nuclear Receptor family 
Nuclear Receptors (NRs) are a family of proteins that function as ligand-dependent 
transcription factors (TFs) (Sever and Glass, 2013). The ligands involved in these 
pathways have the ability to pass through the cell membrane to interact intracellularly with 
their specific receptors (Sever and Glass, 2013). In humans, 48 NRs are currently 
recognised, including Oestrogen Receptors α and β (ERα and ERβ) (Section 1.4) and the 
Androgen Receptor (AR) (Section 1.7), and their roles as TFs regulate a large number of 
different functions, for instance cellular proliferation and metabolism (Sever and Glass, 
2013, Maruthanila et al., 2016, Pietri et al., 2016). NRs have a common basic structure 
consisting of four-five main functional domains: an N-terminal whose sequence widely 
differs between NRs, often containing a domain termed Activation Function 1 (AF1) that 
mediates transcriptional activity; a second activation function site (Activation Function 2, 
AF2), a central DNA Binding Domain (DBD) partially comprising two Zinc Fingers (ZFs) 
and a Ligand Binding Domain (LBD), separated by a hinge region (Sever and Glass, 
2013, Huang et al., 2010, Huss and Kelly, 2004, Maruthanila et al., 2016), which is 
displayed in Figure 1.3.1. NRs often have the ability to homodimerise with each other. 
For instance, the Retinoid X Receptor (RXR) has been demonstrated to interact with the 
Peroxisome Proliferator-Activated Receptor (PPAR), Retinoic Acid Receptor (RAR), 
Vitamin D Receptor (VDR), and Thyroid hormone Receptor (TR) (Dawson and Xia, 2012). 
 36 
 
 
 
(Vranic et al., 2017) (Dehm and Tindall, 2007)  
AF1 Hinge DBD AF2 
 Domain:              A/B                       C               D                   E/F 
Figure 1.3.1: The general structure and domains in Nuclear Receptors 
 
The general Nuclear Receptor (NR) structure is comprised of an A/B domain 
which includes an Activation Function 1 (AF1) that mediates transcriptional 
activity, a C domain which includes DNA Binding Domain (DBD) partially 
comprising two Zinc Fingers, and a E/F domain with a Ligand Binding Domain 
(LBD), separated by a D domain (Hinge).  
 
 
(Figure is adapted from Huss and Kelly, 2004). 
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1.3.2 Type I Nuclear Receptor activation pathway 
NRs can be organised into four classifications according to their activation 
pathways (Figure 1.3.2). The Oestrogen Receptors ERα and ERβ, PR and AR belong to 
the Type I NR category (Sever and Glass, 2013) (Figure 1.3.2a). In the absence of ligand, 
Type I NRs are held in the cytoplasm in an inactive state bound to chaperone proteins 
and co-repressors (co-factors that bind to TFs and repress activity). Once activated by 
ligand binding, the NR undergoes a conformational change, releasing it from this complex 
(Pietri et al., 2016, Sever and Glass, 2013). This reveals the nuclear localisation domain 
and thereby allows the receptor to translocate to the nucleus and to homodimerise. 
Following this, the NR dimer binds to specific DNA sequences termed Hormone 
Response Elements (HREs) located in the promoter or enhancer regions of genes, 
resulting in their transcriptional activation (Figure 1.3.2a) (Sever and Glass, 2013, Brooke 
and Bevan, 2009, Dehm and Tindall, 2007, Maruthanila et al., 2016). It produces this 
effect by binding via two ZF motifs and via the recruitment of co-activators (proteins that 
enhance transcription factor activity), such as Amplified in Breast Cancer 1 (AIB1, 
otherwise known as p160 Steroid Receptor Co-Activator 3, SRC3) and the general 
transcription machinery (Lahusen et al., 2009, Sever and Glass, 2013). 
Type II receptors include the Thyroid Hormone Receptor. This class of NRs are 
located constantly within the nucleus of the cell bound to their HREs, however prior to 
ligand binding they are held in an inactive state bound within a complex including co-
repressors (Figure 1.3.2b). Upon ligand binding, co-repressors release from this complex 
and co-activators bind in exchange, initiating transcriptional activation (Sever and Glass, 
2013). Type III NRs have an activation pathway that strongly resembles that of the Type  
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Figure 1.3.2 Alternative Nuclear Receptor pathways 
 
Nuclear Receptors (NRs) have 4 different activation pathways. (a) Type I NRS are held 
in an inactive state in the cytoplasm bound to co-repressors. Following ligand binding, 
the NR undergoes a conformational change, releasing it from this complex and 
translocates to the nucleus. It interacts as a dimer to Hormone Response Elements 
(HREs) and recruits co-factors to activate gene transcription. (b) Type II NRs are held in 
an inactive state in the nucleus bound to their HREs and co-repressors. Upon ligand 
binding, co-repressors are released and co-activators bind, initiating transcriptional 
activation. (c) Type III NRs have an activation pathway that resembles Type I, but their 
HREs have an alternative structure. (d) Type IV NRs interact as single monomer units to 
half of a HRE site (Sever and Glass, 2013).  
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I class, however their HREs have an alternative structure (Figure 1.3.2c) and Type IV 
NRs interact as monomers to half of a HRE site (Figure 1.3.2d) (Sever and Glass, 2013).  
1.4 Oestrogen Receptor alpha 
1.4.1 The Oestrogens Receptors: structure and function 
Oestrogens are sex hormones, which like other steroid sex hormones, normally 
exist in the bloodstream in a complex with Sex Hormone-Binding Globulin (SHBG) 
(Chuffa et al., 2017, Hewitt et al., 2016). Oestrogens are important in the correct 
functioning of the female reproductive system, such as the development of the mammary 
gland (Section 1.1.2), as well as for other non-related functions, including the regulation 
of bone density and the cardiovascular system (Ali and Coombes, 2002, Knowlton and 
Lee, 2012, Chuffa et al., 2017). In premenopausal women, oestrogens are predominantly 
synthesised in the ovaries, as well as in the corpus luteum and placenta when relevant, 
and released into the bloodstream. Oestrogens are also produced to a lesser degree in 
other organs, for instance the heart and brain (Cui et al., 2013). In postmenopausal 
women, however, the ovaries no longer produce oestrogens and these extragonadal 
oestrogen sources become more vital. In these women, oestrogens are produced to 
function locally, for instance by adipose tissue (Cui et al., 2013). The main oestrogens 
produced in women are Oestrone (E1), 17-β-Oestradiol (E2), and Oestriol (E3). The most 
highly abundant circulating form of oestrogen as well as the most potent is E2 (Bean et 
al., 2014, Speirs and Walker, 2007). E1 becomes more important postmenopause and 
E3 throughout pregnancy (Cui et al., 2013). 
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E2 function is mainly applied through the action of two NRs: Oestrogen Receptors 
α and β (ERα and ERβ), encoded by ESR1 and Oestrogen Receptor 2 (ESR2) genes 
respectively (Bean et al., 2014, Speirs and Walker, 2007). These genes are positioned in 
alternative chromosomes, ESR1 at 6q25.1 and ESR2 at 14q22-24 (Speirs and Walker, 
2007). The structures of ERα and ERβ both follow the common basic NR structure (Figure 
1.3.1). A comparison of the sequences of the two receptors displays a highly conserved 
DBD, but the other regions are less conserved (Figure 1.4.1). For ERα functioning, AF2 
activation occurs following oestrogen binding to the receptor, whereas AF1 activation is 
regulated by ligand-independent phosphorylation of the receptor. These activation 
domains can function either independently or together (Ali and Coombes, 2002, Huang 
et al., 2010, Huss and Kelly, 2004). AF2 is key for ERα action in breast epithelium, but in 
other tissue types, such as the uterus, AF1 activation is more important for ERα function. 
ERα is widely known as more important than ERβ in BCa and has been shown to facilitate 
BCa onset and progression (Ali and Coombes, 2002) (Section 1.4.3).  
1.4.2 The ERα pathway and signalling 
Most oestrogen signalling in mammary tissue occurs through ERα via the classical 
ERα signalling pathway, which can be categorised as a Type I NR activation pathway 
(Sever and Glass, 2013) (Figure 1.4.2). This enables it to interact via its DBD with 
Oestrogen Response Elements (EREs), which contain the specific consensus motif: 
GGTCAnnnTGACC. This motif consists of a palindromic series of bases, inversely 
replicated and connected via 3 variable bases (Hewitt et al., 2016). It has been 
demonstrated that FOXA1 is vital as a pioneer factor in facilitating interactions between 
ERα and EREs (Hewitt et al., 2016, Hurtado et al., 2011).  
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Figure 1.4.1: Homology comparison of the functional domains 
of Oestrogen Receptors alpha and beta 
 
The functional regions of the proteins are displayed: Activation 
Function 1 (AF1); DNA Binding Domain (DBD); hinge; Ligand 
Binding Domain (LBD); and Activation Function 2 (AF2). The 
percentage of similarity between the amino acid sequences of these 
five functional regions of the two proteins is also indicated  
 
(Figure is adapted from Speirs and Walker, 2007). 
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Figure 1.4.2 The Oestrogen Receptor alpha pathway of gene regulation 
The classical oestrogen signalling pathway is ligand-dependent. Following 
ligand (most commonly 17β-Oestradiol, E2) binding, Oestrogen Receptor α 
(ERα) activates gene expression via a direct interaction of the ERα dimer to 
Oestrogen Response Elements (EREs) as part of a complex with co-
activators (Musgrove and Sutherland, 2009, Hewitt et al., 2016).  
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ERα target gene regulation can additionally occur via other mechanisms. For 
instance, it has been demonstrated to regulate gene expression through the receptor 
‘tethering’ to other DNA-bound TFs (for example Activator Protein 1, AP-1), thereby 
bypassing the requirement for EREs (Hewitt et al., 2016, Heldring et al., 2011). A further 
example is through rapid non-transcriptional signalling, often described as ‘non-genomic’ 
(Lipovka and Konhilas, 2016, Hewitt et al., 2016). This involves ERα interacting directly 
with specific proteins upon ligand activation, for instance its activation of the Mitogen-
Activated Protein Kinase (MAPK) signalling pathway (Lipovka and Konhilas, 2016, Chuffa 
et al., 2017). Some rapid E2 effects have been attributed to G-Protein-Coupled Oestrogen 
Receptor 1 (GPER1)  (Liu et al., 2015, Lipovka and Konhilas, 2016) and ERα36, a variant 
of ERα that was identified in 2005 and given its name due to its 36 KDa size (Wang et 
al., 2005), which are both also associated with the cell membrane (Chuffa et al., 2017). 
Additionally, ERα signalling can occur ligand-independently, and this is hypothesised to 
be via phosphorylation of ERα directly or of other proteins in its normal complex, such as 
co-activators (Hewitt et al., 2016). 
1.4.3 Endocrine sensitive Breast Cancer  
It is widely accepted that hormones are important in the development and 
progression of the majority of cases of BCa. As stated previously (Section 1.2.2), 
approximately 70 % of BCas are ERα-positive (Luminal cancers), and are consequently 
dependent upon oestrogens for growth, providing insight into why this disease is much 
more common in women than men (Keen and Davidson, 2003, Rakha and Green, 2016, 
Ali and Coombes, 2002). This effect was first indicated in 1896, when George Beatson 
described his findings that the removal of the ovaries from three female BCa patients with 
inoperable tumours resulted in disease remission (Beatson, 1896). ERα is now widely 
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accepted to be a major factor in driving cancer progression in ERα-positive disease 
(Chuffa et al., 2017). Therefore, these cancers are often termed endocrine sensitive, and 
therapies for these patients often aim to block ERα activity (Section 1.5). 
ERα drives BCa progression via the regulation of various cellular processes. One 
example is through its regulation of kinase cascades. For instance, a recent study 
demonstrated that treatment with Cryptotanshinone (CPT) inhibits BCa cell proliferation 
and the Phosphatidylinositol-4,5-Bisphosphate 3-Kinase/AKT Serine/Threonine 
Kinase/Mammalian Target Of Rapamycin (PI3K/Akt/mTOR) signalling pathway, but that 
this effect is exclusive to endocrine sensitive cells with a functioning ERα (Pan et al., 
2017). Additionally, ERα promotes BCa progression through its regulation of proteins 
involved in apoptosis, such as its downregulation of the pro-apoptotic factor Prostate 
Apoptosis Response 4 (PAR-4) (Casolari et al., 2011).  
1.4.4 Oestrogen Receptor beta 
ERβ has some differing functions compared to ERα, for instance it is not key for 
cellular proliferation in the mammary gland, but it is however involved in oestrogenic 
effects in the correct functioning of the immune, cardiovascular and nervous systems 
(Warner et al., 2017). Also by contrast to ERα, ERβ has been suggested to act as a 
Tumour Suppressor Gene (TSG) in BCa (Warner et al., 2017). It has been demonstrated 
to produce an anti-proliferative effect on BCa cell growth and to promote apoptosis, and 
ERβ levels have been reported to decrease in BCa, indicating it to have an opposing role 
to that of ERα (Huang et al., 2014, Chuffa et al., 2017, Hartman et al., 2009, Williams et 
al., 2008). However, some research has produced conflicting results. For example, it has 
been demonstrated that ERβ over-expression in endocrine sensitive MCF7 and T47D 
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BCa cells resulted in ERβ heterodimerising with ERα, and yet there was no significant 
negative effect on ERα signalling or cell proliferation (Jonsson et al., 2014). Additionally, 
it has been reported that ERβ expression does not correlate with a favourable prognosis 
in endocrine sensitive patients (Tan et al., 2016).  
1.5 Targeting ERα in therapy 
As discussed earlier (Section 1.2.5), endocrine therapies, which aim to block ERα 
activity and/or halt the synthesis of E2, are often preferred for patients with metastatic 
ERα-positive luminal disease. A schematic of these therapies is displayed in Figure 1.2.1. 
Endocrine therapies can be divided into three main categories: anti-oestrogens, 
Aromatase Inhibitors (AIs) and Gonadotropin-Releasing Hormone Agonists (GnRHas), 
which can be used either separately or together (Vorobiof, 2016, Ali and Coombes, 2002). 
Endocrine therapies have been shown to significantly increase disease-free and overall 
survival in BCa patients (Vorobiof, 2016).  
1.5.1 Anti-oestrogens 
The aim of anti-oestrogens is to target ERα to block its action. Anti-oestrogens can 
be grouped into two subclasses: Selective ERα Modulators (SERMs) such as Tamoxifen, 
Raloxifene and Toremifene and Selective ERα Downregulators (SERDs) for instance 
Fulvestrant (Kaklamani and Gradishar, 2017, Cauley et al., 2001). SERMs can be 
described as nonsteroidal cytostatic agents, which inhibit ERα by competitively binding 
as ligands, and have tissue and target gene-specific effects (Kaklamani and Gradishar, 
2017, Martinkovich et al., 2014). SERM binding to ERα in tumour and mammary cells 
results in dimerisation of the receptor as in the normal signalling pathway, however the 
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SERM promotes the formation of an inhibitory  nuclear complex that reduces the levels 
of DNA synthesis and oestrogen signalling (Kaklamani and Gradishar, 2017). The 
consequences of SERMs with binding ERα vary in a tissue specific manner, and this 
additionally varies between different SERMs (Kaklamani and Gradishar, 2017). SERMs 
have the ability to function as antagonists in BCa cells and as partial agonists in various 
other tissues, for instance in the bone or endometrium (Kaklamani and Gradishar, 2017). 
This combined ability to produce agonistic and antagonistic effects is produced by many 
factors which differ between SERMs, including: variations in the affinity of a SERM for 
each of the receptor’s subtypes (ERα and ERβ); alterations in the expression of these 
subtypes and different co-factors between tissues; and the resulting conformational 
changes to ERα, following SERM binding, can affect co-factor interactions that have gene 
specific regulatory effects (Martinkovich et al., 2014).  
Currently, the most widely used anti-oestrogen in all stages of BCa treatment is 
the SERM Tamoxifen (TAM), which was the first extensively used anti-oestrogen to be 
introduced more than 30 years ago (Vorobiof, 2016, Lumachi et al., 2015). SERMs have 
also been displayed to decrease the risk of BCa onset in women that are at a high risk of 
contracting the disease, and therefore have the potential to be useful as preventative 
therapies. This effect has been demonstrated using TAM, and it was approved for 
administration for this use in 1998. However this was not found to be beneficial for long 
term usage, as side effects associated with prolonged administration of this drug included 
endometrial stimulation and an increased risk of development of endometrial cancer 
(Fisher et al., 1998). Raloxifene has also been found to reduce BCa risk and, unlike TAM, 
does not appear to promote endometrial cancers, being approved for this use in 2007 by 
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the U.S. Food and Drug Administration (FDA) (Cauley et al., 2001, Martinkovich et al., 
2014, Waters et al., 2012). 
 SERDs, in comparison, are described as pure ERα antagonists. They act solely 
as anti-oestrogens for ERα by blocking and reducing its activity, advancing the speed of 
its degradation, and inhibiting oestrogen-stimulated cellular proliferation (Kaklamani and 
Gradishar, 2017, Lumachi et al., 2015). A SERD that is commonly prescribed to patients 
with endocrine sensitive disease is Fulvestrant (FULV). FULV competitively interacts with 
ERα in the same fashion as TAM but with a vastly increased affinity (100-fold), and as a 
pure ERα antagonist it does not stimulate cell growth in endometrial tissue (Kaklamani 
and Gradishar, 2017, Martinkovich et al., 2014). Post ERα binding, FULV halts the 
transcription of genes regulated by the ERα pathway, by stopping it from dimerising and  
blocking its nuclear translocation, as well as by advancing the degradation of the receptor 
via proteasomes (Kaklamani and Gradishar, 2017, McDonnell et al., 2015). FULV has 
proved valuable for use with advanced metastatic and TAM-resistant disease. However, 
its use has been limited in BCa as it is administrated through an intramuscular injection, 
resulting in patients experiencing a ‘lag’ in time for it to reach a consistent concentration. 
Therefore, work is being conducted to produce novel SERDS that are administered orally 
(Martinkovich et al., 2014, McDonnell et al., 2015, Xiong et al., 2017). 
1.5.2 Gonadotropin-Releasing Hormone agonists and Oophorectomy  
Another method to inhibit endocrine sensitive breast cancer is to block the 
synthesis of E2, and the method by which this is done is dependent upon whether the 
patient is pre- or post- menopause. In premenopausal women, E2 (and progesterone) 
synthesis predominantly occurs in the ovaries during follicular development, regulated by 
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the action of the pituitary gonadotrophins Follicle-Stimulating Hormone (FSH) and 
Luteinizing Hormone (LH) whose production is regulated by Gonadotropin Releasing 
Hormone (GnRH) (Ali and Coombes, 2002, Lumachi et al., 2015, Nourmoussavi et al., 
2017, Kaklamani and Gradishar, 2017). Therefore, Ovarian Function Suppression (OFS) 
can be utilised for BCa treatment in these patients to vastly decrease E2 levels (Lumachi 
et al., 2015, Nourmoussavi et al., 2017). This can be achieved through surgical removal 
of the patient’s ovaries (oophorectomy), but is more commonly conducted now using 
GnRH agonists (GnRHas) such as Goserelin and Leuprolide (Keen and Davidson, 2003, 
Lumachi et al., 2015, Vorobiof, 2016).  
GnRHas work by reducing LH production and thereby halting follicular activity and 
the ovarian synthesis of oestrogens (Ali and Coombes, 2002). A recent review evaluated 
many studies of the use of OFS in premenopausal BCa patients in combination with other 
endocrine therapies (Nourmoussavi et al., 2017). They found that in low-risk ERα-positive 
patients, OFS did not tend to improve patient outcomes over the use of TAM alone 
(Nourmoussavi et al., 2017). However in higher-risk patients (i.e. those who have already 
undergone chemotherapy or are less than 35 years old) the use of OFS with TAM or AIs 
(Section 1.5.3) in patients resulted in 4.5-7.7 % less disease relapse than using solely 
TAM (Nourmoussavi et al., 2017). However, the disadvantages associated with the 
administration of GnRHas in this way include the increase in cost and that early 
menopause has been linked to a risk of premature mortality in the long run, for instance 
through a higher risk of ischaemic heart disease (Nourmoussavi et al., 2017, Lokkegaard 
et al., 2006, Svejme et al., 2012).  
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1.5.3 Aromatase Inhibitors 
In postmenopausal women, E2 production no longer occurs in the ovaries and 
synthesis of E2 in peripheral, extra-gonadal tissues becomes the main source of E2 
(Nourmoussavi et al., 2017, Patani and Martin, 2014). This E2 is synthesised from 
androgens mediated via the action of aromatase, a steroid hydrolase cytochrome P450 
enzyme, mainly through the synthesis of E1 from androstenedione and E2 from 
testosterone (Section 1.7.3) (Kaklamani and Gradishar, 2017, Patani and Martin, 2014). 
This method of biosynthesis has long been suggested to be exploited in BCa by the 
production of high quantities of aromatase in tumour cells (Harada, 1997). Therefore, in 
postmenopausal BCa patients, Aromatase Inhibitors (AIs) are the most commonly 
administered treatment, which block aromatase activity and therefore reduce E2 
synthesis, thus decreasing circulating oestrogen levels and E2 synthesised within the 
tumour (Kaklamani and Gradishar, 2017). This from of treatment is commonly described 
as oestrogen deprivation (Patani and Martin, 2014). This endocrine therapy is not 
appropriate for premenopausal women, as in these patients AIs result in an elevated 
production of gonadotrophins, and so raise circulating oestrogen levels (Lumachi et al., 
2015). 
AIs can be classified into two differing subtypes, commonly referred to as Types I 
and II (Kaklamani and Gradishar, 2017). Type I AIs are steroidal and include Exemestane. 
These directly compete with endogenous substrates to irreversibly bind aromatase and 
therefore result in its irreversible inactivation, even after administration of this treatment 
has finished (Patani and Martin, 2014, Kaklamani and Gradishar, 2017). Type II AIs, for 
instance Anastrozole and Letrozole, however, are non-steroidal and reversibly bind 
aromatase to halt E2 production (Patani and Martin, 2014). 
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1st and 2nd generation AIs had problems with their specificity and resulted in some 
interference with the activity of additional steroid hydroxylases (Dowsett et al., 1990, 
Patani and Martin, 2014). 3rd generation AIs however, the most commonly used of which 
are Anastrozole, Exemestane and Letrozole, have a much higher specificity for 
aromatase and an improved efficacy (Vorobiof, 2016, Patani and Martin, 2014). However, 
disadvantages can still be associated with the administration of AIs, such as possible 
elevated bone resorption during treatment, meaning an elevated chance of bone fractures 
in patients (Kaklamani and Gradishar, 2017). 
1.6 Endocrine resistance 
Although endocrine therapies have proved highly successful in BCa treatment, 
many patients experience resistance to treatment termed endocrine resistance, either 
initially (de novo, or primary) or developed during the course of therapy (acquired or 
secondary) and relapse, often resulting in advanced metastatic disease (Kaklamani and 
Gradishar, 2017, Vorobiof, 2016, Reinert et al., 2017). De novo resistance is normally 
described as when a patient relapses within 2 years when endocrine therapy is used as 
an adjuvant treatment or 6 months when the therapy is used as first-line (Reinert et al., 
2017). Resistance is therefore normally described as acquired when a patient 
experiences relapse post these time periods (Reinert et al., 2017). It is currently estimated 
that 20-30 % of BCa patients will experience endocrine resistance, and many 
mechanisms by which this occurs have been described (Vorobiof, 2016), several of which 
are outlined in this section. 
In the majority of TAM resistance cases ERα expression is maintained, and some 
patients have responded to alternative endocrine therapies, such as FULV (Osborne, 
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1998, Howell et al., 1995, Howell et al., 1996, Schiff et al., 2003). This indicates that ERα 
is still driving cancer growth, but its regulation has been modulated. In these endocrine 
resistant cases, many studies have suggested that TAM has begun to stimulate rather 
than inhibit cancer progression, so a rapid detection of resistance development is much 
needed (Schiff et al., 2003). Additionally, analysis of 6 AI-resistance cell line models 
developed using the same method resulted in multiple resistance mechanisms, 
sometimes within the same model, indicating that endocrine resistance in BCa is complex 
and can alter in patients, and thereby could be difficult to target (Hayashi and Kimura, 
2015). Therefore, the endocrine resistance mechanisms outlined in this section often 
overlap, as demonstrated in Figure 1.6.1. 
1.6.1 ERα mutations 
Mutations to the ESR1 gene encoding ERα are highly uncommon in early stages 
of BCa (Alluri et al., 2014, Reinert et al., 2017), with a recent study conducting whole 
exome sequencing on ESR1 in different BCa tumours identifying no mutations in the 
primary ERα-positive tumour samples (Yanagawa et al., 2017). However, ESR1 
mutations were identified in more advanced forms of the disease and are believed to 
promote endocrine resistance (Kaklamani and Gradishar, 2017, Ma et al., 2015, Angus 
et al., 2017). For example, Yanagawa et al. detected 6 different ESR1 mutations (3 being 
novel) in 5 out of 47 recurrent tumours from patients with ERα-positive metastatic disease 
undergoing endocrine therapy (Yanagawa et al., 2017). A schematic to represent the 
commonly occurring mutations in advanced BCa is displayed in Figure 1.6.2. 
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Figure 1.6.1 The overlap of mechanisms for endocrine resistance in Breast 
Cancer (BCa) 
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Figure 1.6.2 The most common mutations to the ESR1 gene 
found in advanced Breast Cancer following endocrine therapy 
A schematic representation of the Oestrogen Receptor 1 (ESR1) 
gene encoding the Oestrogen Receptor alpha (ERα) with the 
locations of mutations that have been most commonly identified in 
advanced disease indicated. The two mutations that occur in the 
highest frequencies are highlighted (grey). The main structural 
domains are indicated: Activation Functions 1 and 2 (AF1/2), the 
DNA Binding Domain (DBD), the Hinge (H) domain containing 
sequences important for the receptor dimerization and nuclear 
localization and the Ligand Binding Domain (LBD).  
(Figure is adapted from Angus et al., 2017 and Ma et al., 2015) 
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Often these ESR1 mutations alter the structure/function of the LBD to constitutively 
activate ERα. For instance, Robinson et al. displayed that 6 out of 11 patients with ERα-
positive metastatic BCa had ESR1 mutations that altered the structure of the ERα LBD, 
resulting in the receptor becoming constitutively active and therefore able to function 
ligand-independently (Robinson et al., 2013). Additionally, in a separate study, ERα LBD 
mutations were identified in 17.5 % of samples obtained from 80 patients with ERα-
positive metastatic disease, mainly resulting in a production of the ERα agonist 
conformation to promote its ligand-independent activity and decrease anti-oestrogen 
efficacy (Toy et al., 2013). Y537S and D538G mutations, which have also been 
demonstrated to produce a constitutive activation of the ERα, appear to be the most 
commonly occurring mutations (Figure 1.6.2) (Fanning et al., 2016, Reinert et al., 2017). 
Investigations into treatments that can target mutant forms of ERα are underway, 
including the novel SERD AZD9496 (Weir et al., 2016), for which a clinical trial for its first 
use in patients is currently being conducted to assess the correct dosage, safety, 
tolerability, pharmacokinetics and biological activity, as compared for patients with and 
without ESR1 mutations (ClinicalTrials.gov Identifier: NCT02248090).  
1.6.2 Oestrogen hypersensitivity and over-expression of co-factors 
Altered expression or activity of ERα co-regulators can promote endocrine 
resistance (Kaklamani and Gradishar, 2017). Co-factors are highly involved in regulating 
the transcriptional activity of ERα and its signalling pathway. These co-factors include a 
group of highly researched transcriptional co-activators, the p160 Steroid Receptor Co-
activator (SRC) family consisting of SRC1, SRC2 and SRC3. The over-expression of 
these factors has been displayed in several human cancers, including BCa (Xu et al., 
2009).  Increased levels of co-activators have been linked to endocrine resistant disease, 
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and appears to hypersensitise the pathway. For instance, it has been demonstrated that 
in patients treated with TAM post-surgery, increased levels of SRC3 (otherwise known as 
Amplified in Breast Cancer-1, AIB1) were significantly associated with a decreased 
chance of disease free survival and increased chance of endocrine resistance (Osborne 
et al., 2003). The role of SRC3 in endocrine resistance has been demonstrated in other 
studies, including by Alkner et al. who found its elevated expression in Metachronous 
Contralateral Breast Cancer (a subsequent tumour which has developed over 6 months 
post original BCa diagnosis in the other breast) following past endocrine therapy with 
TAM (Alkner et al., 2016). The involvement of various other co-activators in endocrine 
resistant BCa have been indicated, such as Homeobox B7 (HOXB7) (Jin et al., 2015) and 
Coactivator-Associated Arginine Methyltransferase 1 (CARM1) (Hiken et al., 2016). The 
method via which oestrogen hypersensitivity and co-factor over-expression occurs 
appears to be via post-translational modifications (Section 1.6.3). 
1.6.3 Post-translational modifications 
Post-translational modifications (e.g. phosphorylation, methylation and 
ubiquitination) of ERα and/or its co-regulator proteins and their encoding genes are 
important in BCa development and progression. They have been demonstrated to alter 
ERα signalling and thereby can affect the response to treatment with endocrine therapies 
and potentially promote the onset of resistance (Kaklamani and Gradishar, 2017, Abdel-
Hafiz, 2017, Hayashi and Kimura, 2015).  
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1.6.3.1 Post-translational modifications of ERα and/or its co-regulators 
Hayashi and Kimura (2015) described the phosphorylation of ERα resulting in 
ligand-independent ERα activity as a potential endocrine resistance mechanism, which 
has been supported by several studies. For instance, one group produced a set of 
oestrogen-deprived cell line derivatives of MCF7 endocrine sensitive cells (to mimic AI-
resistance) that were stably transfected with an ERE-Green Fluorescent Protein (GFP) 
reporter (Fujiki et al., 2014). Despite oestrogen deprivation, half of these resistance 
models still demonstrated strong ERα activity, as well as displaying an elevated 
expression of ERα and several of its associated target genes. They discovered an 
increase in phosphorylation of ERα on the amino acid residue Ser167 and Protein Kinase 
B (PKB, more commonly known as Akt) on Thr308, suggesting that the Akt signalling 
pathway was key in this resistance mechanism (Fujiki et al., 2014). Work conducted by 
other groups has supported this mechanism (Campbell et al., 2001, Yamashita et al., 
2005). 
1.6.3.2 Post-translational modifications that directly affect gene expression 
Work conducted by Yu et al. has suggested the involvement of MYST Histone 
Acetyltransferase (Monocytic Leukemia) 3 (MYST3), a protein which functions in histone 
acetylation, in epigenetic activation of the ESR1 gene. They observed that MYST3 gene 
over-expression was associated with a poorer prognosis in endocrine sensitive BCa, and 
demonstrated the ability of MYST3 to interact with the proximal promoter of ESR1 and 
enhance expression of the receptor (Yu et al., 2017). Therefore, this process could play 
a role in endocrine resistance. 
 57 
 
Alterations in gene methylation have also been linked to therapy resistance, 
whereby genes that promote cancer progression are hypomethylated and those that 
would suppress it are hypermethylated (Lubecka et al., 2016). Recently, one group 
performed a genome-wide analysis of DNA methylation and expression using cell line 
models to mimic AI endocrine resistance (Hiken et al., 2017). The authors demonstrated 
that Prostaglandin E2 Receptor 4 (PTGER4) expression was upregulated following gene 
demethylation in these cell lines, and subsequent knockdown analyses indicated the 
importance of its expression for ligand-independent cellular proliferation in these models. 
They demonstrated that this mechanism was at least in part due to PTGER4 enhancing 
the activity of the ERα co-factor CARM1, which interacts with ERα and promotes the 
expression of ERα target genes in the absence of oestrogen (Hiken et al., 2017). It 
appears that different post-translational modifications can occur in endocrine resistance 
and can produce alternative effects. For instance, Tsuboi et al. produced two cell line 
models of FULV resistant BCa and observed differing methylation patterns between them, 
in particular in the promoter regions upstream of ESR1, and consequently there were 
differing characteristics of FULV resistance in the two models (Tsuboi et al., 2017).  
1.6.3.3 Post-translational modifications of ERα co-regulators and ESR1 can be 
linked 
An alternative mechanism of endocrine resistance that has been described is 
through the downregulation or loss of ERα expression, which has been estimated to arise 
in approximately 15–20 % of endocrine resistant tumours (Citro et al., 2015). Work 
conducted by Citro et al. suggested one mechanism via which this could occur is through 
mitogenic (such as Epidermal Growth Factor, EGF) activation of the PI3K/AkT/mTOR 
signalling pathway results in phosphorylation of the Histone Deacetylase 1 (HDAC1) 
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protein, which facilitates deacetylation of ESR1 to downregulate its expression (Citro et 
al., 2015). HDAC1 has been previously demonstrated to control transcriptional activation 
of ESR1 via interacting with its promoter and altering the chromatin structure (Macaluso 
et al., 2003). The role of Histone Deacetylases (HDACs) in endocrine resistance has also 
been attributed to their part in the suppression of ERα co-repressor activity (Legare and 
Basik, 2016), and the use of Histone Deacetylase Inhibitors in BCa therapy is currently 
being explored (Damaskos et al., 2017, Hegedus et al., 2017, Trapani et al., 2017). 
1.6.4 Enhanced growth factor signalling 
Another mechanism thought to drive endocrine resistance is through ligand-
independent stimulation of ERα via activation of growth factor signalling pathways. 
Commonly this involves either the Epidermal Growth Factor (EGFR)/HER-2 or Insulin-
Like Growth Factor (IGFR) Receptor pathways (Abdel-Hafiz, 2017). EGFR is classified 
as a member of the ErbB family of Receptor Tyrosine Kinases, alongside HER-2, and 
EGFR and HER-2, which are known to commonly heterodimerise (Foley et al., 2010). It 
has been suggested that the downstream effects of EGFR and other ErbB signalling 
induces phosphorylation of the ERα co-activator SRC3 and therefore enhances 
oestrogen signalling (Foley et al., 2010).  
GPER1 is a variant of ERα, which has been linked rapid E2 signalling (Liu et al., 
2015, Lipovka and Konhilas, 2016) and much research has suggested the role of GPER1 
in driving endocrine resistance, including through the activation of the EGFR signalling 
pathway (Ignatov et al., 2010, Ignatov et al., 2011). The expression of GPER1 and EGFR 
was found to be directly correlated in metastatic BCa samples. Further, GPER1 
translocation to the cell membrane and subsequent regulation of EGFR signalling has 
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been demonstrated to promote TAM resistance in cell line models (Mo et al., 2013). 
Research has been conducted to investigate the efficacy of the EGFR inhibitor Gefitinib 
in conjunction with endocrine therapy.  However the results showed the that combination 
of these therapeutics provided little benefit compared to endocrine therapy alone (Smith 
et al., 2007, Abdel-Hafiz, 2017, Lluch et al., 2014). This is at least in part believed to be 
due to the lack of clear predictor biomarkers as indicators of response (Abdel-Hafiz, 
2017).  
A recent study demonstrated that the alternative growth factors Fibroblast Growth 
Factors (FGFs), in particular FGF7 (mediated by the Fibroblast Growth Factor Receptor 
FGFR2), can induce proliferation of BCa cells during TAM treatment (Turczyk et al., 
2017). The authors demonstrated that this pathway resulted in alternative post-
translational modifications (via phosphorylation and ubiquitination) to the ERα, resulting 
in its transcriptional activation and receptor degradation, which is not normally induced 
via TAM treatment. Additionally, this FGF7/FGFR2 signalling increased the expression of 
the anti-apoptotic factor B-cell lymphoma 2 (Bcl-2) (Turczyk et al., 2017). FGF7/FGFR2 
signalling also led to PI3K/Akt/mTOR activation (Turczyk et al., 2017). The 
PI3K/Akt/mTOR signalling pathway is involved in cell survival, and is frequently  reported 
to be activated in BCa (Kaklamani and Gradishar, 2017). Therefore, as other mechanisms 
have additionally involved this pathway (Citro et al., 2015) targeting it in conjunction with 
endocrine therapies could be investigated further.  
Alternatively, it has been suggested that growth factors and their receptors could 
act independently of the ERα to drive endocrine resistance, via activating the receptor’s 
target genes and thereby bypassing the ERα signalling pathway (Kaklamani and 
Gradishar, 2017, Osborne and Schiff, 2011, Gluck, 2014). For instance, a study by 
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Moerkens et al. demonstrated that TAM-induced suppression of E2-stimulated BCa cell 
growth could be abrogated via EGFR signalling (Moerkens et al., 2014).  
1.6.5 Non-coding RNA 
Non-coding RNA (ncRNA) are non-protein coding transcripts that can be grouped 
into several subgroups, two of which that have been described as the most important in 
the regulation of gene expression are microRNA and long non-coding RNA (Hayes and 
Lewis-Wambi, 2015). 
MicroRNA (miRNA) is a class of ncRNA that are relatively small (18 - 22 bp in 
size), which post-transcriptionally regulate a gene’s expression via either the inhibition of 
its translation or through the degradation of its transcripts, and their aberrant regulation 
has been associated with endocrine resistance (Muluhngwi and Klinge, 2015, Hayes and 
Lewis-Wambi, 2015). Research has implicated the role of miRNA in promoting endocrine 
resistance through many mechanisms, including: promoting the decreased expression of 
ERα protein (miR-221/222) (Zhao et al., 2008) and adjusting the expression of proteins 
important in the cell cycle, including p27 suppression (miR-221/222 and miR-519a) (Miller 
et al., 2008, Wei et al., 2014). Interestingly, recent research is more focused not on how 
miRNAs drive endocrine resistance, but that the suppression of some miRNAs could 
promote endocrine resistance. Muluhngwi et al. indicated miR-29b-1 to have a tumour 
suppressive role in a cell line model of TAM resistance, whereby its over-expression 
reduced cell growth through the suppression of genes involved in mitochondrial 
bioenergetics (Muluhngwi et al., 2017). Additionally, miR-873 was demonstrated to 
reduce expression of the ERα target gene Cyclin-Dependent Kinase 3 (CDK3). miR-873 
levels were shown to be decreased in a model of TAM resistance, and induced 
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expression of this miRNA enhanced TAM sensitivity (Cui et al., 2015). An further example 
is that the loss of miRNA-200, through p53 mutation in endocrine sensitive cells, can 
promote endocrine resistance through regulation of expression of the oncogene 
Membrane-Organizing Extension Spike Protein (Moesin) (Alam et al., 2017). 
Long non-coding RNA (lncRNA) is an alternative classification of ncRNA that are 
much larger than miRNAs (over 200 bp in size) (Hayes and Lewis-Wambi, 2015). They 
are known to be transcribed from a wide variety of positions on the genome, including 
promoter or enhancer regions of genes or their own unique genomic locations. In contrast 
to miRNAs, lncRNAs have a vast variety of methods for gene regulation, including 
functioning as protein–DNA scaffolds and protein decoys, on top of their role in regulating 
the translation of genes (Hayes and Lewis-Wambi, 2015). Little research has been 
conducted on the role of lncRNAs in endocrine resistance, however, a recent study 
demonstrated that targeting and inhibiting the action of the lncRNA ROR can abrogate 
resistance to TAM treatment (Li et al., 2017). Additionally, lncRNAs (as well as miRNAs) 
have been implicated in progressing endocrine resistance through their regulation of 
Homeobox (HOX) genes, a family of transcription factors with multiple functions, including 
in the regulation of the cell cycle and cellular differentiation (Jin and Sukumar, 2016). 
Therefore, this mechanism may become of more interest. 
1.6.6 Oestrogen Receptor beta 
As described previously (Section 1.4.4), ERβ has been suggested have a tumour 
suppressive role in endocrine sensitive BCa, producing an anti-proliferative effect on BCa 
cells, and a reduction in its expression has been associated with BCa progression and a 
decrease in tumour suppressor proteins such as p53 (Huang et al., 2014, Chuffa et al., 
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2017, Bado et al., 2017, Hartman et al., 2009, Williams et al., 2008, Lu and 
Katzenellenbogen, 2017). However, conflicting results have also been published that 
suggest that ERβ expression in BCa cell lines does not abrogate ERα signalling (Jonsson 
et al., 2014), nor is ERβ expression in tumours correlated with a favourable prognosis in 
endocrine sensitive patients (Tan et al., 2016). Additionally, increasing evidence has now 
associated increased ERβ expression with endocrine resistance and a poorer prognosis 
in ERα-positive patients treated with endocrine therapies (Gao et al., 2005, Speirs et al., 
1999, Guo et al., 2016). However, conflicting studies have indicated ERβ as an indicator 
of positive response to endocrine therapy (Madeira et al., 2013) and low ERβ expression 
has been associated with TAM resistance (Esslimani-Sahla et al., 2004), therefore the 
role of ERβ in endocrine resistance is disputed.  
1.7 Androgen Receptor 
1.7.1 Structure and function 
The Androgen Receptor (AR) is a ligand-dependent NR that applies the functions 
of the male steroid hormones androgens (Rahim and O'Regan, 2017). Androgens are 
involved in the regulation of many functions, including the onset of erythropoiesis, 
metabolism and male sexual differentiation (Murashima et al., 2015, Schweizer and Yu, 
2017). In women, androgens are synthesised in the ovaries, adrenal glands and adipose 
tissues (Rahim and O'Regan, 2017, Schweizer and Yu, 2017). The androgens most 
abundant in circulation in women are Androstenedione (A), Testosterone (T) and 
Dihydrotestosterone (DHT), however of these three, only T and DHT are able to fully 
activate AR (Burger, 2002, Rahim and O'Regan, 2017). The AR protein is 919 amino 
acids in size and is encoded by the AR gene located on chromosome Xq11 (Gao et al., 
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2005, Narayanan and Dalton, 2016). Its structure follows that of most NRs (Figure 1.3.1), 
consisting of an N-terminus, a DBD, and a small hinge region followed by a LBD. Like 
ERα, it contains two activation sites: AF1, which is located in the N-terminus and AF2 that 
is found in the LBD, with the latter being ligand-dependent (Gao et al., 2005, Sever and 
Glass, 2013) (Figure 1.7.1).  
1.7.2 The AR Pathway 
Like ERα, ligand binding to the AR promotes a conformational change promoting 
receptor dimerisation, translocation to the nucleus, binding to Androgen Response 
Elements (AREs) present in the regulatory regions of target genes, and promotes gene 
expression (Figure 1.7.2). AR activity is modulated by interactions with co-repressor and 
co-activator molecules, which are recruited to AREs along with the general transcription 
machinery (Sever and Glass, 2013, Brooke and Bevan, 2009, Dehm and Tindall, 2007). 
 1.7.3 Steroidogenesis and the production of androgens and their relation to 
oestrogens 
Steroidogenesis is highly important in women for the regulation of female sexual 
differentiation and development, and in the consequential functioning of their mammary 
glands and other female organs. The most widely researched hormones in women are 
oestrogens. However, androgens are secreted in significantly higher quantities than 
oestrogens (Burger, 2002). Additionally, it has been indicated that in pre-menopausal 
women AR is actually more highly expressed than ERα and helps to regulate the 
development of the normal functioning mammary gland (Yeh et al., 2003, Fioretti et al.,  
 64 
 
  
Figure 1.7.1 Structural representation of the Androgen Receptor protein and 
gene 
The Androgen Receptor (AR) gene comprises 8 exons. AR is a modular protein 
consisting of two Activation Function sites (AF1 and AF2), an N terminal domain, a 
DNA Binding Domain (DBD), a hinge region and a Ligand Binding Domain (LBD). 
Polyglutamine (PolyGln) and polyglycine (PolyGly) tracts are located in exon 1. 
(Figure is adapted from Gao et al., 2005) 
Protein 
Gene 
Exon Number 1 2 3 4 5 6 7 8 
PolyGln PolyGly 
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Figure 1.7.2 Schematic representation of the AR pathway 
Testosterone enters an androgen-responsive cell and is converted into 
Dihydrotestosterone (DHT) via the action of 5α-reductase. DHT binds to the 
Androgen Receptor (AR). This promotes Phosphorylation (P) and dimerisation 
of AR, which then and binds to specific sequences of DNA within the promoter 
regions of target genes, known as Androgen Response Elements (AREs). Co-
activators bind to AR to promote the recruitment of the General Transcription 
Apparatus (GTA) (Feldman and Feldman, 2001). 
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2014). Androgen production directly affects the ERα pathway, as two of the main 
androgens that are produced in women are precursors for E2: T, which is converted to 
E2 directly by aromatase; and A, which is converted by aromatase to E1, after which it 
can then be used to synthesise E2 via the action of 17β-Hydroxysteroid Dehydrogenase 
(17β-HSD) (Figure 1.7.3) (Kaklamani and Gradishar, 2017, Patani and Martin, 2014, 
Hong and Chen, 2011, Rahim and O'Regan, 2017). 
1.8 AR and Breast Cancer 
1.8.1 AR expression in Breast Cancer 
The AR is more highly expressed than ERα in BCa, being present in 60-90 % of 
cases (Rahim and O'Regan, 2017, Vera-Badillo et al., 2014). For example, IHC 
conducted on BCa tumour samples from 189 patients demonstrated that 80 % of the 
tumours expressed AR, across all of the different disease classifications (Niemeier et al., 
2010). However, one study conducted a large systematic review of BCa research 
between 1946 and 2012, and found that AR expression was much more common in ERα-
positive BCas. They reported that AR expression occurred in 74.8 % of ERα-positive as 
compared to 31.8 % of ERα-negative tumours (Vera-Badillo et al., 2014). A study that 
combined and re-analysed data from nine separate studies, in a total of 663 women who 
proceeded to develop BCa and 1,765 women who did not, displayed that increased 
androgen levels positively correlated with risk of onset of BCa (Key et al., 2002). 
Therefore, research has been conducted into the role of androgens and the AR in women 
with differing BCa subtypes.  
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Figure 1.7.3: Synthesis of oestrogens from androgens 
Schematic representation of the steroidogenic pathways leading to oestrogen 
synthesis (the most highly abundant circulating form being 17-β Oestradiol, E2) from 
androgenic precursors. 17β-HSD indicates 17β-Hydroxysteroid Dehydrogenase and 
CYP3A4 indicates Cytochrome P450 3A4.  
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1.8.2 AR in ERα-positive Breast Cancer 
In ERα-positive disease, AR appears to be an indicator of positive prognostic 
outcome, which has been hypothesised to be due to the AR having an inhibitory effect on 
ERα-driven cancer progression (Rahim and O'Regan, 2017, Fioretti et al., 2014, Tarulli 
et al., 2014). Studies have demonstrated a significant association between AR expression 
in ERα-positive BCa with indicators of a positive clinical outcome, for instance decreased 
tumour size, lower graded tumours and PR expression (Tsang et al., 2014, Niemeier et 
al., 2010). One study found that, in cases of low AR expression (in which less than 75 % 
of cells expressed AR) the risk of patient mortality increased by 4.6-fold (Peters et al., 
2009). Therefore, the ratio of ERα and AR expression and the abundance of their relevant 
ligands has been deemed as potentially important for BCas that are both AR- and ERα-
positive, however this connection is complicated as androgens can be used as precursors 
for oestrogens (Figure 1.7.3) (Rahim and O'Regan, 2017).  
This protective effect of AR in ERα-positive BCa is plausible as androgens are 
known to inhibit breast growth during and following puberty (Tarulli et al., 2014), and 20 
years ago it was demonstrated that over-expression of AR in the MCF7 ERα-positive BCa 
cell line had an inhibitory effect on cell proliferation (Szelei et al., 1997). This was also 
demonstrated in a more recently study, where treatment with DHT and Mibolerone (MIB, 
a synthetic analogue of DHT that cannot be metabolised to oestrogen) inhibited E2-
stimulated cellular proliferation in ERα-positive cell lines MCF7 and T47D, with the effect 
being more pronounced in the T47D cell line which is additionally positive for PR (Cops 
et al., 2008). This tumour suppressive role was confirmed in T47D cells to be directly 
through the action of AR, as additional treatment with Bicalutamide (BIC), an anti-
androgen to inhibit AR action, could reverse this effect (Cops et al., 2008). Additionally, it 
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has been demonstrated that treatment with androgens can induce apoptosis in T47D cells 
(Kampa et al., 2005). 
Several mechanisms through which the AR inhibits oestrogen-induced BCa growth 
have been proposed. Firstly, this has been demonstrated to be brought about by AR 
upregulation of tumour suppressor proteins such as Killin (KKLN), Phosphatase and 
Tensin Homolog (PTEN) and ERβ (Wang et al., 2013, Rizza et al., 2014). One study 
demonstrated that following ligand binding in MCF7 cells, AR induces Dosage-sensitive 
sex reversal, Adrenal hypoplasia critical region, On chromosome X, Gene 1 (DAX-1) 
expression via interacting with an ARE, which resulted in a reduction of aromatase 
expression and activity, supressing cancer progression (Lanzino et al., 2013). 
Furthermore, AR signalling has been shown to enhance the effects of AIs in ERα-positive 
disease. For example, one study in MCF7 cells stably transfected with aromatase 
demonstrated that targeting AR using siRNA or BIC inhibited the anti-proliferative effects 
induced via treatment with the AI Letrozole (Macedo et al., 2006).  
1.8.3 AR and ERα cross-talk  
It has been established that AR and ERα suppress each other’s activity, and this 
cross-talk has been suggested to occur by a variety of alternative mechanisms (Figure 
1.8.1) (Fioretti et al., 2014). Interestingly, it has been demonstrated that AR can supress 
ERα signalling via interaction with EREs (Peters et al., 2009). Using reporter assays, the 
authors demonstrated that AR can potently inhibit ERα activity and only the presence of 
the AR DBD was sufficient for this inhibitory effect (Peters et al., 2009).  
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Figure 1.8.1: Proposed mechanisms of AR and ERα cross-talk from 
current literature 
Studies have demonstrated that Androgen Receptor (AR) and Oestrogen 
Receptor alpha (ERα) suppress each other’s activity by a variety of 
mechanisms: (a) AR can supress ERα signalling via interaction with Oestrogen 
Response Elements (EREs). (b) ERα and AR can heterodimerise, resulting in 
suppression of the transcriptional activity of both receptors. (c) AR and ERα 
pathways overlap, and so oestrogen and androgen antagonise each other’s 
target genes. (d) AR and ERα binding sites are closely located, overlap in 
location or are common for both receptors, so that the binding of one receptor 
could block the other from interacting with a response element, or antagonise 
its desired regulatory effect. (e) The receptors compete for common pioneer 
factors, such as Forkhead Box A1 (FOXA1). (f) AR and ERα compete for 
common co-factors. ARE represents Androgen Response Elements. 
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Yeast and mammalian two-hybrid systems have been used to demonstrate that 
ERα and AR can heterodimerise, resulting in suppression of the transcriptional activity of 
both receptors (Panet-Raymond et al., 2000). ChIP and microarray analyses of the ZR-
75-1 ERα-positive cell line have demonstrated that the regulation of several E2 and DHT 
target genes could be antagonised via their co-treatment, suggesting an overlap of the 
ERα and AR signalling pathways. Need et al. further demonstrated that AR and ERα 
binding sites were often closely located, overlapped or shared for a common gene, which 
indicates that the binding of one receptor could potentially block the other from interacting 
with a response element, or antagonise its desired regulatory effect (Need et al., 2012). 
Additionally, AR and ERα activity is known to be influenced by shared co-factors such as 
Androgen Receptor Co-activator 70 kDa Protein (ARA70) (Fioretti et al., 2014, Lanzino 
et al., 2005). Competition for these limiting factors could also result in inhibitory cross-talk 
between the receptors. Finally, the action of both receptors is highly influenced via the 
pioneer factor FOXA1 (Hurtado et al., 2011, Robinson et al., 2011), which has binding 
sites that overlap substantially with both receptors (Need et al., 2012). These interactions 
between AR and ERα can explain the inhibitory effect displayed by AR on ERα signalling 
in ERα-positive BCa. 
1.8.4 Molecular Apocrine Breast Cancer 
As described previously (Section 1.2.2.3.1), MABC is a sub-classification of ERα-
negative BCas (TNBC or HER-2-Enriched) which express AR and are driven by the AR 
pathway (Fioretti et al., 2014, Badve et al., 2011, Rakha and Green, 2017, Vranic et al., 
2017). MABC was initially defined in 2005 by Farmer et al., who demonstrated these ERα- 
negative AR-positive tumours have increased androgen-signalling with a distinct gene 
expression profile (Farmer et al., 2005). Following this, a study demonstrated that MABC 
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tumours express ERα target genes that are associated with endocrine sensitive disease 
(Doane et al., 2006). They additionally described that the MDA-MB-453 ERα-negative 
and AR-positive BCa cell line displayed androgen-stimulated growth, and that treatment 
of these cells with androgens resulted in the activation of genes that significantly 
overlapped with the oestrogen-associated genes displayed in MABC tumours (Doane et 
al., 2006). The inference of these results is that AR can mimic ERα signalling to promote 
BCa progression in the absence of functioning ERα (Fioretti et al., 2014).  
MABCs are characterised as aggressive tumours and are associated with a poor 
patient prognosis (Lehmann-Che et al., 2013, Liu et al., 2016), as well apocrine 
phenotypical features, a lack of necrosis and a negative correlation with Basal-Like 
markers, for instance Cytokeratin 14 (CK14) (Tsang et al., 2014). Growing evidence has 
emerged to implicate the role of AR in mediating disease progression in MABC patients. 
High AR expression and increased levels of AR signalling have been reported in some 
ERα-negative and AR-positive BCa cell line models, including MDA-MB-453 and 
SUM185PE, and the growth of these cells was decreased following treatment with the 
anti-androgen BIC (Lehmann et al., 2011). Known AR target genes for instance Anterior 
Gradient Protein 2 Homolog (AGR-2) and SAM Pointed Domain Containing ETS 
Transcription Factor (SPDEF) have been found to be significantly upregulated in MABC 
tumours (Lehmann-Che et al., 2013), and AR nuclear localisation has been reported in 
all MABC primary tumours tested (Barton et al., 2015), both suggesting AR transcriptional 
activity. Barton et al. additionally demonstrated that AR upregulates the EGFR ligand 
Amphiregulin (AREG) in AR-positive TNBC cells, which suggests that AR is promoting 
cancer progression at least in part through the EGFR pathway (Barton et al., 2015). The 
authors also demonstrated that AR inhibition via treatment with the anti-androgen 
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Enzalutamide could abrogate proliferation and migration of AR-positive TNBC cell lines 
(Barton et al., 2015). 
It has been demonstrated that the pioneer factor FOXA1 is key for AR function in 
MABC, as silencing this gene inhibits AR binding DNA, cellular proliferation and the 
expression of genes associated with the unique MABC gene signature (Robinson et al., 
2011). Over-expression of FOXA1 was subsequently found to be correlated with MABC 
tumours, however 31 % of Basal-Like tumours also expressed this factor (Lehmann-Che 
et al., 2013). Interestingly, the authors additionally reported that HER2 and/or GCDFP15 
over-expression were also frequent in MABCs, suggesting a potential role of these 
proteins in facilitating the progression of this BCa subtype (Lehmann-Che et al., 2013). In 
addition to this, it has been suggested that AR could promote MABC progression via 
exploiting the PI3K signalling pathway, which has a vital role in cellular proliferation and 
survival. Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha 
(PIK3CA) gene mutations were reported in 19 % of MABC tumours, but absent from 
Basal-Like tumours (Lehmann-Che et al., 2013). Subsequently, Lehmann et al. (2014) 
reported PIK3CA mutations were significantly enriched in AR-positive TNBCs, and the 
authors demonstrated that PI3K inhibitors could have value if administered in combination 
with an AR antagonist in MABC (Lehmann et al., 2014). This suggests that AR and its 
cross-talk with PI3K signalling may be important for promoting cancer progression in this 
subtype of the disease. 
It has been suggested that MABCs should be identified through AR messenger 
RNA (mRNA) and not through IHC, as research from two groups reported that only half 
of tumours which fall into this category by mRNA analysis were identified via IHC (Doane 
et al., 2006, Lehmann-Che et al., 2013). Lehmann-Che et al. therefore proposed 
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combining Real-Time quantitative Polymerase Chain Reaction (qPCR) with IHC of 
GCDFP and HER-2 in order to identify MABC tumours, and demonstrated in their study 
that this correctly identified 94 % of MABC tumours, rather than 58 % through AR IHC 
(Lehmann-Che et al., 2013). AR and HER-2 signalling pathways appear to be closely 
linked (Rahim and O'Regan, 2017) and GCDFP15 is an AR target whose expression has 
been found to be strongly associated with AR expression (Darb-Esfahani et al., 2014). 
An additional study used this proposed IHC staining of HER-2 and GCDFP15 to identify 
MABC tumours, and found that 52 % of the ERα-negative tumours investigated tested 
positive for HER-2/GCDFP/both and were distinct from the other ERα-negative tumours, 
yet only 38 % were AR positive through IHC (Tsang et al., 2014).  
1.8.5 Androgen levels in endocrine resistance 
Research has been suggested that high levels of circulating testosterone are 
associated with BCa that is endocrine sensitive (Secreto et al., 2009). In addition to this, 
several studies have reported that an increase in androgen levels occurs during treatment 
with endocrine therapy. For instance, it has been demonstrated that treatment with the AI 
Exemestane results in an increase in levels of DHT and testosterone in ERα-positive BCa 
tumours (Takagi et al., 2010) and that testosterone levels increased within the serum of 
patients with ERα-positive disease following treatment with the AI Letrozole (Rossi et al., 
2009). In addition to this, increased serum levels of testosterone were reported to be 
significantly associated with patients who developed TAM resistance (Berrino et al., 2005) 
and one group identified the development of growth dependency on 5α-Androstane-3β, 
17β-diol (3β-diol) a metabolite of DHT (converted by 3β-Hydroxysteroid Dehydrogenase 
Type 1, HSD3B1) in endocrine sensitive cells as a potential mechanism of AI resistance 
(Hanamura et al., 2013). However, contradictory reports have indicated that endocrine 
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therapies do not produce this effect, for instance the study conducted by Rossi et al. 
(2009) that indicated increased testosterone levels within patient serum following 
Letrozole treatment, also reported that serum testosterone levels were unaffected 
following TAM treatment (Rossi et al., 2009); but an alternative study reported increased 
androgen levels in plasma following TAM treatment but not AI treatment (Baumgart et al., 
2014). Therefore, role of androgen levels during endocrine treatment and in endocrine 
resistance development are currently unclear. 
1.8.6 AR in endocrine resistance 
It has now been indicated that AR drives some cases of endocrine resistance. 
Several studies conducted by the Fuqua group and others have provided some insights 
into this resistance mechanism (De Amicis et al., 2010, Rechoum et al., 2014, Ciupek et 
al., 2015). Firstly, the Fuqua group conducted a microarray analysis of five tumour 
samples from patients with TAM-resistant disease and four control samples of TAM-
sensitive disease, and identified elevated AR expression in the TAM-resistant samples 
(De Amicis et al., 2010). To recreate this effect in vitro, the group exogenously over-
expressed AR in the MCF7 BCa cell line. In agreement with the data from the clinical 
samples, elevated AR expression promoted TAM resistance, and this effect could be 
abrogated via treatment with the anti-androgen BIC (De Amicis et al., 2010). The study 
also demonstrated that AR over-expression resulted in TAM treatment inducing the 
transcriptional activation of ERα, which was abrogated via BIC, suggesting that AR 
facilitates TAM becoming an agonist in TAM resistance (De Amicis et al., 2010). To 
explore this further, the group demonstrated that AR can facilitate TAM resistance via 
activation of ERα through the EGFR signalling pathway (Ciupek et al., 2015). Ciupek et 
al. demonstrated that TAM acted as an ERα agonist in cells with an AR over-expression, 
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resulting in an increase in its transcriptional activity and cellular proliferation, and this 
effect could be stopped via treatment with the anti-androgen Enzalutamide or the EGFR-
inhibitor Gefitinib (Ciupek et al., 2015). This group previously linked a reduction in Rho 
Guanosine Diphosphate(GDP)-Dissociation Inhibitor (GDI) expression with TAM 
resistance, where they also observed TAM agonist activity (Ciupek et al., 2015, Barone 
et al., 2011). Rho GDI is a negative regulator of the Rho GTPase pathway, which is 
involved in the regulation of many cellular functions including the rearrangement of the 
actin-cytoskeleton and cellular motility, and alterations to this pathway have been 
associated with BCa tumours with features indicating a poor prognosis, for example local 
recurrence (Ciupek et al., 2015, Barone et al., 2011). How this TAM agonist activity occurs 
in these models is currently undetermined, however they proposed that AR signalling and 
Rho GDI resistance mechanisms may be linked to produce this effect (Ciupek et al., 
2015).  
The balance between AR and ERα expression is thought to be important in the 
development of endocrine resistance through AR (Rondon-Lagos et al., 2016). For 
example, it was reported that BCa tumours that have a ratio of AR:ERα of more than 2:1 
are four times more likely to become resistant to TAM than tumours that have a less than 
2:1 ratio (Cochrane et al., 2014, Carreno et al., 2007).   
AR signalling has also been linked to AI resistance. One group stably exogenously 
over-expressed aromatase alone and in combination with AR in MCF7 cells (MCF7 Arom 
and MCF7 AR Arom, consecutively) (Rechoum et al., 2014). Cells were treated with 
androstenedione, an androgen which can be converted into oestrogen via the action of 
aromatase (Figure 1.7.3). Treatment with the AI Anastrazole resulted in the inhibition of 
androstenedione-stimulated proliferation as well as ERα transcriptional activity in the cells 
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which solely over-expressed aromatase, yet had no significant effect in those also over-
expressing AR (Rechoum et al., 2014). They demonstrated that treatment of MCF7 AR 
Arom cells with anti-androgens could increase their sensitivity to Anastrazole, as well as 
treatment with drugs targeting ERα (FULV), Phosphorylated Insulin-like Growth Factor-1 
Receptor (pIGF-1R) or Akt, suggesting the importance of these proteins also in this 
mechanism (Rechoum et al., 2014). AR and ERα appeared to cooperate in this 
mechanism of AI resistance, and MCF7 Arom and MCF7 AR Arom had differentially 
expressed ERα and AR target genes compared to MCF7 cells, which implies that treating 
patients that are both ERα- and AR-positive with anti-androgens as well as anti-
oestrogens could be beneficial (Rechoum et al., 2014). In accordance with these results, 
a different research group performed IHC on tissue samples from BCa patients who had 
recurrence and developed AI resistance following surgery (Fujii et al., 2014). Tissue 
sections were obtained during the initial surgery and following recurrence. The authors 
reported that the recurrent tissues had a significant decrease in ERα and PR expression, 
and an increase in Prostate Specific Antigen (PSA) expression. Additionally, elevated AR 
expression was demonstrated in the recurrent tissues from 62 % of patients, although 
this was not significant (P=0.22) (Fujii et al., 2014). They created a model of AI resistance 
by growing T47D cells in hormone-depleted media.  These cells were subsequently found 
to have a loss of ERα expression and oestrogen responsiveness, and increased AR 
expression and AR signalling (Fujii et al., 2014). Interestingly, however, the same 
research group linked AI resistance to androgens activating ERα and decreased AR 
expression (Hanamura et al., 2013).  
An alternative study has indicated the importance of Prosaposin (PSAP) in AR 
driving the growth of cell line models of AI and TAM resistance (Ali et al., 2015). This 
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study demonstrated that PSAP stimulates cell migration and can promote AR recruitment 
to HREs in AI resistant cells, and that treatment with the anti-androgen Enzalutamide 
could abrogate AR activation of PSAP (Ali et al., 2015). The authors identified a significant 
increase in PSAP levels in the serum of BCa patients prior to surgery who experienced 
subsequent recurrence, and suggested the use of PSAP as a biomarker in endocrine 
therapy treated patients to potentially identify those likely to develop resistance as a result 
of AR signalling (Ali et al., 2015).  
In light of this, work carried out by the Brooke group has displayed that AR levels 
are increased in some models of endocrine resistance and that AR promotes the 
proliferation of endocrine resistant cell lines (Fioretti and Brooke, unpublished). 
Therefore, the AR could become a potential new drug treatment in BCa patients who 
have TNBC or endocrine resistant ERα-positive BCa. 
1.9 Targeting AR in cancer 
1.9.1 Prostate Cancer 
Much knowledge of the AR and how to therapeutically target it comes from studies 
in Prostate Cancer (PCa). Cancer of the prostate, an important constituent of the male 
reproductive system, is currently the most prevalent cancer in men in the UK, contributing 
to approximately 26 % of all male cancer diagnoses (Cancer research UK, 2014c). It is 
well established that AR drives PCa growth and progression through activation of the AR 
pathway (Brooke and Bevan, 2009, Crumbaker et al., 2017).  
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1.9.2 Anti-androgens and their use in Prostate Cancer 
Approximately 25 % of PCa cases are confined to the prostate gland (Brooke and 
Bevan, 2009). In these cases active surveillance, followed by radical prostatectomy, 
external-beam radiotherapy or brachytherapy is the preferred treatment option (Attard et 
al., 2016, Brooke and Bevan, 2009). However, for the remaining 75 % of cases the 
disease will have advanced locally further than the prostate capsule, or metastasised, 
and hence surgery is no longer possible (Brooke and Bevan, 2009). In these cases, 
endocrine therapy is often used to block the AR pathway. This consists of chemical 
castration, where analogues of Luteinizing Hormone-Releasing Hormone (LHRH, e.g. 
Leuprolide and Goserelin) block the androgen synthesis through the pituitary-
hypothalamus signalling axis (Brooke and Bevan, 2009, Pelekanou and Castanas, 2016). 
This form of chemical castration effectively decreases circulatory testosterone levels, 
however it is much less effective at decreasing the concentration of adrenally produced 
androgen precursors, for instance Dehydroepiandrosterone (DHEA), which can be 
converted to DHT. Therefore this therapy is commonly combined with anti-androgens, 
ligands that interact with the AR and keep it in an inactive form (Brooke and Bevan, 2009, 
Gillatt, 2006). Originally, the steroidal anti-androgen Cyproterone acetate was 
administered to patients (Culig, 2014). Since, non-steroidal anti-androgens have been 
developed, including first generation anti-androgens such as BIC and Flutamide, as well 
as the second generation anti-androgen Enzalutamide (Pelekanou and Castanas, 2016). 
Enzalutamide has a higher relative binding affinity for AR than BIC (Culig, 2014). It differs 
from the first generation anti-androgens as it halts the AR pathway via not only competing 
with ligands to block AR action, but it additionally stops AR nuclear translocation and AR 
interaction with DNA and co-factors (Nadal and Bellmunt, 2016, Rahim and O'Regan, 
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2017). Interestingly, it has also been demonstrated that the anti-oestrogen FULV can 
reduce AR signalling and androgen-induced proliferation in the LNCaP PCa cell line 
(Bhattacharyya et al., 2006). Therefore, treatment options are readily available which 
target the AR pathway, which could be repurposed for the treatment of endocrine resistant 
BCa. 
1.9.3 Administration of androgens in Breast Cancer therapy 
It is well established that steroidal androgens can result in breast tumour 
regression, and their administration was utilised in BCa patients in 1940s prior to the 
development of anti-oestrogens and AIs (Tarulli et al., 2014, Narayanan and Dalton, 
2016). Steroidal androgens were reviewed to result in tumour regression in patients by 
30–50 %, with the effects being more significant in AR-positive BCas (Tarulli et al., 2014, 
Narayanan and Dalton, 2016). The movement to oestrogen-targeting therapies came as 
a result of the masculine side-effects associated with using androgens for treatment, and 
the realisation that through steroidogenesis androgens could be precursors to oestrogens 
(Narayanan and Dalton, 2016, Garay et al., 2012).  
Clinically, the administration of androgens in BCa therapy appears to have begun 
with the use of the synthetic steroidal androgen Fluoxymesterone and the progestin 
Medroxyprogesterone acetate which has reported androgenic properties (Africander et 
al., 2014, Ghatge et al., 2005). Both of these compounds have demonstrated inhibition 
on BCa proliferation, and were subsequently found to enhance the effects of TAM 
treatment (Reviewed: Narayanan and Dalton, 2016). The aim behind this treatment is to 
activate the AR to promote inhibitor cross-talk with ERα. 
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1.9.4 Anti-androgens in Molecular Apocrine disease and endocrine resistance 
As discussed previously (Section 1.8.4), in contrast to ERα-positive disease, AR 
expression in MABC can drive tumour growth (Fioretti et al., 2014, Badve et al., 2011, 
Rakha and Green, 2017, Vranic et al., 2017), and evidence now supports the hypothesis 
that AR can drive endocrine resistance (Section 1.8.6). The anti-androgen Flutamide was 
previously tested on advanced and metastatic BCa patients in 1988 and showed no 
clinical benefit, however molecular subtype was not into consideration (Rahim and 
O'Regan, 2017, Zhao and He, 1988, Perrault et al., 1988). Therefore, clinical trials have 
now been conducted which have been selective in identifying MABC patients, and have 
shown promising results. For instance, one study identified AR expression in 51 out of 
424 patients (12 %) with TNBC. These AR-positive patients were consequently enlisted 
in a Phase II clinical trial for daily treatment with the anti-androgen BIC. A complete/partial 
response or stable disease was observed in 19 % of these patients after 6 months of 
treatment, and across all patients who received BIC treatment few adverse side-effects 
were seen and none serious (mainly grade I toxicities, including fatigue and hot flushes) 
(Gucalp et al., 2013). However, as this therapy was not beneficial in all the AR-positive 
patients, other pathways are presumably driving tumour growth and therefore further 
research is needed to understand this more fully. Additionally, a case study was recently 
published describing an AR-positive patient with metastatic TNBC, who had been 
undergoing palliative chemotherapy, who subsequently displayed a complete response 
to BIC following 4 months of treatment and remained in remission for at least 12 months 
(Arce-Salinas et al., 2016).  
Current on-going clinical trials with anti-androgens can be observed in Table 1.9.1. 
In particular Enzalutamide, alone and in combinations with other drugs, is being trialled  
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Drug Subtype Reference 
Bicalutamide ER-, PR-, AR+, metastatic  NCT00468715 
Enobosarm ER+ and AR+ 
NCT02463032,  
NCT02746328 
Enobosarm ER+ metastatic NCT01616758 
Enobosarm TNBC, AR+, advanced NCT02368691 
Enobosarm (and pembrolizumab) TNBC, AR+, metastatic NCT02971761 
Enzalutamide (alone and with 
Exemestane) 
1:Primary, ER+ 
2: Primary, TNBC, AR+ 
NCT02676986 
Enzalutamide (and with Paclitaxel) TNBC, AR+ NCT02689427 
Enzalutamide (and with Fulvestrant) ER+, HER-2-, Advanced NCT02953860 
Enzalutamide (alone and with 
Exemestane/Fulvestrant/Anastrazole: 
Phase I) 
AR+, incurable NCT01597193 
Enzalutamide TNBC, AR+ NCT01889238 
Enzalutamide (with Exemestane) ER+ or PR+ or both NCT02007512 
Enzalutamide Early stage, AR+, TNBC NCT02750358 
Enzalutamide (alone and with 
Paclitaxel) 
TNBC NCT02929576 
Enzalutamide (and with Fulvestrant) 
Preoperative 
ER+, HER-2- NCT02955394 
Enzalutamide (and with 
Trastuzumab) 
AR+, HER-2+, 
advanced/metastatic 
NCT02091960 
Enzalutamide (and with Taselisib) TNBC, AR+ NCT02457910 
Table 1.9.1 A summary of current clinical trials that are 
recruiting/ongoing/awaiting published results targeting Androgen 
Receptor (AR) in different molecular subtypes of Breast Cancer  
Results obtained from ClinicalTrials.gov. Trials are Phase II unless 
otherwise stated. 
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in BCa patients, including in patients with incurable and advanced disease, some of whom 
have presumably failed to respond or developed resistance to endocrine therapies. A 
clinical trial has been recently published, which investigated the pharmacokinetic 
interactions, safety, and tolerability of the use of Enzalutamide and established the correct 
dosage for its use in combination with endocrine therapy (for patients with less advanced 
cancer) and as a singular treatment (for patients with more advanced cancer) for ERα- 
and PR- positive BCa patients (Schwartzberg et al., 2017). The authors suggested that 
as well as targeting AR, Enzalutamide could aid endocrine therapy via inducing 
Cytochrome P450 3A4 (CYP3A4), a protein which often metabolises endocrine therapies. 
The results demonstrated that Enzalutamide was safe and generally well-tolerated in BCa 
patients, and that the pharmacokinetic interactions of Enzalutamide treatment alone was 
comparable to male patients with PCa. They additionally reported that Enzalutamide 
treatment in combination with the AI Exemestane would require doubling the 
concentration of Exemestane administered (Schwartzberg et al., 2017). However, the 
authors did not explore clinical benefit. Additionally, Enzalutamide is showing much 
promise in various other tumour types, for example Ovarian, Primary Peritoneal and 
Fallopian Tube Cancer (ClinicalTrials.gov Identifier: NCT01974765), and therefore the 
results of these further trials outlined in Table 1.9.1 will provide further insight into whether 
targeting AR therapeutically with Enzalutamide is of benefit to ERα- positive and negative 
BCa patients expressing AR. 
In addition, Selective Androgen Receptor Modulators (SARMs) have been 
developed, which can act as agonists or antagonists specifically in for example breast, 
muscle and bone (Narayanan and Dalton, 2016). The novel SARM Enobosarm has 
received a lot of interest (Dobs et al., 2013). For instance, one study indicated that 
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Enobosarm treatment of an MABC xenograft model (MDA-MB-453-AR cells) reduced 
tumour proliferation and size, and decreased metastasis-promoting paracrine factors, 
such as Interleukin 6 (IL6) (Narayanan et al., 2014). A case study on a patient with ERα-
, PR- and AR- positive disease who was enrolled in a recent clinical trial for treatment 
with Enobosarm, demonstrated the first incidence of a positive clinical response to a 
SARM following failure and developed resistance to a vast number of ERα-targeted 
endocrine therapies (Vontela et al., 2017). As Enobosarm can interact with aromatase 
and 5α-reductase but cannot be metabolised by them, Vontela et al. suggested therefore 
that as well as acting as an anti-androgen in postmenopausal patients with ERα-positive 
BCa, it could potentially decrease E2 synthesis via directly competing with oestrogen-
precursors (Vontela et al., 2017). Currently, many clinical trials are investigating the 
efficacy of Enobosarm, for instance to explore its benefit in metastatic and locally 
advanced cases of ERα-positive and AR-positive BCa, as well as MABC (Table 1.9.1). 
The SARM is additionally being trialled for ERα-positive disease, as it may have benefit 
to patients who experience alternative endocrine resistance pathways to AR signalling.  
Additionally, targeting AR through treatments other than anti-androgens, could 
prove useful in some AR-positive BCa patients. Abiraterone Acetate (AA), a 17α-
hydroxylase and CYP17 inhibitor (and thereby an androgen synthesis inhibitor, often 
used for treatment in castrate-resistant PCa patients), was used in a Phase II clinical trial 
in AR-positive TNBC patients, in combination with Prednisone (Bonnefoi et al., 2016). 
Prednisone was combined with AA in order to try and prevent secondary 
mineralocorticoid excess, and to try and enhance the effect of AA treatment due to the 
well-established link of Prednisone to decreasing androgen production in PCa patients 
(Tannock et al., 1989, Auchus et al., 2014, de Bono et al., 2010, Bonnefoi et al., 2016). 
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Bonnefoi et al. demonstrated that 20 % of patients enrolled in this study experienced a 
clinical benefit within 6 months of the start of the trial, including one patient with a 
complete response (Bonnefoi et al., 2016). Currently, more clinical trials are underway in 
BCa patients with AA, including one with ERα- or AR-positive metastatic BCa patients 
(ClinicalTrials.gov Identifier: NCT00755885) and one specifically for ERα-positive 
patients who have relapsed following AI treatment (ClinicalTrials.gov Identifier: 
NCT01381874). Furthermore, Seviteronel, a CYP17A1 inhibitor that is also being trialled 
in PCa patients, is being explored for ERα-positive as well as AR-positive TNBC patients 
(ClinicalTrials.gov Identifiers: NCT02130700, NCT02580448). 
1.10 Project objective 
Clinical trials have demonstrated that targeting androgen signalling can have a 
good response in some BCa patients, but not others. Therefore, there is a need to better 
understand why some patients respond better to this treatment method than others. 
Further, it is important to identity methods to stratify patients into those that are more likely 
to benefit from such therapies. In order to do this, we need to better understand the role 
of the AR in BCa and its role in endocrine resistance, so that we can identify how to better 
use current therapeutics. Therefore, the aim of this project is to explore the hypothesis 
that there is a clinical benefit in therapies that target the AR to prevent the development 
of endocrine resistance and for a subset of patients who have developed endocrine 
resistance. 
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Chapter 2: Materials and Methods 
The research in this thesis was conducted ethically. 
2.1 Reagents, general media, buffers and solutions 
 
Name Recipe Sterilisation Storage 
General stock solutions 
1 % Bovine serum 
albumin (BSA) in 
PBS-T (1 % BSA-
PBS-T) 
0.1 g BSA lyophilised powder (Sigma-
Aldrich) in a total volume of 10 mL PBS-
T. 
0.22 µm filter 
sterilise 
4 °C, used 
within 24 
hrs of 
making 
0.08 % Crystal violet 32 mg crystal violet (Sigma-Aldrich) in 
a final volume of 40 mL double distilled 
water (ddH2O). 
0.22 µm filter 
sterilise 
RT 
0.5 M 
Ethylenediaminetet-
raacetic acid (EDTA) 
186.12 g EDTA disodium salt (Fisher 
Scientific) to a final volume of 1 L using 
ddH2O, adjusted to pH 8.0 using 5 M 
NaOH stock solution. 
N/A RT 
4 M Hydrochloric 
acid (HCl) 
19.6 mL of 32 % HCl (Fisher Sceintific) 
with 30.4 mL of ddH2O. 
N/A RT 
4 % 
Paraformaldehyde 
(PFA) 
4 g of PFA (Sigma-Aldrich) dissolved in 
PBS to a final volume of 100 mL, whilst 
heated on a stirring plate within a fume 
cupboard. 
N/A -20 °C, in 5-
10 mL 
aliquots 
1 x Phosphate 
buffered saline 
(PBS) 
10 (Dulbecco A) tablets (Oxoid Limited) 
dissolved in ddH2O to a final volume of 
1 L.  
Autoclave RT 
PBS-0.1 %-Tween 
(PBS-T) 
0.5 mL of Tween®-20 (Sigma-Aldrich) 
in a total of 500 mL PBS. 
N/A 4 °C 
0.2 M 
Phenylmethanesul-
phonylfluoride 
(PMSF) 
0.35 g of PMSF (Sigma-Aldrich) to a 
total of 10 mL using ddH2O. 
N/A -20 °C 
5 M Sodium 
hydroxide (NaOH) 
20 g of NaOH pellets (Fisher Scientific) 
to a final volume of 100 mL with ddH2O. 
N/A RT  
Agarose gel electrophoresis 
1 % and 1.4 % 
Agarose gels 
1 g (1 %) or 1.4 g (1.4 %) of agarose 
(Fisher Scientific) dissolved in 100 mL 
of 1 X TAE via boiling. This is briefly 
allowed to cool prior to the addition of 
5 µL of ethidium bromide (10 mg/mL, 
Sigma-Aldrich) and casting. For 
analysis of ChIP sonication, a more 
N/A RT, or 
gels can 
be 
wrapped 
and stored 
at 4 °C 
Table 2.1.1: Preparations of reagents, general media, buffers and solutions 
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fine-tooth comb was utilised than for 
general applications. 
O/N if 
necessary 
Name Recipe Sterilisation Storage 
1 X Tris-acetate-
EDTA (TAE) 
 
40 mM Tris base (4.846 g, Fisher 
Scientific), 1.114 mL glacial acetic acid 
(Fisher Scientific) and 1 mM EDTA (2 
mL of 0.5 M stock), in a total of 1 L 
ddH2O. 
N/A RT 
Bacterial culture 
100 mg / mL 
Ampicillin stock 
1 g ampicillin sodium salt (Sigma-
Aldrich) to a final volume of 10 mL 
ddH2O. Added to LB broth/agar to a 
final concentration of 100 µg/mL. 
0.22 µm filter 
sterilise 
-20 °C in 1 
mL aliquots 
1 M Glucose stock 90.08 g of Glucose (Fisher Scientific) 
in a final volume of 500 mL ddH2O. 
0.22 µm filter 
sterilise 
RT 
20 mg / mL 
Isopropyl β-D-1-
thiogalactopyranosi
de (IPTG) stock 
200 mg of IPTG powder (Sigma-
Aldrich) dissolved to a final volume of 
1 mL in ddH2O. 
N/A -20 °C in 50 
µL aliquots 
50 mg / mL 
Kanamycin stock 
0.5 g kanamycin (Sigma-Aldrich) 
added to LB broth/agar to a final 
concentration of 50 µg/mL. 
0.22 µm filter 
sterilise 
-20 °C in 1 
mL aliquots 
Luria Broth (LB)
  
 
20 g LB (Lennox, larger granules, 
Fisher Scientific) dissolved in a total of 
1 L of ddH2O, with the pH adjusted to 
7.2 where necessary. Supplemented if 
required using antibiotics.  
Autoclave 4 °C 
LB Agar plates
  
8.75 g of LB Agar (Sigma-Aldrich) to a 
final volume of 250 mL ddH2O, 
supplemented if required with 
antibiotics. Melted prior to use and 
poured to make agar plates whilst still 
molten. 
Autoclave 4 °C 
LB/ampicillin/IPTG/X
-gal plates 
Mix 40 µL Xgal stock solution with 4 
µL of IPTG stock solution per plate. To 
a prepared LB Agar plate 
supplemented with ampicillin 
(equilibrated to RT after 4 °C storage), 
spread 44 µL of Xgal-IPTG solution 
over the plate surface, and leave to 
dry agar side up at 37 °C for 
approximately 2 hrs prior to use. 
N/A Prepared 
immediately 
before use 
1 M Magnesium 
chloride (MgCl2) 
stock 
101.655 g of MgCl2 (Fisher Scientific) 
in a final volume of 500 mL ddH2O. 
 
Autoclave RT 
1 M Magnesium 
sulphate (MgSO4) 
stock 
120.366 g of MgSO4 (Fisher Scientific) 
in a final volume of 500 mL ddH2O. 
 
 
Autoclave RT 
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Name Recipe Sterilisation Storage 
Super Optimal Broth 
(SOB) media 
20 g of Tryptone (Oxoid), 5 g of Yeast 
Extract (Oxoid), 0.58 g of Sodium 
chloride (10 mM, NaCl, Sigma-
Aldrich), 0.18 g Potassium chloride 
(2.5 mM, KCl, Sigma-Aldrich), 10 mL 
of 1 M MgCl2 stock (10 mM) and 10 
mL of 1M MgSO4 stock (10 mM), 
dissolved in ddH2O up to 1 L. 
Autoclave 4 °C 
Super 
Optimal broth with 
Catabolite 
repression (SOC) 
media 
20 g of Tryptone (Oxoid), 5 g of yeast 
extract (Oxoid), 0.58 g of NaCl (10 
mM, Sigma-Aldrich), 0.18 g KCl (2.5 
mM, Sigma-Aldrich), 10 mL of 1 M 
MgCl2 stock (10 mM), 10 mL of 1M 
MgSO4 stock (10 mM), and 20 mL of 1 
M Glucose stock, dissolved in ddH2O 
up to 1 L. 
Autoclave 
(prior to 
adding 
glucose) 
4 °C 
20 mg/mL 5-Bromo-
4-chloro-3-indolyl β-
D-galactopyranoside 
(X-gal) stocks 
100 mg of X-gal powder (Sigma-
Aldrich) dissolved to a final volume of 
5 mL in DMSO (Sigma-Aldrich). 
N/A -20 °C in 
120 µL 
aliquots, 
kept in the 
dark 
Mammalian cell culture 
Cell line/s Media Supplements Storage 
Normal culture media 
MCF7, COS-1 Dulbecco's 
Modified Eagle's 
Medium (DMEM) 
(Gibco®, Life 
TechnologiesTM) 
Per 500 mL of media: 50 mL Foetal bovine 
serum (10% FBS, Hyclone®, Thermo 
Scientific); 5 mL of L-Glutamine-Penicillin-
Streptomycin solution (Sigma-Aldrich) 
resulting in a final concentration of 2 mM L-
glutamine, 100 U penicillin and 0.1 mg/mL 
streptomycin, henceforth described as L-
Glutamine-PenStrep. 
4 oC, once 
made 
used 
within 1 
month. 
ZR-75-1, T47D Roswell Park 
Memorial 
Institute medium 
(RPMI) (Lonza) 
Per 500 mL of media: 50 mL (10 %) FBS 
(Hyclone®, Thermo Scientific) and L-
Glutamine-PenStrep. 
4 oC, once 
made 
used 
within 1 
month. 
MCF7-TAMR, 
MCF7-LTED, 
MCF7-FULVR 
Phenol-red free 
DMEM (Gibco®, 
Life 
TechnologiesTM) 
Per 500 mL of media: L-Glutamine-
PenStrep and 50 mL (10 %) Double 
charcoal Stripped Foetal calf serum (FCS, 
First Link (UK) Ltd.) that was treated via 
overnight gentle mixing at 4 oC with 5 g of 
dextran coated charcoal (Sigma-Aldrich) 
per 500 mL of FCS which is then removed 
via filtration. This form of FBS is henceforth 
described as stripped FCS (SFCS). 
 
 
4 oC, once 
made 
used 
within 1 
month. 
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Cell line/s Media Supplements Storage 
T47D-TAMR, 
T47D-LTED 
 
 
Phenol-red free 
RPMI (Gibco®, 
Life 
TechnologiesTM) 
Per 500 mL of media: L-Glutamine-
PenStrep and 50 mL (10 %) SFCS. 
4 oC, once 
made 
used 
within 1 
month. 
Hormone-depleted culture media 
MCF7, MCF7-
TAMR, MCF7-
LTED, 
MCF7-FULVR 
Phenol-red free 
DMEM (Gibco®, 
Life 
TechnologiesTM) 
Per 500 mL of media: L-Glutamine-
PenStrep and 25 mL (5 %) SFCS. 
4 oC, once 
made 
used 
within 1 
month. 
ZR-75-1, T47D, 
T47D-TAMR, 
T47D-LTED 
Phenol-red free 
RPMI (Gibco®, 
Life 
TechnologiesTM) 
Per 500 mL of media: L-Glutamine-
PenStrep and 25 mL (5 %) SFCS. 
4 oC, once 
made 
used 
within 1 
month. 
COS-1 Phenol-red free 
DMEM (Lonza) 
Per 500 mL of media: L-Glutamine-
PenStrep and 10 mL (2 %) SFCS 
4 oC, once 
made 
used 
within 1 
month. 
Freezing media 
MCF7, COS-1, 
ZR-75-1, T47D 
 
90 % FBS, 10 % 
Dimethyl 
sulphoxide 
(DMSO, Sigma-
Aldrich). 
N/A -20 oC, in 
10 mL 
aliquots.  
MCF7-TAMR, 
MCF7-LTED, 
MCF7-FULVR, 
T47D-TAMR, 
T47D-LTED 
90 % SFCS, 10 
% DMSO 
(Sigma-Aldrich). 
N/A -20 oC, in 
10 mL 
aliquots. 
 
Name Recipe Sterilisation Storage 
Transfections 
N,N-Bis(2-
hydroxyethyl)-2-
aminoethanesulpho
nic acid (BES)-
buffered saline 
(BBS) 2 x solution 
50 mM BES (10.66 g, Sigma-Aldrich), 
280 mM NaCl (16.36 g, Sigma-
Aldrich), 1.5 mM Sodium phosphate 
dibasic (Na2HPO4, 0.21 g, Sigma-
Aldrich), to a final volume of 1 L using 
ddH2O, adjusted to pH 6.95 using 5 M 
NaOH stock solution. 
0.22 µm filter 
sterilise 
-20 °C, in 
50 mL 
aliquots 
2.5 M Calcium 
Chloride (CaCl2) 
138.73 g of anhydrous granular CaCl2 
(Sigma-Aldrich) to a total of 500 mL in 
ddH2O. 
 
0.22 µm filter 
sterilise 
-20 °C, in 
50 mL 
aliquots 
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Western blotting 
Name Recipe Sterilisation Storage 
10 % Ammonium 
persulphate (APS) 
1 g of APS (Sigma-Aldrich) dissolved 
in a total volume of 10 mL ddH2O. 
N/A -20 °C, in 
160 µL 
aliquots 
Blocking solution 2.5 g (5 %) dried skimmed milk 
powder (Marvel) to a total of 50 mL in 
PBS-T. 
N/A 4 °C, used 
within 24 
hrs. 
10 % 
Polyacrylamide Gel 
Per gel, a 10 % resolving gel was 
made, consisting of 1.65 mL 
Acrylamide/Bis-acrylamide 30 % 
solution (Sigma-Aldrich), 1.9 mL of 1 
M Tris/HCl at pH 8.9, 1.4 mL of ddH2O 
and 50 µL of 10 % SDS. Immediately 
prior to pouring, 10 µL of 10 % APS 
stock and 2.5 µL N,N,N’,N’-
Tetramethylethylenediamine (TEMED, 
Sigma-Aldrich) were added. 
Additionally a stacking gel was made, 
consisting of 425 µL of 
Acrylamide/Bis-acrylamide 30 % 
solution (Sigma-Aldrich), 937.5 µL of 1 
M Tris/HCl at pH 6.8, 1.0875 mL of 
ddH2O and 25 µL of 10 % SDS. 
Immediately prior to pouring, 10 µL of 
10 % APS and 2.5 µL TEMED were 
added. 
N/A 4 °C, kept 
moist and 
used within 
a week. 
Radioimmunopreci-
pitation assay 
(RIPA) buffer 
0.5 mL of 1 M Tris-Cl (pH 8.0) stock 
(10 mM), 20 mg of EDTA (1 mM, 
Fisher Scientific), 0.5 mL of Triton X-
100 (1 %, Sigma-Aldrich), 50 mg of 
Sodium deoxycholate (0.1 %, Sigma-
Aldrich), 0.5 mL of 10 % SDS stock 
solution (0.1 %) and 0.41 g of NaCl 
(Sigma-Aldrich). 
Supplemented with 5 µL of 0.2 M 
PMSF stock and 10 µL of Halt 
Protease Inhibitor (PI) Cocktail 
(ThermoScientific) per 1 mL of RIPA 
just prior to use. 
0.22 µm filter 
sterilise 
4 °C 
1 x Running Buffer 3 g of Tris base (25 mM, Fisher 
Scientific), 14.45 g of Glycine (0.2 M, 
Fisher Scientific) and 0.5 g of SDS 
(0.05 %, Fisher Scientific) were 
dissolved in a total volume of 1 L 
ddH2O.  
N/A RT 
10 % Sodium 
dodecyl sulphate 
(SDS) 
50 g of SDS (Fisher Scientific) 
dissolved in a total volume of 500 mL 
ddH2O. 
 
N/A RT 
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Name Recipe Sterilisation Storage 
Semi-Dry Transfer 
Buffer 
5.63 g Glycine (150 mM, Fisher 
Scientific), 1.22 g Tris base (20 mM) 
and 100 ml of Methanol (20 %, MeOH, 
Fisher Scientific), dissolved in a total 
volume of 500 mL ddH2O. 
N/A 4 °C, used 
within 1 
month 
1 M Tris 12.114 g of Tris base (Fisher 
Scientific) dissolved to a final volume 
of 100 mL, adjusted to pH 6.8/8.0/8.9 
using 4 M HCl stock solution. 
Autoclave RT 
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2.2 Bacterial cultures, transformation and DNA preparation 
2.2.1 Bacterial strains and cultures 
For transformation procedures using ligated vectors, the max efficiency DH5α 
(Invitrogen) strain of competent Escherichia coli (E. coli) was utilised. JM109 High 
Efficiency competent cells were selected for cloning with the pGEM®-T Easy Vector 
system (Promega) (Section 2.3). All bacterial work was conducted under sterile 
conditions, and where bacterial suspensions were incubated with shaking, this was 
conducted at 225 rpm. 
2.2.2 Transformation  
DH5α cells were transformed using the standard protocol outlined by Invitrogen 
with a few minor adjustments. In brief, 50 μL of DH5α cells were thawed on ice and gently 
mixed with 50 ng of plasmid DNA. The mixture was incubated on ice for 30 mins before 
heat shocking for 45 secs using a 42 ºC water bath. The cells were immediately incubated 
on ice for a further 2 mins and then incubated in 950 μL of pre-warmed SOC media for 1 
hr at 37 oC with shaking as a recovery period. The required volume of cell suspension 
was spread onto LB Agar plates with the appropriate antibiotic selection 
(ampicillin/kanamycin) (Table 2.1) and incubated overnight (O/N) at 37 oC.  
2.2.3 DNA preparation 
A single transformed bacterial colony was selected from each bacterial plate using 
a pipette tip sterilised by autoclaving. This was used to inoculate 5 mL of LB 
 93 
 
supplemented with the appropriate antibiotic for 12 hrs (37 oC, with shaking). Initially, 
small scale isolation of plasmid DNA was conducted using the Plamid Miniprep Kit 
(Qiagen), following the standard protocol. DNA harvested in this way was used for 
plasmid verification via sequencing (Source Bioscience) if cloning was conducted, or 
through a diagnostic digestion using fast digestion restriction enzymes (Thermo 
Scientific), according to the manufacturer’s guidelines, assessed via 1 % agarose gel 
electrophoresis (Table 2.1). Glycerol stocks of plasmids were created by combining 200 
µL of glycerol (Fisher Scientific) with 800 µL of cell suspension from a bacterial culture 
and stored at -80 oC. 
Isolation of plasmid DNA was subsequently conducted on a larger scale. Initially, 
glycerol stocks were streaked onto LB Agar plates (with the correct antibiotic selection) 
and grown O/N. Again, a single bacterial colony was used to inoculate 5 mL of LB broth 
supplemented with the appropriate antibiotic, this time for 16 hrs (37 oC, with shaking). 
This suspension was transferred to 200 mL of LB and incubated O/N (37 oC, with 
shaking). Plasmids were harvested using the Plasmid Midiprep Kit (Qiagen), according 
to the standard protocol. Following mini and midi DNA preparation, the NanoDrop® ND-
1000 UV/VIS Spectrophotometer (Nanodrop, LabTech) was used to quantify the plasmid 
concentration and assess purity, according to the manufacturer’s guidelines.  
 
  
 94 
 
2.3 Plasmids 
 
  
 
Plasmid 
 
Source/Reference 
pSV-AR (Brinkmann et al., 1989) 
Bos-β-galactosidase C. Bevan 
pGL3-TAT-GRE-LUC (ARE-luciferase) (Jenster et al., 1997) 
3 x ERE TATA LUC (ERE-luciferase) Addgene 
pSG5-ERα M. Parker 
pSG5-Empty Stratagene 
pGL4.18 Promega 
pGL4.18-ERE-19,247-18,610 R.A. Bryan/ G. Brooke 
pGL4.18-ERE-18,889-18,783 R.A. Bryan/ G. Brooke 
pGL4.18-ERE+150,441-758 R.A. Bryan/ G. Brooke 
pGL4.18-ERE+151,438-726 R.A. Bryan/ G. Brooke 
pEGFP-NI-AR G. Brooke 
pcDNA3.1-RFP-ERα R.A. Bryan/ G. Brooke 
 
  
Table 2.3.1 Plasmids used throughout this study 
The source or reference of these primers is indicated. 
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2.3.1 Cloning 
Identified EREs in the AR promoter were cloned for intended use with luciferase 
reporter assays and ERα was cloned into the pcDNA3.1-Red Fluorescent Protein (RFP) 
plasmid for use with fluorescence microscopy. Initially, the ERE sites and ERα sequence 
were amplified by PCR using REDTaq® ReadyMix™ PCR Reaction Mix (Sigma-Aldrich), 
with primers designed to add either KpnI and XhoI (ERE+150,441-758 and ERE+151,438-726), 
KpnI and BglII (ERE-19,247-18,610 and ERE-18,889-18,783) or BamHI and EcoRI (ERα-RFP) 
restriction sites (Table 2.3.2). Amplified regions for the ERE suites were sub-cloned into 
the pGEM®-T Easy Vector (Promega) and transformed into JM109 High Efficiency 
Competent cells, according to the manufacturer’s guidelines. Transformation cultures 
were spread onto prepared LB/ampicillin/IPTG/X-Gal plates (Table 2.1), and incubated 
O/N. A single white bacterial colony was selected per plate and used to inoculate 5 mL of 
LB supplemented with ampicillin for 12 hrs (37 oC, with shaking). Subsequently, isolation 
of plasmid DNA was conducted using the Plasmid Miniprep Kit (Qiagen), following the 
standard protocol (As in Section 2.2.3). This step was not conducted for ERα-RFP. 
Isolated plasmids were digested using KpnI and XhoI (ERE+150,441-758 and ERE+151,438-726), 
KpnI and BglII (ERE-19,247-18,610 and ERE-18,889-18,783) or BamHI and EcoRI (ERα-RFP) fast 
digestion restriction enzymes (ThermoFisher Scientific), according to the manufacturer’s 
guidelines. The pGL4.18 (Promega) or pcDNA3.1-RFP plasmids were also digested 
using the relevant enzymes, and then subsequently treated using FastAP 
Thermosensitive Alkaline Phosphatase (ThermoFisher Scientific), according to the 
standard protocol. The resulting products of these reactions were separated using 1 % 
agarose gel electrophoresis, from which they were extracted and purified using the 
QIAquick Gel Extraction Kit (Qiagen), according to the manufacturer’s guidelines.  
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Primer Name Sequence 
ERE+150,441-758 FP  
(KpnI restriction site) 
GGGGTACCCCttgactcaggcggatgca 
ERE+150,441-758 RP  
(XhoI restriction site) 
CCGCTCGAGCGGctggcttcttctcctggag 
pGL4.18-ERE+151,438-726  
FP(KpnI restriction site) 
GGGGTACCCCtaagccattaatacaccaatcgtatt 
pGL4.18-ERE+151,438-726 RP  
(XhoI restriction site) 
CCGCTCGAGCGGcctgctcatatgaaattgcagag 
ERE-19,247-18,610 FP  
(KpnI restriction site) 
GGGGTACCCCTttgatttctaaggccagataactg     
ERE-19,247-18,610 RP  
(BglII restriction site) 
GAAGATCTTCactctaatgcctcagagccaag  
ERE-18,889-18,783 FP  
(KpnI restriction site) 
GGGGTACCCCTctcaccttcctgatcagcc     
ERE-18,889-18,783 RP  
(BglII restriction site) 
GAAGATCTTCgaagaaacaccttctctcctcca      
pcDNA3.1-RFP-ERα FP 
(BamHI restriction site) 
CGGGATCCCGaatgaccatgaccctccaca 
pcDNA3.1-RFP-ERα RP 
(EcoRI restriction site) 
GGAATTCCtcagaccgtggcagggaa 
Table 2.3.2 Sequences of primers used to amplify cloning sites and to add on 
restriction sites 
Sequences are displayed in 5’ to 3’ direction. The recommended oligo sequence for 
the restriction enzyme site by New England BioLabs is indicated (Capital letters), with 
the exact restriction enzyme sites also indicated (white). 
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Plasmid and inserts were ligated using a Rapid DNA Ligation kit (ThermoFisher 
Scientific), following the standard protocol. The resulting ligated plasmids were 
transformed into DH5α (Section 2.2.2) and the plasmid DNA isolated (Section 2.2.3). The 
cloning procedure was confirmed initially through a diagnostic digestion using the same 
fast digestion restriction enzymes as for the cloning procedure, and 1 % agarose gel 
electrophoresis was conducted to confirm the correct size plasmid and insert. If this was 
correct, the plasmid was additionally verified via sequencing (Source Bioscience). 
2.4 Mammalian cell culture 
Two established adherent human BCa cell lines were utilised: MCF7 and T47D. 
These cell lines are models of endocrine sensitive BCa and express ERα and AR. 
Additionally the established cell line COS-1 was utilised, as these cells are negative for 
both ERα and AR (Brooke, unpublished). These three cell lines were obtained from the 
American Type Culture Collection and were cultured in their relevant media, described in 
Table 2.1. The endocrine resistant cell line derivatives were produced via the method 
outlined in Figure 2.1 by Dr Greg Brooke. These were cultured using the hormone-
depleted media described in Table 2.1 and in the presence of 100 nM 
Fulvestrant/Tamoxifen where necessary (Figure 2.4.1). 
All cells were cultured under incubation conditions of 37 oC and 5 % Carbon dioxide 
(CO2), with regular microscopy observations to monitor cell confluence and health. Once 
the cell confluence reached approximately 70–80 %, cell passaging was completed (twice 
weekly).  
 
 
 98 
 
  
Figure 2.4.1 Outline of the production of various endocrine resistant cell 
lines using MCF7 and T47D endocrine sensitive Breast Cancer parental 
lines (conducted by Dr Greg Brooke) 
Cells were grown for 6 months using hormone-depleted phenol red free 
Dulbecco's Modified Eagle Medium (DMEM) (MCF7) or Roswell Park Memorial 
Institute (RPMI) (T47D) supplemented with charcoal stripped foetal calf serum 
(FCS), penicillin streptomycin and glutamine (hormone-depleted). Additionally 
100 nM Tamoxifen was added in the Tamoxifen Resistant (TAMR) derivative 
and 100 nM Fulvestrant for the Fulvestrant Resistant (FULVR) derivative. 
Following this, a cell colony was picked and continued to be grown under the 
specified conditions. 
MCF7/ T47D 
LTED TAMR 
Tamoxifen 
Resistant 
FULVR 
Fulvestrant 
Resistant 
Long Term Oestrogen 
Deprived (Aromatase 
Inhibitor resistant) 
Parental Line 
Endocrine Sensitive 
 
+10 nM Tamoxifen +10 nM Fulvestrant -Oestrogen 
       6 Months Treatment 
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2.4.1 Freezing and defrosting cells 
To make frozen cell stocks, cells were passaged, pelleted (1,500 rpm for 3 mins) 
and re-suspended using pre-warmed freezing mixture (Table 2.1). The mixture was 
transferred into cryotubes (1 mL per tube), wrapped in insulating material and maintained 
at -80 oC for short term storage, but transferred to liquid nitrogen for longer term storage. 
To defrost frozen stocks, 1 mL of frozen cells were defrosted at 37 oC, then transferred 
immediately into 10 mL of pre-warmed medium. The resulting cell suspension was 
centrifuged (1,500 rpm for 3 mins), the supernatant removed and the cells re-suspended 
in the required volume of relevant media (Table 2.1) and returned to culture conditions 
(Section 2.4.1). 
2.5 Transient transfection of mammalian cells 
2.5.1 Calcium phosphate   
The Calcium phosphate method was conducted as outlined previously (Chen and 
Okayama, 1987). Per well of a 24 well plate, the required DNA was mixed and diluted to 
45 µL using ddH2O (Refer: Section 2.6). Subsequently, 5 µL of 2.5 M CaCl2 and 50 µL of 
2 x BBS were added, and mixed gently via bubbling with a Gilson pipette. The resulting 
transfection mix was incubated at RT for 15 mins, before being added to the well in a 
drop-wise manner. 
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2.5.2 jetPRIME 
Alternatively, transections were conducted for use with confocal microscopy. Cells 
were seeded at a low confluency (approximately 20 %) on cover-slips in the relevant 
hormone-depleted media, and incubated for 24 hrs. Following this, cells were transfected 
using jetPRIME transfection reagent (Polypus Transfection) according to the standard 
protocol. After 48 hrs, cells were treated with the required hormones for 2 hrs and washed 
three times using PBS, prior to fixing. Fixing was accomplished using 200 µL of 4 % 
Paraformaldehyde (PFA) for 15 mins, whilst rocking gently at RT and coverslips were 
fixed onto microscope slides and visualisation accomplished as outlined in Section 2.9. 
2.5.3 siRNA knockdown   
Cells were plated in 96 well or 6 well plates in the relevant hormone-depleted 
media for 24 hrs prior to transfection. On-target small interfering RNA (siRNA) pool 
targeting AR/ERα or control non-target (NT) siRNA (Dharmacon, catalogue numbers L-
003400-00-0005, L-003401-00-0005 and D-001206-13-05 respectively) to a final 
concentration of 20 nM (96 well) or 50 nM (6 well) was transfected using Lipofectamine 
RNAiMAX Reagent, according to the manufacturer’s guidelines (Invitrogen). The 
knockdown was confirmed using immunoblotting and qPCR.  
2.6 Reporter assays 
COS-1 cells were plated in the relevant hormone-depleted media (Table 2.1) at 
approximately 60 % confluency in 24 well plates and incubated for 24 hrs prior to 
transfection. Cells were transfected using 50 ng pSV-AR, pSG5-ERα or Empty Vector 
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(EV); 10 ng β-galactosidase; and 1 µg ARE-/ERE-luciferase reporter (Table 2.3.1) using 
the Calcium phosphate Method (Section 2.5.1). 24 hrs post transfection, cells were 
washed twice using pre-warmed hormone-depleted media, before being replaced with 
fresh hormone-depleted media containing the desired concentration of 
hormone/drug/vehicle. After a 24 hr incubation period, cells were washed twice using pre-
chilled PBS and lysed by adding 60 µL of 1 x Reporter Lysis Buffer (Promega) and being 
transferred to -80 oC until frozen. Luciferase assays (Promega) were conducted on 20 µL 
of defrosted lysate alongside the β-galactosidase assay Galacto-Light (Life Technologies) 
on 5 µL for normalisation, according to each manufacturer’s guidelines. Luminescence 
was quantified using the FLUOstar Omega plate reader (BMG Labtech). 
2.7 Gene expression analysis 
To prepare samples, the relevant cells were seeded at approximately 70 % 
confluency in either 6 or 12 well plates and cultured in hormone-depleted media (Refer: 
Table 2.1) for 120 hrs. Following this, cells were treated with the required ligand or drug 
concentration for either an 8 or 24 hr time period.  
2.7.1 RNA extraction 
Following treatment, cells were washed twice using ice cold PBS and lysed in 
TRIsure reagent (Bioline). RNA extraction was conducted according to the standard 
protocol. Visualisation of the RNA pellet was aided using Glycoblue (Ambion). Once 
pelleted, an additional 75 % Ethanol (EtOH) wash step for the RNA was added, and 
pellets were re-suspended post air-drying in 30 µL (6 well) or 20 µL (12 well) RNase free, 
sterile ddH2O. RNA was quantified and its quality assessed using the NanoDrop® ND-
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1000 UV/VIS Spectrophotometer (Nanodrop, LabTech), according to the manufacturer’s 
guidelines. 
2.7.2 cDNA synthesis 
Reverse transcription was conducted to synthesise complementary DNA (cDNA) 
using either the Transcriptor First Strand cDNA Synthesis Kit (Roche) or High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Thermo Fisher Scientific), 
according to each manufacturer’s guidelines. 500 ng of RNA was utilised per cDNA 
synthesis reaction and the resulting cDNA was diluted 1:4. 
2.7.3 Primer design 
To design primers for gene expression analysis, mRNA and genomic sequences 
of the gene were obtained using the National Centre for Biotechnology Information (NCBI) 
and converted from a FASTA to a tabulated format using the FaBox (1.4.1) Fasta2excel 
converter. To design primers for use with ChIP analysis, the sequences to input were 
obtained from the relevant DNA site under investigation using the University of California, 
Santa Cruz (UCSC) Genome Browser, following assessment of TF binding using the 
PROMO tool for the identification of putative transcription factor binding sites 
(Algorithmics and Genetics Group, ALGGEN, Universitat Politècnica de Catalunya). 
These sequences were input into PerlPrimer Software and designed for use with qPCR. 
The parameters were set to create primers 20-25 bp in length with an amplicon size near 
to 100 bp, ideally spanning the intron/exon boundary, with the other parameters kept as 
recommended.  
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2.7.4 Real-Time quantitative PCR (qPCR) 
Real-Time quantitative PCR (qPCR) was performed on 2 µL of cDNA with the 
LightCycler® 480 SYBR Green I Master (Roche) or Fast SYBRTM Green Master Mix 
(Applied Biosystems) where specified, in the reaction conditions according to each 
manufacturer’s specifications. qPCR was conducted using the LightCycler® 480 (Roche) 
and a melt curve was observed for each reaction. Gene expression was normalised using 
the RPL19 ribosomal protein (L19) reference gene and analysed using the delta-delta Ct 
(∆∆Ct) method. The primers used are displayed in Table 2.7.1. 
2.8 Protein analysis 
2.8.1 Cell collection 
Cells were washed twice using ice cold PBS and detached via scraping in fresh 
PBS. Cells were subsequently centrifuged (13,000 rpm for 1 min at 4 oC), the supernatant 
discarded and the remaining cell pellet snap frozen and stored at -80 oC. When required, 
cell pellets were re-suspended in Radioimmunoprecipitation buffer (RIPA) supplemented 
with Halt Protease Inhibitor (PI) Cocktail (ThermoScientific) and 
Phenylmethanesulphonylfluoride (PMSF) to a final concentration of 1 µM (Table 2.1) (100 
µL of RIPA was utilised per well of a 6 well plate). Lysates were sonicated for 3 cycles on 
‘high’ of 30 secs on and 30 secs off using Biorupter® Plus (Diagenode). Following this, 
samples were centrifuged (13,000 rpm for 10 mins at 4 oC) and the supernatant was 
transferred to a fresh pre-chilled 1.5 mL tube. 
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Gene 
Forward Primer 
Sequence 
Reverse Primer 
sequence 
Source 
Myelocytom-
atosis 
Oncogene 
Cellular 
Homolog 
(MYC) 
GGCTCCTGGCAAAAGG
TCA 
CTGCGTAGTTGTGCTG
ATGT 
(Qinyu et al., 2013) 
Deiodinase, 
Iodothyroni-
ne Type II 
(DIO2) 
ACTCGGTCATTCTGCTC
AAG 
TCACCCAATTTCACCTG
TTTGT 
(Fujii et al., 2014) 
Dopa 
Decarboxyla-
se (DDC) 
GACTGGACCCTTGTCG
AAACT 
TCTTCACCAACTTTCAC
TGTTCC 
 (Fujii et al., 2014) 
Gene 
Regulated in 
Breast 
Cancer 1 
(GREB1) 
ATGGGAAATTCTTACGC
TGGAC 
CACTCGGCTACCACCT
TCT 
(von der Heyde et 
al., 2015) 
N-myc 
Downstream-
Regulated 
Gene 1 
(NDRG1) 
CTCCTGCAAGAGTTTG
ATGTCC 
TCATGCCGATGTCATG
GTAGG 
(Wu et al., 2015) 
 
RPL19 
ribosomal 
protein (L19) 
GCGGAAGGGTACAGCC
AAT 
GCAGCCGGCGCAAA (Millour et al., 2010) 
SEC14 like 
Lipid binding 
2 (SEC14L2) 
CCGAAACACTGAAGCG
TCTTT 
CTCCTTCCAATTTGCTC
CCAG 
R.A. Bryan 
Trefoil Factor 
1 (TFF1) 
CATGGAGAACAAGGTG
ATCTG 
CACTGTACACGTCTCT
GTCTG 
R.A. Bryan 
Zinc Finger 
And BTB 
Domain 
Containing 16 
(ZBTB16) 
CTGGATAGTTTGCGGC
TGAG 
ATGTCAGTGCCAGTAT
GGGT 
R.A. Bryan 
Table 2.7.1 Sequences of gene expression primers for use with qPCR 
Sequences are displayed in 5’ to 3’ direction, and the source of the primers is 
included. 
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2.8.2 DC protein assay 
The protein concentration was quantified using the Detergent Compatible (DC) 
Protein assay (Bio-Rad), using 5 µL of sample against standard concentrations of BSA 
as a guideline, according to the manufacturer’s protocol. Protein concentrations were 
measured at absorbance λ = 650 nm using the FLUOstar Omega plate reader (BMG 
Labtech). Samples were diluted to an equal volume of protein per set (10–20 µg/10 µL of 
sample) with 4 x Laemmli protein sample buffer (Bio-rad) (2.5 µL/10 µL of sample). 
2.8.3 SDS-PAGE 
Prior to running, lysates were vortexed and incubated at 95 oC for 5-10 mins. 
Immediately following this, samples were transferred to ice and vortexed once cool. 15-
20 μL of lysate was loaded per well of a 10 % polyacrylamide gel, against 5 µL of the 
Page Ruler Prestained Protein Ladder (Thermo Scientific) unless otherwise stated in 
results. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
conducted at 120 V with pre-made running buffer. 
2.8.4 Immunoblotting 
 Proteins were transferred onto a Polyvinylidene difluoride (PVDF) membrane 
(Immobilion P, Millipore Inc., hydrated in preparation using 100 % Methanol, MeOH) via 
semi-dry transfer. This was conducted at 15 V and 100 mA for 2 hrs, using semi-dry 
electro blotting apparatus (Bio-Rad) and pre-made transfer buffer. Following this, 
membranes were incubated with blocking solution for 15 mins, followed by probing with 
the required primary (1o) antibody (Ab) (Table 2.8.1a) for 1 hr at RT or O/N at 4 oC, with 
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gentle rocking. Three washes were conducted using PBS-T for 5 mins, prior to the 
relevant secondary (2o) Ab incubation (Table 2.8.1a) for 1 hr at RT, both with rocking. 
Three washes were conducted again using PBS-T for 5 mins, and an additional wash 
with PBS was conducted for 5 mins, each with rocking. Proteins were subsequently 
visualised via chemiluminescence using LuminataTM Forte (Millipore) with the Fusion FX 
imager (Vilber Lourmat). 
2.9 Cell staining and confocal imaging 
Cells were seeded at a low confluency (approximately 20 %) on cover-slips in the 
relevant hormone-depleted media, and incubated for 24 hrs. Following this, cells were 
either transfected (Section 2.5.2) or treated with the required hormones for 2 hrs and 
washed three times using PBS, prior to fixing. Fixing was accomplished using 200 µL of 
4 % PFA for 15 mins, whilst rocking gently at RT. Subsequently, cells were washed three 
more times with PBS for 5 mins (shaking), and fixed using 200 µL of ice cold 100 % MeOH 
for 10 mins at -20 oC.  
For staining, cells were initially incubated with 250 µL of 1 % BSA in PBS-T for 30 
mins at RT, with gentle shaking. 1o Ab incubation was conducted for AR or ERα (Table 
2.8.1b) in 100 µL 1 % BSA PBS-T, for 1 hr at RT (or O/N at 4 oC), shaking gently. Cells 
were washed three times for 5 mins again, and 2o Ab incubation was conducted as per 
Table 2.8.1b, in 100 µL of 1 % BSA PBS-T for 1 hr at RT in the dark, shaking gently. Cells 
were washed an additional three times for 5 mins, and coverslips were fixed onto 
microscope slides with Fluoroshield Mounting Medium with 4',6-diamidino-2-phenylindole 
(DAPI, Abcam) and sealed using Fixogum (Marubu). Cells could then be visualised using 
confocal microscopy. 
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Protein Primary Antibody Secondary Antibody 
Androgen 
Receptor (AR) 
AR (N-20) sc-816 (Santa 
Cruz, diluted 1:1,00) 
Anti-Rabbit IgG (whole 
molecule)-Peroxidase (Sigma-
Aldrich, diluted 1:2,000) 
Beta-Actin (β-
Actin) 
Beta Actin Ab8226 
(Abcam diluted 1:3,000) 
Anti-Rabbit IgG (whole 
molecule)-Peroxidase (Sigma-
Aldrich, diluted 1:2,000) 
Beta-Tubulin (β-
Tubulin) 
Beta Tubulin T5168 
(Sigma-Aldrich diluted 
1:3,00) 
Anti-Mouse IgG (whole 
molecule)-Peroxidase (Sigma-
Aldrich, diluted 1:2,000) 
Oestrogen 
Receptor alpha 
(ERα) 
ERα HC-20 sc-543 
(Santa Cruz diluted 
1:2,00) 
Anti-Rabbit IgG (whole 
molecule)-Peroxidase (Sigma-
Aldrich, diluted 1:2,000) 
Protein Primary Antibody Secondary Antibody 
Androgen 
Receptor (AR) 
Ms mAb to AR 441 
(Abcam, diluted 1:200 for 
MCF7 derivatives and 
1:150 for T47D 
derivatives) 
Goat pAb to Ms IgG (Alexa 488, 
Abcam, diluted 1:4,000) 
Oestrogen 
Receptor alpha 
(ERα) 
ERα HC-20 sc-543 
(Santa Cruz, diluted 
1:400 for MCF7 
derivatives and 1:300 for 
T47D derivatives) 
Goat pAb to Rb IgG (Alexa 488, 
Abcam, diluted 1:4,000) 
Protein Primary Antibody Secondary Antibody 
Androgen 
Receptor (AR) 
AR (N-20) sc-816 (Santa 
Cruz) 
Dynabeads Protein A (Life 
Technologies) 
Oestrogen 
Receptor alpha 
(ERα) 
ERα (HC-20) sc-543 
Santa Cruz) 
Dynabeads Protein A (Life 
Technologies) 
Table 2.8.1 Antibodies  
A description of the antibodies used for (a) immunoblotting (b) Confocal 
Microscopy and (c) Chromatin Immunoprecipitation (ChIP) experiments. ChIP 
concentrations were used as recommended by the Zymo-Spin™ ChIP Kit. 
(a) Immunoblotting  
 
Protein Primary Antibody Secondary Antibody 
Androgen Receptor 
(AR) 
AR (N-20) sc-816 (Santa 
Cruz, diluted 1:1,00, 
catalogue number sc-7305) 
Anti-Rabbit IgG (whole 
molecule)-Peroxidase 
(Sigma-Aldrich, diluted 
1:2,000,  catalogue 
number ) 
Beta-Actin (β-Actin) Beta Actin Ab8226 (Abcam 
diluted 1:3,000,  catalogue 
number ) 
Anti-Rabbit IgG (whole 
molecule)-Peroxidase 
(Sigma-Aldrich, diluted 
1:2,000,  catalogue 
number ) 
Beta-Tubulin (β-
Tubulin) 
Beta Tubulin T5168 (Sigma-
Aldrich diluted 1:3,00,  
catalogue number) 
Anti-Mouse IgG (whole 
mol cule)-Peroxidase 
(Sigma-Aldrich, diluted 
1:2,000,  catalogue 
number) 
Oestrogen 
Receptor alpha 
(ERα) 
ERα HC-20 sc-543 (Santa 
Cruz diluted 1:2,00,  
catalogue number ) 
Anti-Rabbit IgG (whole 
molecule)-Peroxidase 
(Sigma-Aldrich, diluted 
1:2,000) 
(b)  Immunoblotting  
(c) Confocal Microscopy 
 
 
(c) Confocal Microscopy 
 
(b) ChIP  
 
(d) ChIP  
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2.10 Proliferation assays 
Cells were grown in a 96-well plate with the relevant hormone-depleted culture 
media (Table 2.1), and treated using the desired concentration of hormone/drug 
treatment/vehicle for 72–120 hrs (both specified per experiment). Cell proliferation was 
then assessed using WST-1 Cell Proliferation Reagent (Abcam), according to the 
manufacturer’s protocol. Growth was quantified by measuring the resulting absorbance λ 
= 440 nm on the FLUOstar Omega plate reader (BMG Labtech). 
2.11 Colony formation assays 
Cells were seeded at a low confluency in 6 well plates (approximately 10 %) in the 
required hormone-depleted media (Table 2.1). Cells were cultured in the presence of the 
relevant ligand/drug concentration or vehicle, with twice weekly media changes with fresh 
treatments, for 4 weeks. The wells were washed three times using PBS, followed by fixing 
at RT with 500 µL of 4 % PFA for 1 hr. Subsequently, cells were washed a further three 
times with PBS and left O/N to air dry fully. Fixed cells could then be stained using 500 
µL of 0.08 % crystal violet at RT for 1 hr, with gentle rocking. Wells were washed a further 
three times using ddH2O and following air drying O/N were visualised using a the Epson 
Perfection 1250 scanner. 
2.12 ChIP 
Chromatin Immunoprecipitation (ChIP) was conducted to assess AR and ERα 
DNA binding in MCF7 or MCF7-TAMR cells. To prepare samples, cells were cultured in 
hormone-depleted media (Table 2.1) for 120 hrs and treated with EtOH (vehicle)/1 nM 
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MIB/1 nM E2/E2 + MIB for 4 hrs. ChIP assays were then conducted via the Zymo-Spin™ 
ChIP Kit (Zymo Research), according to the manufacturer’s guidelines. Briefly, cells were 
treated with formaldehyde to crosslink DNA-protein complexes and this reaction was 
quenched using Glycine to a final concentration of 250 µM. Cells were then lysed and 
sonicated to fragments approximately 200 bp in size (analysed using 1% agarose gel 
electrophoresis). Following this, 4 µg per assay of AR and ERα antibodies (Table 2.8.1c) 
were used to pull down DNA target sites. The following adjustments to the protocol were 
used: samples were sonicated for 25 cycles on ‘high’ of 30 secs on and 30 secs off using 
Biorupter® Plus (Diagenode) and 3 x 106 rather than 1 x 106 sonicated cells were utilised 
per assay. AR and ERα binding sites were assed via qPCR (Refer: Section 2.7.3) with 
primers for validated and suspected binding sites against control regions (Table 2.12.1). 
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Description 
Forward Primer 
Sequence 
Reverse Primer 
sequence 
Source 
TFF1 ERE +ve TATGAATCACTTCT
GCAGTGAG 
GAGCGTTAGATA
ACATTTGCC 
(Periyasamy et al., 
2015) 
TFF1 ERE –ve GTGATTCTCCTGA
CTTAACC 
TGGCGCAGTGGC
TCACGCTG 
(Periyasamy et al., 
2015) 
ZBTB16 ARE +ve ATGCCCTGCGTCT
GTACTCATT 
TGTTCTGATGAG
ATCTGCACGCCT 
(Robinson et al., 
2011) 
ZBTB16 ARE -ve GTCCTGTCTCCCA
TTCCAGA 
GAGAAGCCCAAT
CGCAATAA 
R.A. Bryan 
AR ERE-19,247-18,610 TGGCTTGGGACTT
TAGCCTC 
TGAGGTGACCTG
GTTTAGCC 
R.A. Bryan 
AR ERE -ve CAGCATTGCATAG
CCAGAAA    
AAAGCCTTCCAC
AGCTTTCA 
R.A. Bryan 
Table 2.12.1 Sequences of primers to identify Androgen and 
Oestrogen Response Elements 
Sequences are displayed in 5’ to 3’ direction. Positive (+ve) and negative         
(-ve) regions are indicated for each Androgen Response Element (ARE) or 
Oestrogen Response Element (ERE) on the Androgen Receptor (AR), Trefoil 
Factor 1 (TFF1) or Zinc Finger And BTB Domain Containing 16 (ZBTB16) 
genes. The source of the primers is included. 
 
Table 2.12.1 Sequences of primers to identify Androgen and 
Oestrogen Response Elements 
Sequences are displayed in 5’ to 3’ direction. Positive (+ve) and negative         
(-ve) regions are indicated for each Androgen Response Element (ARE) or 
Oestrogen Response Element (ERE) on the Androgen Receptor (AR), Trefoil 
Factor 1 (TFF1) or Zinc Finger And BTB Domain Containing 16 (ZBTB16) 
genes. The source of the primers is included. 
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Chapter 3. Results: Androgen Receptor and Oestrogen Receptor 
alpha cross-talk in endocrine sensitive Breast Cancer 
3.1 Introduction  
Breast cancer (BCa) is currently the most highly prevalent cancer among women 
in the UK (Cancer Research UK, 2014a). In 2014 in the UK alone, there were 55,222 BCa 
diagnoses (Wu et al., 2015). The majority of BCas are endocrine sensitive: Oestrogen 
Receptor α (ERα)-positive (Luminal) cancers that are dependent upon oestrogens for 
progression (Chuffa et al., 2017, Rakha and Green, 2016, Ali and Coombes, 2002). ERα 
is a Type I Nuclear Receptor (NR), a family of ligand-dependent transcription factors that 
translocate to the nucleus to exert their effects (Sever and Glass, 2013). The most 
abundant circulating form of oestrogen as well as the most potent is 17-β-Oestradiol (E2) 
(Bean et al., 2014, Speirs and Walker, 2007).  
For endocrine sensitive patients where the disease has spread from its primary 
site or metastasised, treatment often involves endocrine therapies (Vorobiof, 2016). 
These include anti-oestrogens, which bind to ERα and block its action. The anti-
oestrogens used in this study are the Selective ERα Modulator (SERM) Tamoxifen (TAM) 
and the Selective ERα Downregulator (SERD) Fulvestrant (FULV), with the latter 
additionally enhancing ERα degradation (Kaklamani and Gradishar, 2017, Cauley et al., 
2001, Lumachi et al., 2015). Additionally, Aromatase Inhibitors (AIs) are commonly 
administered, which block aromatase activity to reduce E2 synthesis, and therefore 
decrease circulating oestrogen levels (Kaklamani and Gradishar, 2017). However, 
resistance to anti-oestrogens and AIs commonly occurs, termed endocrine resistance, 
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and often results in advanced metastatic disease for which few treatment options are 
available (Kaklamani and Gradishar, 2017, Vorobiof, 2016, Reinert et al., 2017). 
The Androgen Receptor (AR) is also a Type I NR, and is activated in response to 
androgens (Rahim and O'Regan, 2017). Androgens are secreted in significantly higher 
quantities than oestrogens in women (Burger, 2002) and directly affect the ERα pathway, 
as two of the main androgens that are produced in women (androstenedione and 
testosterone) are precursors for E2 (Kaklamani and Gradishar, 2017, Patani and Martin, 
2014). It has additionally been reported that AR is more highly expressed than ERα in 
BCa tissues (Rahim and O'Regan, 2017, Vera-Badillo et al., 2014). In ERα-positive 
disease, AR appears to be an indicator of positive prognostic outcome, which has been 
hypothesised to occur by AR having an inhibitory effect on ERα-driven cancer 
progression (Rahim and O'Regan, 2017, Fioretti et al., 2014, Tarulli et al., 2014). It has 
been established that AR and ERα suppress each other’s activity, and this cross-talk 
(Fioretti et al., 2014) could explain the inhibitory effect displayed by androgen signalling 
in ERα-positive BCa. However, in ERα-negative disease it has been suggested that AR 
can mimic ERα signalling to promote BCa progression in the absence of a functioning 
ERα (Fioretti et al., 2014). Further, recently AR signalling has been indicated as a driver 
in some cases of endocrine resistance (De Amicis et al., 2010, Rechoum et al., 2014, 
Ciupek et al., 2015, Ali et al., 2015).  
The aim of this chapter was to explore, using the endocrine sensitive cell line 
MCF7, how therapeutic interventions may alter this cross-talk and promote the onset of 
endocrine resistance.  
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3.2 ERα regulates AR in endocrine sensitive BCa 
3.2.1 ERα and AR expression is correlated in BCa, and siRNA knockdown of ERα 
decreases AR expression in endocrine sensitive cells 
Data obtained via interrogation of the METABRIC (Molecular Taxonomy of Breast 
Cancer International Consortium) dataset (Pereira et al., 2016) using the cBioPortal for 
cancer genomics (Gao et al., 2013, Cerami et al., 2012), indicated that several Type I 
NRs are co-expressed in BCa, and the strongest association was observed between ERα 
and AR (Table 3.2.1 and Figure 3.2.1). From this it can be inferred that one of these 
receptors could regulate the other or that both receptors are regulated by a common 
factor in endocrine sensitive (ERα-positive) disease. To expand upon this, immunoblotting 
analysis was conducted on lysates from a cell line model of endocrine sensitive disease 
(MCF7) following siRNA knockdown of AR or ERα (Figure 3.2.2). This revealed that ERα 
knockdown in MCF7 cells also resulted in a 51.5 % reduction in AR expression, however 
ERα expression remained constant following AR knockdown. Therefore, it was concluded 
that there is a possibility that ERα regulates AR expression.  
3.2.2 ERα interacts with an ERE upstream of AR and can transcriptionally activate 
an ERE within the AR gene 
To investigate this further, analysis was conducted on ERα Chromatin 
Immunoprecipitation-Sequencing (ChIP-Seq) data from MCF7 cells provided by Carroll 
et al. (2006) using the UCSC Genome Browser to identify the presence of an Oestrogen 
Response Element (ERE) within a 637 bp region 19,247-18,610 bp upstream of the AR 
gene. Subsequently, the PROMO tool for the identification of putative transcription factor  
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Gene A Gene B P-Value Log Odds Ratio 
AR ERα <0.001 2.702 
ERα ERβ 0.001 1.472 
GR MR 0.003 1.219 
GR ERβ 0.012 1.049 
ERα MR 0.018 1.149 
PR MR 0.073 1.006 
AR PR 0.096 <-3 
AR ERβ 0.123 0.572 
MR ERβ 0.170 0.579 
PR ERβ 0.187 <-3 
AR MR 0.224 0.422 
AR GR 0.273 0.346 
ERα PR 0.299 <-3 
PR GR 0.514 0.170 
ERα GR 0.598 -0.141 
Table 3.2.1 Comparison of Steroid Receptor expression in 2,433 Breast 
Cancers obtained from the METABRIC dataset 
The co-occurrence or mutual exclusivity of expression of Type I Nuclear Receptors 
(Steroid Receptors) was obtained via interrogation of the METABRIC (Molecular 
Taxonomy of Breast Cancer International Consortium) dataset (Pereira et al., 2016) 
using the cBioPortal for cancer genomics (Gao et al., 2013, Cerami et al., 2012). 
The receptors investigated were: Progesterone Receptor (PR), Oestrogen Receptor 
alpha (ERα), Oestrogen Receptor beta (ERβ), Glucocorticoid Receptor (GR), 
Androgen Receptor (AR) and Mineralocorticoid Receptor (MR). Rows have been 
colour-coded to indicate a tendency towards co-occurrence or mutual exclusivity 
and significant differences have been indicated in bold. P-values were obtained 
through the software via the Fisher Exact Test and the Log Odds Ratio is a 
quantification of co-occurrence or mutual exclusivity in the Breast Cancers analysed. 
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Figure 3.2.1 AR and ERα are significantly co-expressed in 2,433 
Breast Cancers obtained from the METABRIC dataset 
The pattern of co-expression of Androgen Receptor (AR) and 
Oestrogen Receptor alpha (ERα) mRNA in Breast Cancers obtained 
via interrogation of the METABRIC (Molecular Taxonomy of Breast 
Cancer International Consortium) (Pereira et al., 2016) using the 
cBioPortal for cancer genomics (Gao et al., 2013, Cerami et al., 2012). 
The Pearson correlation coefficient test was calculated to test for co-
occurrence. 
 
Figure 3.2.1 AR and ERα are significantly co-expressed in 2,433 
Breast Cancers obtained from the METABRIC dataset 
The pattern of co-expression of Androgen Receptor (AR) and 
Oestrogen Receptor alpha (ERα) mRNA in Breast Cancers obtained 
via interrogation of the METABRIC (Molecular Taxonomy of Breast 
Cancer International Consortium) (Pereira et al., 2016) using the 
cBioPortal for cancer genomics (Gao et al., 2013, Cerami et al., 2012). 
The Pearson correlation coefficient test was calculated to test for co-
occurrence. 
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Figure 3.2.2 siRNA knockdown of ERα decreases AR 
expression in endocrine sensitive cells 
(a) Androgen Receptor (AR) or Oestrogen Receptor alpha (ERα) 
levels were depleted using siRNA in MCF7 cells alongside a Non-
Targeting (NT) siRNA control, then collected after 72 hours for 
Western blotting analysis of AR expression. The percentage 
expression of ERα or AR following knockdown as compared to 
the NT siRNA control samples were analysed using Fusion X 
Software with β-Tubulin as a loading control. (b) The average 
expression of AR and ERα from one replicate in MCF7 cells and 
two replicates in MCF7-TAMR cells is displayed following AR or 
ERα depletion using siRNA ±SE. T-Test *P<0.05, **P<0.005. 
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binding sites (Algorithmics and Genetics Group, ALGGEN, Universitat Politècnica de 
Catalunya) was used to identify a consensus ERE within this region (AGGTCA), the 
sequence of which corresponds with a described consensus binding motif for ERα 
(Carroll et al., 2006). To verify this as a functional ERE, a 637 bp region containing the 
ERE (ERE-19,247-18,610) and a shorter 106 bp region 18,889-18,783 bp upstream of AR 
(ERE-18,889-18,783) (Figure 3.2.3a), were cloned into the pGL4.18 Luciferase Reporter 
plasmid (Promega) and successful cloning confirmed via sequencing.  
COS-1 cells were co-transfected with pSG5-ERα or Empty Vector (EV) and 
pGL4.18-ERE-19,247-18,610 or pGL4.18-ERE-18,889-18,783, an Empty pGL4.18 (negative 
control) or a known oestrogen responsive luciferase reporter (ERE-LUC) as a positive 
control. Luciferase assays were conducted to assess activity in the presence/absence of 
ERα ligand (E2) (Figure 3.2.3b). The results produced demonstrated that ERα activity 
was highly responsive to E2 in the positive control (ERE-LUC), whereas no activity was 
evident for the negative control. Neither of the AR-promoter regions cloned showed 
transcriptional activity (Figure 3.2.3b) and hence it appears that this ERE is not functional. 
To investigate this result further, ChIP assays were conducted in MCF7 cells treated +/- 
E2. Primers were designed to test whether ERα interacts within this region of DNA or a 
negative control region 2,066 bp upstream of this site (confirmed via the PROMO tool to 
not contain any ERα binding sites) (Figure 3.2.4a). These were tested alongside a known 
ERE in the promoter region of the Trefoil Factor 1 (TFF1) gene 340-354 bp upstream and 
a negative control region approximately 685-520 bp upstream (Figure 3.2.4b). TFF1 
otherwise known as Presenilin 2 (PS2), is a strongly established positively regulated ERα 
target gene in BCa (Lin et al., 2004, Brown et al., 1984, Westley et al., 1984, Welboren 
et al., 2007). In contrast to the reporter assays, this region was demonstrated to be 
significantly enriched over 3-fold following E2 stimulation (Figure 3.2.4c).   
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Figure 3.2.3 ERα does not activate a predicted ERE upstream of the AR gene 
(a) Schematic of an Oestrogen Response Element (ERE) identified upstream of 
Androgen Receptor (AR) from ChIP-Sequencing data on MCF7 cells provided by 
Carroll et al. (2006) using the University of California, Santa Cruz (UCSC) Genome 
Browser. The primers used to clone this ERE into the pGL4.18 Luciferase Reporter 
plasmid are indicated for the full length region (ERE-19,247-18,610) as well as a shorter 
region within this containing the AGGTCA sequence (ERE-18,889-18,783) which 
corresponds with a described consensus binding motif for ERα. (b) COS-1 cells were 
co-transfected with plasmids encoding Oestrogen Receptor α (ERα) or empty vector 
(EV) and either ERE-19,247-18,610, ERE-18,889-18,783, an Empty Vector pGL4.18 plasmid 
(negative control) or a known ERE luciferase reporter (positive control). Cells were 
treated for 24 hours with 1 nM 17-β-Oestradiol (E2) ligand or vehicle (Ethanol, EtOH). 
ERα activity was measured using luciferase and normalised to β-galactosidase 
activity. Mean of 3 independent duplicates ±SE. T-Test *P<0.05, **P<0.005. 
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Figure 3.2.4 ERα is recruited ligand-dependently to a predicted ERE upstream 
of the AR gene 
(a) Schematic of an Oestrogen Response Element (ERE) identified upstream of 
Androgen Receptor (AR) from ChIP-sequencing data on MCF7 cells provided by 
Carroll et al. (2006) using the University of California, Santa Cruz (UCSC) Genome 
Browser. Primers are indicated to detect this ERE (ERE-19,247-18,610) or a negative 
control region upstream (AR ERE -ve). (b) Schematic of a known ERE in the promoter 
region of Trefoil Factor 1 (TFF1) gene (TFF1 +ve) and its relative control region 
approximately 2 kb upstream (TFF1 -ve). (c) MCF7 cells were treated with Ethanol 
(EtOH), or 1 nM 17-β-Oestradiol (E2) and crosslinked with formaldehyde prior to DNA 
shearing using sonication. Chromatin Immunopreceipitation (ChIP) was performed 
with an ERα-specific antibody. Subsequent qPCR analysis was conducted to amplify 
ERE-19,247-18,610, AR ERE -ve, TFF1 +ve and TFF1 -ve. Results are displayed relative 
to the relevent negative regions. Mean of 3 independent duplicates ±SE. T-Test 
*P<0.05, **P<0.005. 
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To follow on from these results, two alternative EREs located between exons 3 
and 4 on the AR gene were identified in ChIP-Seq studies by Prof S. Ali (Imperial College 
London, Pers. Comm.) in both MCF7 and ZR-75-1 endocrine sensitive cell lines. These 
regions were additionally cloned into the pGL4.18 Luciferase reporter plasmid (Promega). 
The first region was 273 bp in size, located 150,441-150,758 bp from the start site 
(ERE+150,441-758) and contained two ERα binding sequences (gtGTCAcctTGgaCa and 
AGGTtcctgTGgCCa); and the second was 287 bp, located 151,438-151,726 bp from the 
start site (ERE+151,438-726) and included a perfect palindromic ERE sequence 
(AGGTCAtgcTGACCT) (Figure 3.2.5a). Luciferase reporter assays were conducted in the 
same manner (Figure 3.2.5b). The results demonstrated that, again, ERα in the presence 
of E2 activated the positive control (ERE-LUC), whereas no activity was evident for the 
negative control (pGL4-Empty). Interestingly, ERα activity was significantly responsive to 
E2 1.9-fold in the ERE+151,438-726 which contains the perfect palindromic ERE sequence, 
confirming this as a functional site (Figure 3.2.5b). This suggests that ERα can regulate 
AR through inducing transcription at this region. However, ERα activity was not 
responsive to E2 for ERE+150,441-758, but appeared to be constitutively active (Figure 
3.2.5b), suggesting that an alternative transcription factor could be regulating AR 
expression through this region.  
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Figure 3.2.5 ERα activates a predicted ERE on the AR gene and another is 
constitutively active 
(a) Schematic of two Oestrogen Response Elements (EREs) identified within 
Androgen Receptor (AR): ERE+150,441-758 and ERE+151,438-726. Primers are indicated 
to clone both EREs. (b) COS-1 cells were co-transfected with plasmids encoding 
Oestrogen Receptor α (ERα) or Empty Vector (EV) and either ERE+150,441-758, 
ERE+151,438-726, an Empty Vector pGL4.18 plasmid (negative control) or a known 
ERE luciferase reporter (positive control). Cells then treated for 24 hours with 1 nM 
17-β-Oestradiol (E2) ligand or vehicle (Ethanol, EtOH). ERα activity was measured 
using luciferase and normalised to β-galactosidase activity. Mean of 4 independent 
duplicates ±SE. T-Test *P<0.05, ** P<0.005. 
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3.2.3 Identification of transcription factors that could be regulating AR through a 
proposed ERE on the AR gene 
To investigate whether an alternative transcription factor to ERα is regulating AR 
through ERE+150,441-758, the cloned region was analysed for alternative transcription factor 
binding utilising the PROMO tool (Algorithmics and Genetics Group, ALGGEN, 
Universitat Politècnica de Catalunya). The results produced indicated binding sites for 44 
alternative transcription factors to ERα, which were subsequently investigated via the 
METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) dataset 
(Pereira et al., 2016) using the cBioPortal for cancer genomics (Gao et al., 2013, Cerami 
et al., 2012) for their association with AR in BCa. The results produced demonstrated a 
significant association in expression between 20 of these transcription factors and AR 
(Table 3.2.2), the two most significant being X-box binding protein 1 (XBP1) and MYB 
Proto-Oncogene, transcription factor (c-Myb) (Figure 3.2.6). Interestingly, Forkhead box 
protein A1 (FOXA1), a known pioneer factor that has been described as key for AR 
functioning (Robinson et al., 2011), was also found to be significantly associated with AR 
expression (Figure 3.2.6). Therefore, ERα may regulate AR, but other transcription factors 
such as XBP1, c-Myb and FOXA1 are also likely to be involved and these warrant further 
investigation. 
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Gene A 
 
Gene B 
 
P-Value 
 
Log Odds Ratio 
 
XBP-1 AR <0.001 2.802 
c-Myb AR <0.001 2.004 
NFATC1 AR <0.001 1.88 
P53 AR <0.001 1.084 
NFIA AR <0.001 2.49 
IRF1 AR <0.001 1.222 
FOXA1 AR <0.001 >3 
C/EBPα AR <0.001 1.605 
MEF-2A AR <0.001 1.653 
AR NFIC <0.001 1.564 
AR Elk-1 0.001 1.046 
VDR AR 0.003 1.099 
STAT1 AR 0.006 1.197 
c-Ets-1 AR 0.009 1.039 
Gtf2i AR 0.01 0.955 
YY1 AR 0.013 0.964 
STAT4 AR 0.014 0.95 
PROKR1 AR 0.017 0.921 
AR E2F-1 0.022 0.867 
TFAP2A AR 0.027 0.828 
Table 3.2.2 Correlation analysis of the AR with transcription factors that might 
regulate its expression 
Several transcription factors were found to interact with a region within the Androgen 
Receptor gene (ERE+150,441-758) using the PROMO tool (Algorithmics and Genetics 
Group, ALGGEN, Universitat Politècnica de Catalunya). The co-occurrence or mutual 
exclusivity of these receptors in Breast Cancers was obtained via interrogation of the 
METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) dataset 
(Pereira et al., 2016) using the cBioPortal for cancer genomics (Gao et al., 2013, Cerami 
et al., 2012). Rows have been colour-coded to indicate a tendency towards co-
occurrence or mutual exclusivity and only significant differences have been included. 
P-values adjusted for multiple comparisons were obtained through the software via the 
Fisher Extact Test and the Log Odds Ratio is a quantification of co-occurrence or mutual 
exclusivity in the Breast Cancers analysed. 
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METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) dataset 
(Pereira et al., 2016) using the cBioPortal for cancer genomics (Gao et al., 2013, Cerami 
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Figure 3.2.6 AR is significantly co-expressed with other transcription factors in 
2,433 Breast Cancers obtained from the METABRIC dataset 
 
The pattern of co-expression of Androgen Receptor (AR) with X-box binding protein 1 
(XBP1), MYB Proto-Oncogene, transcription factor (c-Myb) and Forkhead box protein 
A1 (FOXA1) mRNA in Breast Cancers obtained via interrogation of the METABRIC 
(Molecular Taxonomy of Breast Cancer International Consortium) dataset (Pereira et 
al., 2016) using the cBioPortal for cancer genomics (Gao et al., 2013, Cerami et al., 
2012). The Pearson correlation coefficient test was calculated to test for co-
occurrence. 
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3.3 The effect of anti-oestrogen treatment on ERα and AR activity 
It appears that ERα may regulate AR activity. It is also known that AR and ERα 
cross-talk at the protein level (Panet-Raymond et al., 2000). To investigate this cross-talk 
and the effect of anti-oestrogens upon this, reporter assays were performed. Initially, the 
effect of the anti-oestrogens upon each receptor was analysed. It has been suggested 
that the anti-oestrogen Fulvestrant (FULV) may also have anti-androgen activity, having 
been demonstrated to suppress AR-induced growth in the LNCaP Prostate Cancer (PCa) 
cell line (Bhattacharyya et al., 2006), therefore, it was of interest to see if these inhibitors 
are also able to block AR activity. The anti-oestrogens Tamoxifen (TAM, a SERM) and 
FULV (a SERD) were chosen for study. COS-1 cells (negative for both of these receptors) 
were transfected with ERα or AR and an oestrogen responsive luciferase reporter (ERE-
LUC) or a luciferase reporter under the control of an Androgen Response Element (TAT-
GRE-EIB-LUC-1), respectively. Cells were also transfected with a β-galactosidase control 
expression vector (PDM-LAC-Z-β-GAL). Receptor activity was measured using luciferase 
assays following treatment with a dose range of TAM (Figure 3.3.1) or FULV (Figure 
3.3.2) in the presence of the relevant ligand or EtOH (vehicle). The AR ligand used was 
Mibolerone (MIB), a synthetic analogue of DHT that cannot be metabolised to oestrogen, 
and the ERα ligand was E2. 
The results demonstrated that ERα activity increased with E2 treatment and that 
this effect was potently inhibited by the addition of TAM or FULV, even at the lowest 
concentration tested of 0.001 µM (Figures 3.3.1a and 3.3.2a). AR activity was increased 
with MIB treatment and this was unaffected by TAM or FULV except at the highest 
concentration tested of 10 µM (Figures 3.3.1b and 3.3.2b). To support these results, 
immunoblotting was performed on the lysates from these assays (Figures 3.3.1-2). The  
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Figure 3.3.1 ERα and AR activity and expression in response to Tamoxifen  
COS-1 cells were transfected with plasmids encoding (a) Oestrogen Receptor α (ERα) 
and an oestrogen responsive luciferase reporter (ERE-LUC) or (b) Androgen Receptor 
(AR) and a luciferase reporter under the control of an Androgen Response Element 
(TAT-GRE-EIB-LUC-1). Cells were also transfected with a β-galactosidase control 
vector (PDM-LAC-Z-β-GAL). Cells were treated for 24 hours with 1 nM AR ligand 
(Mibolerone, MIB) or ERα ligand (17-β-Oestradiol, E2), along with varying 
concentrations of the anti-oestrogen Tamoxifen. ERα or AR activity was measured 
using luciferase and normalised to β-galactosidase activity. Mean of at least 3 
independent duplicates ±SE. T-Test comparing receptor activity in the presence of 
ligand +/- Tamoxifen. ***P<0.0005. Western Blotting was conducted on the ligand 
treated samples to assess ERα and AR expression, with β-Tubulin included as a 
loading control. The percentage expression of ERα or as compared to the untreated 
samples was analysed using Fusion X Software. 
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(AR) and a luciferase reporter under the control of an Androgen Response Element 
(TAT-GRE-EIB-LUC-1). Cells were also transfected with a β-galactosidase control 
vector (PDM-LAC-Z-β-GAL). Cells were treated for 24 hours with 1 nM AR ligand 
(Mibolerone, MIB) or ERα ligand (17-β-Oestradiol, E2), along with varying 
concentrations of the anti-oestrogen Tamoxifen. ERα or AR activity was measured 
using luciferase and normalised to β-galactosidase activity. Mean of at least 3 
independent duplicates ±SE. T-Test comparing receptor activity in the presence of 
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Figure 3.3.2 ERα and AR activity and expression in response to Fulvestrant  
COS-1 cells were transfected with plasmids encoding (a) Oestrogen Receptor α (ERα) 
and an oestrogen responsive luciferase reporter (ERE-LUC) or (b) Androgen Receptor 
(AR) and a luciferase reporter under the control of an androgen response element 
(TAT-GRE-EIB-LUC-1). Cells were also transfected with a β-galactosidase control 
vector (PDM-LAC-Z-β-GAL). Cells were treated for 24 hours with 1 nM AR ligand 
(Mibolerone, MIB) or ERα ligand (17-β-Oestradiol, E2), along with varying 
concentrations of the anti-oestrogen Fulvestrant (FULV). ERα or AR activity was 
measured using luciferase and normalised to β-galactosidase activity. Mean of 3 
independent duplicates ±SE. T-Test comparing receptor activity in the presence of 
ligand +/- FULV. ***P< 0.0005. Western Blotting was conducted on the ligand treated 
samples to assess ERα and AR expression, with β-Tubulin included as a loading 
control. Densitometry analysis was completed using the Fusion FX software to identify 
the percentage of AR and ERα in FULV treated samples as compared to untreated. 
The percentage expression of ERα or AR as compared to the untreated samples was 
analysed using Fusion X Software. 
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results produced demonstrated that upon TAM treatment both ERα and AR levels 
remained relatively constant (Figures 3.3.1a-b). In contrast, increasing FULV treatment 
resulted in a decrease in ERα levels (Figure 3.3.2a) but AR expression remained 
relatively constant (Figure 3.3.2b). As a control, the activity of AR in the presence of the 
anti-androgen Bicalutamide (BIC) was investigated (Figure 3.3.3). As expected, AR 
activity was increased with MIB treatment and this was abrogated by BIC from the 1 µM 
concentration. This is in accordance with other work, as for PCa research a 10 µM BIC 
concentration or higher is often used (Barboro et al., 2013, Nunes et al., 2017). 
3.4 Anti-oestrogen treatment blocks AR/ERα cross-talk, resulting in enhanced AR 
activity  
It has previously been demonstrated that AR and ERα cross-talk supresses the 
activity of both receptors (Panet-Raymond et al., 2000, Fioretti et al., 2014, Lanzino et al., 
2005). Several mechanisms have been proposed to explain this inhibitory activity. For 
example, a direct interaction between the receptors and competition for common co-
factors have been demonstrated to repress receptor activity (Panet-Raymond et al., 2000, 
Fioretti et al., 2014, Lanzino et al., 2005). Additionally, work conducted by Peters et al., 
2009 has demonstrated that AR can supress ERα signalling via interaction with EREs, 
and reporter assays demonstrated that AR can inhibit ERα activity. However, there has 
been no investigation focussing on the effect of endocrine therapies upon this cross-talk.   
Initially it was confirmed that AR and ERα can inhibit each other’s activity.  COS-1 
cells were transfected with AR and/or ERα and an oestrogen responsive luciferase  
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Figure 3.3.3 Bicalutamide inhibits ligand-dependent activation of AR 
COS-1 cells were transfected with plasmids encoding Androgen Receptor (AR) 
and a luciferase reporter under the control of an androgen response element 
(TAT-GRE-EIB-LUC-1). Cells were also transfected with a β-galactosidase 
control vector (PDM-LAC-Z-β-GAL). Cells were treated for 24 hours with 1 nM 
AR ligand (Mibolerone, MIB), along with varying concentrations of the anti-
androgen Bicalutamide (BIC). AR activity was measured using luciferase and 
normalised to β-galactosidase activity. Mean of 3 independent duplicates ±SE. 
T-Test comparing receptor activity in the presence of ligand +/- BIC. *P<0.05, 
***P<0.0005. 
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normalised to β-galactosidase activity. Mean of 3 independent duplicates ±SE. 
T-Test comparing receptor activity in the presence of ligand +/- BIC. *P<0.05, 
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reporter (ERE-LUC) or a luciferase reporter under the control of an ARE (TAT-GRE-EIB-
LUC-1). Cells were additionally either co-transfected with the other receptor or an Empty 
Vector (EV control) and a β-galactosidase control expression vector (PDM-LAC-Z-β-
GAL). Receptor activity was measured using luciferase assays in the presence of the 
relevant ligands (MIB/E2 respectively) (Figure 3.4.1). The results demonstrated that co-
expression of AR and ERα significantly supressed ERα by 2.8-fold (Figure 3.4.1a) and 
AR activity by 4.4-fold (Figure 3.4.1b).  
 To investigate the effect of anti-oestrogen therapies on this AR/ERα cross-talk, 
luciferase assays were conducted using COS-1 cells as above. Cells were treated with 
the relevant ligand/both ligands and with different concentrations of either TAM (Figure 
3.4.2) or FULV (Figure 3.4.4) prior to luciferase assays being conducted. As an inhibitory 
effect on ERα activity was previously observed from the lowest concentrations of both 
anti-oestrogens (Figures 3.3.1a and 3.3.2a), 1 nM and 10 nM FULV/TAM concentrations 
were selected for this experiment. To support these results, immunoblotting of the lysates 
from these assays were also conducted (Figures 3.4.3 and 3.4.5). 
As expected, ERα activity was inhibited by both TAM (Figure 3.4.2a) and FULV 
(Figure 3.4.4a). The presence of AR reduced ERα activity, but both TAM and FULV -
induced ERα inhibition was still observed (Figures 3.4.2b and 3.4.4b). A small increase 
in AR activity following anti-oestrogen treatment was observed in the absence of ERα, 
but this was not always significant (Figure 3.4.2c and 3.4.4c). The presence of ERα 
reduced AR activity, and this effect was reversed with the addition of TAM (Figure 3.4.2d) 
or FULV (Figure 3.4.4d). Interestingly, AR activity increased approximately 250 % in 
response to 10 nM FULV treatment.  Therefore, ERα inhibits AR activity and this inhibition  
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Figure 3.4.1 ERα and AR inhibit each other’s activity 
COS-1 cells were seeded in hormone-depleted media and transfected with plasmids 
encoding (a) Oestrogen Receptor α (ERα) and an oestrogen responsive luciferase 
reporter (ERE-LUC) or (b) Androgen Receptor (AR) and a luciferase reporter under 
the control of an Androgen Response Element (TAT-GRE-EIB-LUC-1). Cells were also 
co-transfected with either the alternative receptor or an Empty Vector (EV) and a β-
galactosidase control vector (PDM-LAC-Z-β-GAL). Following transfection, cells were 
incubated for 24 hrs prior to treatment with the relevant ligands 1 nM Mibolerone (MIB) 
for AR/1 nM 17-β-Oestradiol (E2) for ERα/both. (a) ERα and (b) AR activity was 
measured using luciferase assays, normalised to β-galactosidase activity and 
expressed as a percentage of AR/ERα activity in the absence of the alternative 
receptor. Mean of 3 independent duplicates ±SE. T-Test **P<0.005, ***P<0.0005. 
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reporter (ERE-LUC) or (b) Androgen Receptor (AR) and a luciferase reporter under 
the control of an Androgen Response Element (TAT-GRE-EIB-LUC-1). Cells were also 
co-transfected with either the alternative receptor or an Empty Vector (EV) and a β-
galactosidase control vector (PDM-LAC-Z-β-GAL). Following transfection, cells were 
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Figure 3.4.2 Tamoxifen reverses the inhibitory effect of ERα upon AR signalling 
COS-1 cells were seeded in hormone-depleted media and transfected with plasmids 
encoding (a,b) Oestrogen Receptor α (ERα) and an oestrogen responsive luciferase 
reporter (ERE-LUC) or (c,d) Androgen Receptor (AR) and a luciferase reporter under 
the control of an Androgen Response Element (TAT-GRE-EIB-LUC-1). Cells were also 
co-transfected with either the alternative receptor (b,c) or an Empty Vector (EV) (a,c) 
and a β-galactosidase control vector (PDM-LAC-Z-β-GAL). Following transfection, 
cells were incubated for 24 hrs prior to treatment with 1 nM Mibolerone (MIB)/1 nM 17-
β-Oestradiol (E2)/both, along with varying concentrations of Tamoxifen (TAM). (a and 
b) ERα activity in response to ± AR and (c and d) AR activity in response to ± ERα 
activity were measured using luciferase assays. Luciferase activity was normalised to 
β-galactosidase expression and expressed as a percentage of AR/ERα activity in the 
absence of the alternative receptor and in the presence of MIB/E2. Mean of at least 3 
independent duplicates ± SE. T-Test *P<0.05, **P<0.005, ***P<0.0005. 
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Figure 3.4.3 ERα and AR expression in response to Tamoxifen 
COS-1 cells were seeded in hormone-depleted media and double transfections were 
conducted with plasmids encoding (a,b) Oestrogen Receptor α (ERα) and an 
oestrogen responsive luciferase reporter (ERE-LUC) or (c,d) Androgen Receptor (AR) 
and a luciferase reporter under the control of an androgen response element (TAT-
GRE-EIB-LUC-1). Cells were also transfected with either the other receptor (b,c) or 
an Empty Vector (EV) (a,c) and a β-galactosidase control vector (PDM-LAC-Z-β-GAL). 
Following transfection, cells were incubated for 24 hrs prior to treatment with 1 nM 
Mibolerone (MIB)/1 nM 17-β-Oestradiol (E2)/both, along with varying concentrations 
of Tamoxifen (TAM). Western blotting was conducted to assess ERα and AR 
expression, with β-Actin included as a loading control. Densitometry analysis was 
completed using the Fusion FX software to quantify AR and ERα levels in TAM treated 
samples as compared to untreated. 
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Figure 3.4.4 Fulvestrant reverses the inhibitory effect of ERα upon AR 
signalling 
COS-1 cells were seeded in hormone-depleted media and transfected with plasmids 
encoding (a,b) Oestrogen Receptor α (ERα) and an oestrogen responsive luciferase 
reporter (ERE-LUC) or (c,d) Androgen Receptor (AR) and a luciferase reporter under 
the control of an Androgen Response Element (TAT-GRE-EIB-LUC-1). Cells were also 
co-transfected with either the alternative receptor (b,c) or an Empty Vector (EV) (a,c) 
and a β-galactosidase control vector (PDM-LAC-Z-β-GAL). Following transfection, 
cells were incubated for 24 hrs prior to treatment with 1 nM Mibolerone (MIB)/1 nM 17-
β-Oestradiol (E2)/both, along with varying concentrations of Fulvestrant (FULV) and 
(a and b) ERα activity in response to ± AR. (c and d) AR activity in response to ± ERα 
activity were measured using luciferase assays. Luciferase activity was normalised to 
β-galactosidase expression and expressed as a percentage of AR/ERα activity in the 
absence of the alternative receptor and in the presence of MIB/E2. Mean of at least 3 
independent duplicates ± SE. T-Test, *P<0.05, **P<0.005, ***P<0.0005. 
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Figure 3.4.5 ERα and AR expression in response to Fulvestrant 
COS-1 cells were seeded in hormone depleted media and double transfections were 
condcuted with plasmids encoding (a,b) Oestrogen Receptor α (ERα) and an 
oestrogen responsive luciferase reporter (ERE-LUC) or (c,d) Androgen Receptor (AR) 
and a luciferase reporter under the control of an androgen response element (TAT-
GRE-EIB-LUC-1). Cells were also transfected with either the other receptor (b,c) or 
an Empty Vector (EV) (a,c) and a β-galactosidase control vector (PDM-LAC-Z-β-GAL). 
Following transfection, cells were incubated for 24hrs prior to treatment for 24 hours 
with 1 nM Mibolerone (MIB)/1 nM 17-β-Oestradiol (E2)/both, along with varying 
concentrations of Fulvestrant (FULV). Western Blotting was conducted to assess ERα 
and AR expression, with β-Actin included as a loading control. Densitometry analysis 
was completed using the Fusion FX software to identify the percentage of AR and ERα 
in TAM treated samples as compared to untreated. 
 
Figure 3.4.5 ERα and AR expression in response to Fulvestrant 
COS-1 cells were seeded in hormone depleted media and double transfections were 
condcuted with plasmids encoding (a,b) Oestrogen Receptor α (ERα) and an 
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can be abrogated through TAM treatment, and FULV appears to lead to hyperactivation 
of the AR (Figure 3.4.4d). 
As demonstrated previously in Figures 3.3.1a and 3.3.2a, in the absence of AR, 
ERα expression remained relatively constant with TAM treatment (Figure 3.4.3a) but was 
degraded by FULV (Figure 3.4.5a). However, in the presence of AR, FULV was unable 
to decrease ERα expression (Figures 3.4.5b, d) and TAM treatment appeared to stabilise 
ERα expression (Figures 3.4.3b, d). As expected from the reporter assays (Figure 
3.4.2a), E2-induced ERα expression was not affected by MIB treatment when ERα only 
was transfected (Figure 3.4.3a and 3.4.5.a). When the receptors were co-expressed in 
the presence of ARE-LUC, co-treatment with E2 stabilises ERα expression, but this effect 
was much greater in Figure 3.4.5 than Figure 3.4.3.  
It was demonstrated previously (Figures 3.3.1b and 3.3.2b) that AR expression 
remained relatively constant upon both TAM and FULV treatment at 1 nM and 10 nM anti-
oestrogen concentrations, and this was confirmed in Figure 3.4.3c and 3.4.5c. 
Additionally, AR expression remained relatively constant with FULV treatment, regardless 
of ERα co-expression (Figures 3.4.5b, d). When ERα and AR were co-expressed, AR 
expression remained relatively constant with TAM treatment when an ERE-LUC was 
present (Figure 3.4.3b), but when an ARE-LUC was present TAM treatment increased 
AR expression in the presence of MIB and co-treatment with E2 abrogated this effect 
(Figure 3.4.3d).  
To ensure that the activity seen in Figures 3.4.1, 2 and 4 was not due to AR or 
ERα binding to and activating the other receptor’s luciferase reporter, control experiments 
were performed where COS-1 cells were transfected with the ARE/ERE luciferase 
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reporters and Empty Vector (EV), AR and ERα separately and treated with the relevant 
ligand or ethanol (EtOH) as a control (Figure 3.4.6). The results demonstrated that the 
ARE/ERE luciferase reporters can only be significantly activated by the relevant receptor 
upon ligand binding. 
In conclusion, AR and ERα inhibit each other’s activity. Treatment with anti-
oestrogens (FULV/TAM) inhibit ERα activity, regardless of the presence of AR. 
FULV/TAM do not inhibit AR activity until higher concentrations (10 µM), however ERα 
inhibition of AR activity can be reversed through TAM/FULV treatment. 
3.5 The role of Androgen Receptor in the development of endocrine resistance 
3.5.1 Androgen promotes endocrine resistance in long term but not short term 
growth assays 
Growth assays were conducted to investigate if E2- or MIB-induced cellular 
proliferation of endocrine sensitive MCF7 cells is affected by anti-oestrogen (TAM or 
FULV) or anti-androgen (BIC) treatment (Figure 3.5.1). The results demonstrated that, as 
expected, MCF7 cells were responsive to E2 for growth, and slightly less responsive 
when co-treated with MIB, but this reduction was not significant. MIB treatment alone did 
not stimulate MCF7 cell growth. Following TAM treatment, E2-stimulated proliferation was 
not significantly reduced, but was significantly decreased with FULV treatment, and the 
presence of MIB could not rescue this effect, as was expected from the earlier reporter 
assays (Section 3.4). The addition of the anti-androgen BIC did not significantly enhance 
or abrogate the inhibitory action of the anti-oestrogen treated samples (Figure 3.5.1). 
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Figure 3.4.6 Investigation of the specificity of an Oestrogen Response Element 
(ERE) and an Androgen Response Element (ARE) luciferase reporter 
COS-1 cells were seeded in hormone depleted media and transfected with plasmids 
encoding Androgen Receptor (AR) and Oestrogen Receptor α (ERα) or Empty Vector 
(EV) and (a) a luciferase reporter under the control of an ARE (TAT-GRE-EIB-LUC-1) 
or (b) an oestrogen responsive luciferase reporter (ERE-LUC). Cells were also 
transfected with a β-galactosidase control vector (PDM-LAC-Z-β-GAL). Following 
transfection, cells were incubated for 24hrs prior to treatment for 24 hours with the 
relevant ligand,1 nM Mibolerone (MIB for AR/1 nM 17-β-Oestradiol (E2) for ERα. 
Activity was measured using luciferase and normalised to β-galactosidase expression 
and expressed as a percentage of AR/ERα activity with the correct response element 
in the presence of the relevant ligand. Mean of 3 independent duplicates ± SE. T-Test, 
**P<0.005, ****P<0.00005.   
 
 
Figure 3.4.6 Investigation of the specificity of an Oestrogen Response Element 
(ERE) and an Androgen Response Element (ARE) luciferase reporter 
 139 
 
To expand upon this work, colony formation assays were conducted in MCF7 cells 
over a period of 4 weeks using the same concentrations and combinations of hormones 
+/- anti-oestrogen treatments and stained using crystal violet (Figure 3.5.2). Additional 
treatments of MIB +/- TAM/FULV were included. These results demonstrated that MCF7 
cells were responsive to E2 for growth, and this effect was not abrogated by co-treatment 
with MIB. Interestingly, over this longer term assay, MCF7 cells were responsive to MIB 
for growth, although E2-induced growth was more pronounced. Treatment with 
TAM/FULV inhibited E2- or MIB-induced growth, but co-treatment with both MIB and E2 
was able to partially reverse this effect. Importantly, in contrast to a previous study that 
suggested BIC could antagonise the anti-proliferative effect of an AI (Macedo et al., 
2006), the anti-androgen BIC was able to block this androgen-induced growth and aid 
anti-oestrogen treatment. 
3.5.2 Anti-oestrogen treatment effects on ERα and AR target gene expression in 
endocrine sensitive cells 
To investigate target gene expression in endocrine sensitive cells and how 
endocrine therapies affects this, MCF7 cells were incubated in hormone-depleted media 
for 120 hours prior to treatment with 1 nM E2 ± 1 nM MIB ± the anti-oestrogens TAM or 
FULV for 8 hours, and qPCR performed. The regulation of two ERα target genes Trefoil 
Factor 1, (TFF1) and Myelocytomatosis Oncogene Cellular Homolog (MYC) (Figure 
3.5.3); two AR target genes N-myc Downstream-Regulated Gene 1 (NDRG1) and Zinc 
Finger And BTB Domain Containing 16 (ZBTB16) (Figure 3.5.4); and a gene regulated 
by both Gene Regulated in Breast Cancer 1 (GREB1) (Figure 3.5.5) were investigated. 
The references describing these target genes to explain why they were selected are  
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Gene 
AR / ERα Regulated 
Breast Cancer Prostate Cancer 
Gene Regulated in 
Breast Cancer 1 (GREB1) 
Positively regulated ERα 
target gene, important for 
oestrogen-induced BCa 
cell proliferation that has 
also been displayed as a 
ERα co-factor 
(Chand et al., 2012, 
Mohammed et al., 2013, Rae 
et al., 2005, Deschenes et 
al., 2007, Hodgkinson and 
Vanderhyden, 2014) 
Androgen-regulated gene 
important for PCa growth, 
but has been associated 
with organ-confined PCa 
and good prognosis  
(Rae et al., 2006, Antunes et 
al., 2012, Ngan et al., 2009, 
Hodgkinson and 
Vanderhyden, 2014) 
Myelocytomatosis 
Oncogene Cellular 
Homolog (MYC) 
Positively regulated, 
oestrogen-induced ERα 
target gene, which 
promotes BCa proliferation 
and whose deregulation is 
associated with BCa 
progression 
(Wang et al., 2011, Musgrove 
et al., 2008, Zhu et al., 2014, 
Dubik et al., 1987, Xu et al., 
2010) 
MYC overexpression 
deregulates AR in PCa and 
is linked to androgen-
independent PCa cell 
growth  
(Barfeld et al., 2017, Bernard 
et al., 2003) 
N-Myc Downstream-
Regulated Gene 1 
(NDRG1) 
Negatively associated with 
BCa progression  
(Wang et al., 2006) 
 
 
AR target gene, positively 
regulated by androgen in 
PCa cells, with a TSG 
function in PCa 
progression 
 (Nelson et al., 2002, Ngan et 
al., 2009, Masuda et al., 
2005, Li et al., 2015b, 
Bandyopadhyay et al., 2003) 
Trefoil Factor 1 (TFF1) Positively regulated ERα 
target gene in BCa, 
involved in BCa cell 
migration and anti-
apoptotic effects 
(Lin et al., 2004, Brown et al., 
1984, Westley et al., 1984, 
Welboren et al., 2007, Prest 
et al., 2002, Pelden et al., 
2013) 
Appears to promote PCa 
progression, but not so far 
linked to ERα or AR and its 
role is unclear  
(Abdou et al., 2008, Ather et 
al., 2004, Vestergaard et al., 
2010) 
Zinc Finger and BTB 
Domain Containing 16 
(ZBTB16) 
Androgen-regulated AR 
target gene in MABC 
(Robinson et al., 2011) 
Androgen Receptor target 
gene in PCa cells  
(van de Wijngaart et al., 
2009) 
Table 3.5.1 The regulation of AR and ERα target genes in Breast and Prostate 
Cancers 
References linking the Androgen Receptor (AR) and Oestrogen Receptor alpha (ERα) 
target genes to Prostate Cancer (PCa) and Breast Cancer (BCa) are provided. 
 
Figure 3.5.1: The effect of anti-oestrogen treatment on oestrogen and drogen 
stimulated grow h in MCF7 cell  
Table 3.5.1 The regulation of AR and ERα target genes in Breast and Prostate 
Cancers 
References linking the Androgen Receptor (AR) and Oestrogen Receptor alpha (ERα) 
target genes to Prostate Cancer (PCa) and Breast Cancer BCa) are provided. 
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Figure 3.5.1: The effect of anti-oestrogen treatment on oestrogen and 
androgen stimulated growth in MCF7 cells 
 
Cells were treated for 120 hours in hormone-depleted media with 1 nM of the 
synthetic androgen Mibolerone (M) or 17-β-Oestradiol (E), separately and in 
combination (EM) +/- 100 nM Tamoxifen (T), Fulvestrant (F) or Bicalutamide (B). 
Ethanol (EtOH) treatment was used as a vehicle control. Proliferation was 
assessed using WST-1 assays. Mean of at least 3 independent experiments, ±SE. 
T-test *P<0.05, ***P<0.005. 
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Figure 3.5.2: The effect of anti-oestrogen and anti-androgen treatment on 
long term oestrogen and androgen stimulated growth in MCF7 cells 
 
Cells were treated for 4 weeks in hormone-depleted media with 1 nM of the 
synthetic androgen Mibolerone (MIB) or 17-β-Oestradiol (E2), separately and in 
combination +/- 100 nM Tamoxifen (TAM), Fulvestrant (FULV) or Bicalutamide 
(BIC). Ethanol (EtOH) treatment was used as a vehicle control. A colony 
formation assay was conducted and the cells fixed with 4 % Paraformaldehyde 
and stained using 0.08 % crystal violet.  
 
 
Figure 3.5.2: The effect of anti-oestrogen and anti-androgen treatment on 
long term oestrogen and androgen stimulated growth in MCF7 cells 
 
Cells were treated for 4 weeks in hormone-depleted media with 1 nM of the 
synthetic androgen Mibolerone (MIB) or 17-β-Oestradiol (E2), separately and in 
combination +/- 100 nM Tamoxifen (TAM), Fulvestrant (FULV) or Bicalutamide 
(BIC). Ethanol (EtOH) treatment was used as a vehicle control. A colony 
formation assay was conducted and the cells fixed with 4 % Paraformaldehyde 
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summarised in Table 3.5.1. The concentration of the anti-oestrogens utilised in this study 
was 100 nM, consistent with recent studies (e.g. Periyasamy et al., 2015) and a pre- 
treatment with them 24 hours prior to hormone treatment was also explored.  
E2 treatment significantly increased the expression of both the ERα targets, TFF1 
3.4-fold and MYC 2.1-fold (Figures 3.5.3a-b). Co-treatment of MIB with E2 was unable to 
compete with the E2-induced gene expression for either TFF1 or MYC (Figures 3.5.3a-
b), as also demonstrated in earlier reporter assays (Figures 3.4.2 and 4). As expected, 
E2-induced expression of these ERα targets was inhibited via both anti-oestrogens 
(Figures 3.5.3a-b). MIB was not able to enhance TFF1 (Figure 3.5.3a) or MYC expression 
(Figure 3.5.3b). 
The expression of the AR target gene ZBTB16 was not induced via E2 treatment 
(Figure 3.5.4a). MIB strongly induced ZBTB16 expression by approximately 1,000 % and 
co-treatment with E2 inhibited this increase by 54.9 %. Importantly, the anti-oestrogen 
treatments reversed this inhibitive action of oestrogen, enhancing AR activity, but pre-
treatment with anti-oestrogens appears to reduce this effect (Figure 3.5.4a). Additionally, 
the expression of the alternative AR target NDRG1 was not induced following MIB 
treatment, however co-treatment with E2 still inhibited its expression by 55.1 % and pre-
treatment with anti-oestrogens were able to restore its expression (Figure 3.5.4b).  
Finally, the expression of a target gene for both AR and ERα GREB1 was explored 
(Figure 3.5.5). Both E2 and MIB significantly enhanced GREB1 expression by 12.5-fold 
and 3.8-fold respectively. This gene is therefore more responsive to oestrogen than 
androgen. Co-treatment with MIB did not reduce the E2-induction of this gene. All anti-
oestrogen treatments were able to significantly reduce E2-induced GREB1 expression, 
regardless of MIB co-treatment (Figure 3.5.5).  
 144 
 
 
   
0
0.5
1
1.5
2
2.5
3
Et E2 ET ETp EF EFp M EM EMT EMTp EMF EMFp
R
e
la
ti
v
e
 E
x
p
re
s
s
io
n
* 
 
* 
 
* 
 
* 
 * 
 
* 
 
* 
 
* 
 
0
1
2
3
4
5
6
Et E2 ET ETp EF EFp M EM EMT EMTp EMF EMFp
R
e
la
ti
v
e
 E
x
p
re
s
s
io
n
*  * 
*  * 
*  * 
*  * 
*  * 
Figure 3.5.3 Expression of ERα target genes in MCF7 cells 
MCF7 cells were incubated in hormone depleted media for 120 hours, treated with 
1 nM of the relevant hormones 17-β-Oestradiol (E2) ± Mibolerone (M) or Ethanol 
(Et) as a control ± 100 nM Fulvestrant (F) or Tamoxifen (T) for 8 hours. Some 
samples were pre-treated with Fulvestrant/Tamoxifen 24 hours prior to hormone 
treatments (Fp/Tp respectively). RNA was extracted, reverse transcribed into 
cDNA and qPCR was conducted using SYBR green to measure the expression 
level of Oestrogen Receptor alpha (ERα) targets (a) Trefoil Factor 1 (TFF1) and 
(b) Myelocytomatosis Oncogene Cellular Homolog (MYC). Expression was 
normalised to RPL19 ribosomal protein, L19, and expression is relative to the MIB-
treated MCF7 sample. Mean of 3 independent experiments are displayed ±SE. T-
Test *P<0.05. 
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Figure 3.5.4 Expression of AR target genes in MCF7 cells 
MCF7 cells were incubated in hormone depleted media for 120 hours, treated with 
1 nM of the relevant hormones 17-β-Oestradiol (E2) ± Mibolerone (M) or Ethanol 
(Et) as a control ± 100 nM Fulvestrant (F) or Tamoxifen (T) for 8 hours. Some 
samples were pre-treated with Fulvestrant/Tamoxifen 24 hours prior to hormone 
treatments (Fp/Tp respectively). RNA was extracted, reverse transcribed into cDNA 
and qPCR was conducted using SYBR green to measure the expression level of 
Androgen Receptor (AR) target genes (a) Zinc Finger And BTB Domain Containing 
16 (ZBTB16) and (b) N-myc Downstream-Regulated Gene 1 (NDRG1). Expression 
was normalised to RPL19 ribosomal protein, L19, and expression is relative to the 
(a) EtOH or (b) MIB-treated MCF7 sample. Mean of 3 independent experiments are 
displayed, ±SE. T-Test *P<0.05, ***P<0.0005. 
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Figure 3.5.5 Expression of an AR and ERα target gene in MCF7 cells 
MCF7 cells were incubated in hormone depleted media for 120 hours, treated with 
1 nM of the relevant hormones 17-β-Oestradiol (E2) ± Mibolerone (M) or Ethanol 
(Et) as a control ± 100 nM Fulvestrant (F) or Tamoxifen (T) for 8 hours. Some 
samples were pre-treated with Fulvestrant/Tamoxifen 24 hours prior to hormone 
treatments (Fp/Tp respectively). RNA was extracted, reverse transcribed into cDNA 
and qPCR was conducted using SYBR green to measure the expression level of 
Androgen Receptor (AR) and Oestrogen Receptor alpha (ERα) target Gene 
Regulated in Breast Cancer 1 (GREB1). Expression was normalised to RPL19 
ribosomal protein, L19, and expression is relative to the MIB-treated MCF7 sample. 
Mean of 3 independent experiments are displayed, ±SE. T-Test *P<0.05, 
***P<0.0005. 
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In conclusion, the results demonstrated that the addition of anti-oestrogens 
decreases the hormone-induced expression of ERα regulatory target genes and genes 
regulated by AR and ERα, yet reverses the inhibitory action of E2 upon AR target genes. 
This demonstrates that treating endocrine sensitive disease with anti-oestrogens inhibits 
ERα, which could reduce this cross-talk and therefore increase AR activity. 
3.5.3 E2 abrogates MIB-induced AR enrichment at an ARE, and anti-oestrogens can 
partially rescue this effect  
It has been previously shown that AR/ERα cross-talk inhibits signalling and that 
anti-oestrogens can reverse this. To investigate the possible mechanism of this cross-
talk, Chromatin Immunoprecipitation (ChIP) assays were used to assess ligand-
dependent AR recruitment to DNA in MCF7 cells, and how this is altered by anti-
oestrogen treatment. MCF7 cells were treated with ± 1 nM MIB ± 1 nM E2 for 4 hours ± 
pre-treatment with 100 nM TAM/FULV 24 hours prior to hormone treatments. Cells were 
crosslinked using formaldehyde and sonicated to approximately 200 bp (Figure 3.6a), 
and ChIP performed using an antibody specific for the AR. qPCR was conducted to 
quantify DNA enrichment at a known ARE located between exons 3 and 4 of the ZBTB16 
gene (ZBT ARE) and a relative negative control region (ZBT ARE -ve) 2,443 bp upstream 
(Figures 3.5.6c-d). A schematic to demonstrate the location of these sites is included 
(Figure 3.5.6b). As expected, AR bound to the ARE region in response to MIB and this 
binding was reduced by E2 treatment (Figures 3.5.6c-d). This effect could be partially 
rescued via pre-treatment with TAM (Figures 3.5.6c) or FULV (Figure 3.5.6d). 
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Figure 3.5.6: E2 reduces MIB-induced AR enrichment at an ARE, and this effect 
can be partially rescued via Tamoxifen or Fulvestrant 
 
MCF7 cells were treated with ± 1 nM MIB ± 1 nM E2 for 4 hours ± pre-treatment with 
100 nM TAM (c) / FULV (d) 24 hours prior to hormone treatments. Ethanol (EtOH) was 
used as vehicle control. Cells were crosslinked using formaldehyde and sonicated to 
approximately 200 bp (a). ChIP assays were performed using an antibody specific for 
the AR. Subsequent qPCR was conducted to identify DNA enrichment at a known 
Androgen Response Element (ARE) upstream of the Zinc Finger And BTB Domain 
Containing 16 (ZBTB16) gene (ZBT ARE) and its relative negative control region (ZBT 
ARE -ve) (c, d). Enrichment values are relative to the ZBT ARE -ve EtOH sample. 
Mean of 2 independent experiments are displayed for (c) and a representative 
replicate for (d) ±SE. A schematic of ZBT ARE and its negative region is included (b).  
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3.6 Discussion  
3.6.1 ERα regulates AR in endocrine sensitive disease 
The majority of BCas are endocrine sensitive, for which cancer progression is 
driven by ERα (Chuffa et al., 2017, Rakha and Green, 2016, Ali and Coombes, 2002). 
ERα is a ligand-dependent transcription factor, and upon ligand (commonly E2) binding, 
it translocates to the nucleus and interacts as a dimer with specific DNA sequences 
termed Oestrogen Response Elements (EREs) to regulate transcription (Sever and 
Glass, 2013, Brooke and Bevan, 2009, Dehm and Tindall, 2007, Maruthanila et al., 2016).  
It has been demonstrated that ERα and AR expression is often correlated in BCa 
(Table 3.2.1 and Figure 3.2.1) as has been previously reported by others (Vera-Badillo et 
al., 2014, Collins et al., 2011, Lin et al., 2015). This co-expression suggests that the 
receptors could both be regulated by a common factor, or that one receptor regulates the 
expression of the other. Knockdown of each receptor separately and subsequent 
immunoblotting analysis revealed that ERα knockdown also resulted in a reduction in AR 
expression, indicating that ERα might regulate AR expression (Figure 3.2.2). 
Consequently, three potential ERE sites were identified: one upstream of AR (ERE-19,247-
18,610), and two were located between exons 3 and 4 of the AR gene (ERE+150,441-758 and 
ERE+151,438-726). Luciferase reporter assays were conducted to investigate whether these 
were functional sites (Figures 3.2.3 and 3.2.5). The results demonstrated that, 
interestingly, ERα activity was significantly responsive to E2 in ERE+151,438-726 which 
contains a perfect palindromic ERE sequence (Figure 3.2.5b) suggesting that ERα might 
regulate AR expression via this site.  
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On the other hand, for the two additional sites investigated, one upstream of AR 
(ERE-19,247-18,610) and one located between exons 3 and 4 of the AR gene (ERE+150,441-
758), ERα activity was not responsive to E2 for either site under the conditions employed 
(Figures 3.2.3b and 3.2.5b). However, ERE+150,441-758 appeared to be constitutively active, 
regardless of ERα expression or E2 treatment (Figure 3.2.5b), suggesting that an 
alternative transcription factor could be inducing expression through this region. 
Bioinformatics analysis of this region revealed transcription factor response elements for 
20 alternative transcription factors, whose expression were significantly associated with 
AR in BCa (Table 3.2.2). The two most significant proteins were XBP1, involved in 
immune and cellular stress responses (He et al., 2010) and previously linked to BCa 
including the promotion of endocrine resistance (Gomez et al., 2007, Gupta et al., 2016); 
and c-Myb, involved in hematopoiesis (Lorenzo et al., 2011, Bengtsen et al., 2015) and 
has been previously implicated in promoting BCa progression and metastasis through 
enhancing the Wnt/β-catenin/Axin2 signalling pathway (Li et al., 2016) (Figure 3.2.6). 
Additionally, it was discovered that another transcription factor with binding sites in this 
region and significantly associated with AR in BCa was FOXA1, a known pioneer factor 
that has been demonstrated as key for AR functioning in Molecular Apocrine (ERα-
negative, AR-positive) BCa progression (Robinson et al., 2011). These results could be 
explored further in the future to identify which factors might be regulating AR expression, 
which might subsequently lead to an increase in AR levels during therapy resistance. For 
example, by conducting siRNA knockdown of the factors or ChIP assays to confirm which 
factors have a role in this regulation could be beneficial. 
Although ERE-19,247-18,610 appeared to be non-functional from the luciferase 
reporter assays, ChIP analysis revealed that ERα was indeed recruited to this site. A 
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potential explanation for this apparent lack of consistency between the two results could 
be explained by a study by Pan et al. (2008). The authors demonstrated that a distal ERE 
for the TFF1 gene acts as a transcriptional enhancer to enable maximum gene 
expression, and this is achieved via long-range chromosomal interactions with a proximal 
TFF1 ERE (Pan et al., 2008). The inference from this is that either this site could require 
the presence of another ERE for other transcription factors or pioneer factors for its 
transcriptional activation, that are unable to bind to the short region of DNA cloned for 
these studies.   
3.6.2 Anti-oestrogen effects on ERα or AR activity 
The effects of endocrine therapies on ERα and AR activity was investigated using 
two commonly prescribed anti-oestrogens: TAM and FULV. As expected, both anti-
oestrogens successfully inhibited E2-induced ERα activity, from the lowest 
concentrations of the drugs tested (Figures 3.3.1a and 3.3.2a). Immunoblotting analysis 
of these lysates demonstrated that ERα expression remained relatively constant with 
TAM treatment, but FULV decreased its expression (Figures 3.3.1a and 3.3.2a). These 
differences can be explained by the differences in the mechanism of these anti-
oestrogens. TAM (a SERM) has tissue-specific activity, and in tumour and mammary cells 
competitively binds to ERα. TAM promotes receptor dimerisation, similar to oestrogen, 
however instead of promoting the formation a transcriptional complex, it promotes the 
formation of an inhibitory nuclear complex that reduces the levels of DNA synthesis and 
oestrogen signalling (Kaklamani and Gradishar, 2017). On the other hand, FULV (a 
SERD) acts as a pure ERα antagonist, competitively interacting with ERα, which 
additionally to blocking and reducing its activity, advances the speed of its degradation 
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(Kaklamani and Gradishar, 2017, Lumachi et al., 2015, Lanvin et al., 2007, Osborne et 
al., 2004), as demonstrated by immunoblotting in Figure 3.3.2a. 
MIB-induced AR activity was unaffected by anti-oestrogen treatment except at the 
highest concentration tested of 10 µM (Figures 3.3.1b and 3.3.2b). Previously it has been 
suggested that FULV may also have anti-androgen activity, having been demonstrated 
to downregulate AR expression and suppress AR-induced growth in the LNCaP PCa cell 
line (Bhattacharyya et al., 2006). However, the AR in this cell line is known to have a 
mutation causing an alteration in its LBD (Veldscholte et al., 1992), therefore it was 
unknown whether FULV would have an effect on wildtype AR activity. Interestingly, MIB-
induced wildtype AR activity in our study was significantly decreased by FULV treatment 
only at the highest concentration tested of 10 µM (Figure 3.3.2b), which corresponded 
with the concentration used by Bhattacharyya et al. (2006), and therefore their study 
agrees with these findings. However, our findings demonstrated that AR expression was 
not decreased by 24-hour FULV treatment at this concentration, therefore the 48-hour 
treatment period used by Bhattacharyya et al. (2006) could be required to demonstrate 
this effect. Furthermore, Bhattacharyya et al. (2006) described the mechanism by which 
FULV leads to reduced AR levels in LNCaP cells is not via a direct interaction with AR or 
an induction of AR proteasomal degradation as may be expected. Instead, the authors 
demonstrated that FULV reduces AR expression at the transcriptional level 
(Bhattacharyya et al., 2006). Our results, however, have indicated that ERα regulates AR 
(Sections 3.2 and 3.6.1), and therefore it could be inferred that in fact FULV is targeting 
and degrading ERα, and thereby down-regulating AR expression.  
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3.6.3 Anti-oestrogen treatment abrogates AR/ERα cross-talk in endocrine sensitive 
disease 
In endocrine-sensitive disease, AR has been widely demonstrated to have an 
inhibitory effect on BCa progression and its expression is associated with indicators of a 
positive clinical outcome (Tsang et al., 2014, Niemeier et al., 2010, Fioretti et al., 2014). 
It has previously been demonstrated that AR and ERα cross-talk supresses the activity 
of both receptors (Panet-Raymond et al., 2000, Fioretti et al., 2014, Lanzino et al., 2005). 
Mechanisms of AR and ERα cross-talk include a direct interaction between the receptors 
(Panet-Raymond et al., 2000) and competition for binding to the regulatory regions of 
target genes (Peters et al., 2009). In support of this, Figure 3.4.1 indicates that when both 
the AR and ERα are co-expressed they compete, and inhibit each other’s activity. This 
competitive role of the receptors could explain why co-expression is associated with a 
good prognosis. 
To explore the effect of endocrine therapies upon AR/ERα cross-talk, the effect of 
TAM and FULV on AR and ERα activity when both receptors were co-transfected was 
investigated. AR expression had no impact on the inhibitory effects of the anti-oestrogens 
on ERα activity. However, TAM reversed ERα suppression of AR activity, and FULV 
treatment actually increased AR activity to levels 2.7-fold higher than those induced by 
androgen alone (Figures 3.4.2 and 3.4.4).  
This more potent activity induced by FULV does not appear to be as a result of 
ERα degradation, because at the concentrations tested, ERα levels (although showing a 
slight decrease) still remained fairly constant. Additionally, it does not appear that this 
effect is due to the higher affinity of FULV to ERα than TAM as described by others 
 154 
 
(Kaklamani and Gradishar, 2017, Martinkovich et al., 2014, Osborne et al., 2004), as a 
comparison of Figures 3.3.1a and 3.3.2a demonstrate that at the 1 nM or 10 nM 
concentrations FULV does not have a more potent inhibition of ERα than TAM. Therefore, 
this mechanism is presumably due to the difference in the mechanism via which these 
two anti-oestrogens work, as described previously in Section 3.6.2. 
 In Molecular Apocrine (ERα-negative, AR-positive) BCa, AR has a putative 
oncogenic effect and its expression is associated with aggressive tumours (Doane et al., 
2006; Robinson et al., 2011; Lehmann-Che et al., 2013). This suggests that in the 
absence of a functioning ERα, AR signalling can be oncogenic in certain circumstances. 
In accordance with this, our results demonstrate that in the absence of functional ERα, 
as a result of endocrine therapy, AR activity is increased.  
To extend these results into a more physiologically relevant system, the effects of 
anti-oestrogens upon the expression of ERα target genes TFF1 and MYC (Figure 3.5.3); 
AR target genes NDRG1 and ZBTB16 (Figure 3.5.4); and a gene regulated by both 
GREB1 (Figure 3.5.5) was investigated in MCF7 cells.  
TFF1 is a strongly established positively regulated ERα target gene in BCa (Lin et 
al., 2004, Brown et al., 1984, Westley et al., 1984, Welboren et al., 2007). Target gene 
analysis in MCF7 cells revealed that TFF1 expression was induced following E2 
treatment, and this increase was inhibited by the anti-oestrogens FULV and TAM (Figure 
3.5.3a). This demonstrates that, as expected, ERα target gene expression is responsive 
to E2 treatment and anti-oestrogens in endocrine sensitive disease. This was additionally 
confirmed in an alternative ERα target gene MYC (Wang et al., 2011) (Figure 3.5.3b). 
Interestingly, co-treatment of MIB with E2 was unable to compete with the E2-induced 
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gene expression for either TFF1 or MYC (Figures 3.5.3a-b), as also demonstrated in 
earlier reporter assays (Figures 3.4.2 and 4), suggesting that AR/ERα cross-talk is ligand 
independent. 
The ZBTB16 gene has been shown by Robinson et al. (2011) to be an androgen-
regulated AR target in Molecular Apocrine BCa. Therefore, its androgen-regulation in 
endocrine sensitive disease (MCF7 cells) was explored. ZBTB16 expression was strongly 
induced via MIB treatment (by 1,024.8 %), and co-treatment with E2 inhibited this 
increase by 54.9 %. Importantly, all of the anti-oestrogen treatments reversed this 
inhibitive action of oestrogen, enhancing AR activity (Figure 3.5.4a). This suggests that 
ERα inhibits AR signalling, and that anti-oestrogen inhibition of ERα results in an increase 
in AR signalling, in accordance with other results (Sections 3.6.3 and 3.6.7). To explore 
the mechanism via which this occurs, ChIP assays were conducted to investigate the 
effect of E2 and TAM/FULV treatment on ligand-dependent AR recruitment to a known 
ARE upstream of the ZBTB16 gene. The results produced demonstrated that AR bound 
to the ARE region in response to MIB, binding was inhibited by E2 treatment (Figures 
3.5.6c-d), and that this effect could be partially reversed via treatment with TAM (Figure 
3.5.6c) or FULV (Figure 3.5.6d). It has been demonstrated previously that AR and ERα 
can compete for common sites (Peters et al., 2009), which could explain the mechanism 
via which this ERα antagonism is occurring. 
NDRG1 expression was not significantly altered following androgen treatment, 
however co-treatment with E2 still inhibited its expression by 55.1 %, and pre-treatment 
with anti-oestrogens were able to significantly induce its expression (Figure 3.5.4b). 
NDRG1 is gene that is positively regulated by androgen in the LNCaP PCa cell line 
(Nelson et al., 2002, Ngan et al., 2009) that has been identified as an AR target gene 
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(Masuda et al., 2005). However, contrastingly to these findings, many studies have also 
indicated that NDRG1 acts as a Tumour Suppressor Gene in PCa, associating it’s 
downregulation with enhanced cellular proliferation and invasion (Li et al., 2015b) and 
metastasis (Bandyopadhyay et al., 2003). Genes regulated in PCa by AR are therefore 
not necessarily regulated by AR in BCa, which could be due to differences in co-
factors/pioneer factors and/or genomic modifications. 
GREB1 is a known target gene for both AR (Rae et al., 2006) and ERα (Chand et 
al., 2012). GREB1 expression was induced via both E2 or MIB, 12.5-fold and 3.8-fold 
respectively, so this gene was much more responsive to oestrogen than androgen (Figure 
3.5.5). All anti-oestrogen treatments were able to significantly reduce E2-induced GREB1 
expression, regardless of MIB co-treatment (Figure 3.5.5). This suggests that ERα activity 
is key for this gene’s expression, and during inhibition of ERα, AR regulation of this gene 
does not increase. Therefore, it could be inferred that for the expression of GREB1 AR 
and ERα are not competing and therefore its expression is inhibited by anti-oestrogen 
treatment. 
In conclusion, anti-oestrogen treatment inhibited the oestrogen-induced 
expression of ERα regulatory target genes, but androgen can abrogate this effect for 
certain targets. On the other hand, anti-oestrogen treatment enhanced the AR target 
genes, demonstrating that treating endocrine sensitive disease with anti-oestrogens 
inhibits ERα, which subsequently results in an increase in AR activity on AR target genes. 
However, anti-oestrogen treatment inhibited the gene regulated by both AR and ERα, 
which suggests that genes where it appears that AR and ERα are not competing are 
inhibited by anti-oestrogen treatment. 
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3.6.4 Anti-oestrogen treatment enhances androgen-induced growth in endocrine 
sensitive BCa 
The effects of androgen (MIB) and oestrogen (E2) on MCF7 proliferation were 
explored. It is well established that endocrine sensitive cell lines are highly responsive to 
E2 for growth (Keen and Davidson, 2003, Rakha and Green, 2016, Ali and Coombes, 
2002, Pan et al., 2017). Growth assays demonstrated that the proliferation of MCF7s, as 
expected, was stimulated by E2, but co-treatment with MIB reduced this E2-induced 
growth (Figure 3.5.1). This is in support of previous work conducted where treatment with 
the androgens DHT and MIB inhibited E2-stimulated cellular proliferation in MCF7 cells 
and in the additional ERα- and AR- positive cell line T47D (Cops et al., 2008). This is 
likely to be a result of the AR/ERα cross-talk discussed in Section 3.6.3, where AR 
appears to have an opposing role to ERα and supresses BCa progression (Rahim and 
O'Regan, 2017, Fioretti et al., 2014, Tarulli et al., 2014, Lanzino et al., 2013). This also 
supports past studies that have demonstrated the potential therapeutic benefit of the 
administration of androgens in ERα-positive BCa (Poulin et al., 1988, Cops et al., 2008, 
Kampa et al., 2005, Dauvois et al., 1991). However, in contrast to these results, long term 
colony formation assays conducted on MCF7 cells demonstrated that following 4 weeks 
of treatment, MIB could stimulate MCF7 cell growth (Figure 3.5.2). This colony formation 
assay could be seen as a model of the development of AI resistance as the cells were 
grown in E2-depleted media, suggesting that MIB could begin to stimulate growth as a 
resistance mechanism. An inference that could be concluded from this is that the 
antagonistic effect of AR on ERα-induced growth can be overcome over time with 
exposure to MIB, and AR can in some cases begin to drive BCa cell growth.  
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The effects of anti-oestrogen (TAM/FULV) treatment on E2/MIB-stimulated growth 
in MCF7 cells was investigated in both short term proliferation assays (Figure 3.5.1) and 
long term colony formation assays (Figure 3.5.2). FULV effectively inhibited E2-
stimulated growth in both assays, but TAM only over the longer time period (Figures 3.5.1-
2). Treatment with androgen was not able to rescue anti-oestrogen induced inhibition of 
oestrogen-stimulated growth in the short term growth assays (Figure 3.5.1). However, 
when cells were grown for 4 weeks, androgen was able to rescue both FULV- and TAM-
induced inhibition of oestrogen-stimulated growth (Figure 3.5.2). Therefore, it appears 
that AR is able to drive resistance to these therapies in an endocrine sensitive cell line. 
From this it can be inferred that when ERα function is inhibited through endocrine therapy, 
over time androgen signalling can begin to stimulate growth. This is in accordance with 
the results produced from reporter assays and gene expression analysis suggesting that 
TAM and FULV treatment remove the repressive cross-talk of ERα with AR and therefore 
AR activity is enabled (Figures 3.4.2d and 3.4.4d). However, both TAM and FULV 
inhibited MIB-stimulated growth in the colony formation assays (Figure 3.5.2), suggesting 
that the presence of an inhibited ERα is key for enhanced AR signalling to occur. 
However, it is unclear why in the absence of E2 that this effect is not seen as it would be 
expected that ERα would sequester shared co-repressors such as the Silencing Mediator 
of Retinoic Acid and Thyroid Hormone Receptor (SMRT) (Blackmore et al., 2014, Liao et 
al., 2003). The data instead suggests that the presence of E2 and an anti-oestrogen is 
essential for this effect. 
Importantly, treatment with an anti-androgen (BIC) could prevent androgen-
induced FULV/TAM resistance in the colony formation assays (Figure 3.5.2). Additionally, 
even in the shorter term growth assays (Figure 3.5.1), BIC enhanced the abrogation of 
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growth in both TAM and FULV treated samples. This confirmed that the MIB-induced 
effect was produced via the AR, and indicates that combining anti-androgens with anti-
oestrogens in endocrine sensitive BCa treatment could help to prevent activation of AR 
signalling and potentially halt this resistance mechanism from occurring. 
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Chapter 4. Results: Androgen Receptor regulation of endocrine 
resistant Breast Cancer  
4.1 Introduction  
As discussed in Chapter 3, the majority of BCas are ERα-positive, endocrine 
sensitive cancers, dependent on oestrogens such as E2 for progression (Chuffa et al., 
2017, Rakha and Green, 2016, Ali and Coombes, 2002). Endocrine therapies are often 
administered to these patients, including anti-oestrogens to block ERα action (for instance 
TAM and FULV), and AIs (for example Anastrozole) to reduce oestrogen levels 
(Kaklamani and Gradishar, 2017, Cauley et al., 2001, Lumachi et al., 2015). However 
endocrine resistance is a major issue, and often results in advanced metastatic disease 
for which few treatment options are available (Kaklamani and Gradishar, 2017, Vorobiof, 
2016, Reinert et al., 2017). 
Chapter 3 explored how the AR (an alternative ligand-dependent transcription 
factor, activated by androgens) can become activated in response to endocrine therapies, 
which aids in the development of endocrine resistance. The aim of this Chapter was to 
explore this mechanism of resistance further, by investigating the role of AR and ERα 
signalling in endocrine resistant cell lines. Two endocrine sensitive cell lines were utilised 
(MCF7 and T47D) and their TAM Resistant (TAMR), FULV Resistant (FULVR) and Long 
Term Oestrogen Deprived (LTED, a model of AI resistance) derivatives (Figure 2.4.1). 
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4.2 AR and ERα expression alters in endocrine resistance 
To investigate AR and ERα expression in MCF7 and T47D cells, and how this is 
altered in their endocrine resistant derivatives, immunoblotting was performed (Figure 
4.2.1a). The results demonstrated that ERα expression was decreased in the endocrine 
resistant derivatives as compared to their endocrine sensitive parental lines, apart from 
the T47D-TAMR line where it increased by 1.8-fold. AR expression was found to be 2.6-
fold higher in MCF7-LTED cells and by 3.9-fold in T47D-TAMR cells as compared to the 
relevant parental lines, whereas AR and ERα expression remained relatively constant in 
MCF7-TAMR cells (Figure 4.2.1a). However, both AR and ERα expression were strongly 
decreased in T74D-LTED and MCF7-FULVR derivatives, indicating that these cells may 
not be dependent upon AR or ERα signalling (Figure 4.2.1a). In light of these results, and 
as TAM is the most widely used anti-oestrogen in treatment (Vorobiof, 2016, Lumachi et 
al., 2015), MCF7-TAMR and MCF7-LTED derivatives were selected for in depth study of 
AR signalling. 
To explore the correlation between ERα and AR expression across these cell lines, 
these results were plotted onto a graph (Figure 4.2.1b). Although AR and ERα expression 
differs in the endocrine resistant cell lines, the general pattern observed was that AR and 
ERα expression was correlated across all the cell lines. These results are in accordance 
with data presented previously from the METABRIC dataset, which indicated an 
association between ERα and AR in BCa (Table 3.2.1 and Figure 3.2.1). 
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Figure 4.2.1 AR and ERα expression is altered in endocrine resistant Breast 
Cancer cell line models 
 
Parental endocrine sensitive MCF7 and T47D cells and their endocrine resistant 
derivatives: Tamoxifen Resistant (TAMR), Long Term Oestrogen Deprived (LTED) and 
Fulvestrant Resistant (FULVR) were grown in DMEM (MCF7) or RPMI (T47D) 
supplemented with 10 % foetal calf serum, penicillin streptomycin and glutamine for 
72 hours. Cells were lysed and immunoblotting conducted to examine Androgen 
Receptor (AR) and Oestrogen Receptor α (ERα) expression, with β-Actin included as 
a loading control. Densitometry analysis was conducted using the Fusion FX software 
to identify the percentage of AR and ERα in the resistant cell lines as compared to 
their relevant parental cell lines. 
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4.3 An alteration in the regulation of AR and ERα target genes occurs in response 
to hormones and anti-oestrogens in endocrine resistant BCa cells  
To investigate how anti-oestrogen treatment affects gene regulation in endocrine 
resistance, analysis of the regulation of various AR and ERα target genes previously 
conducted in MCF7 cells (Figures 3.4.2.1-3) were expanded to the MCF7-TAMR and 
MCF7-LTED resistant cell lines (Figures 4.3.1-5). The expression of target genes were 
measured following 8 hour treatment with E2, MIB or both (EtOH treatments were 
included as a control). Two ERα target genes were explored (TFF1 and MYC), a target 
gene for both AR and ERα (GREB1) as well as two AR target genes (NDRG1 and 
ZBTB16) (Figures 4.3.1-5). The references describing these target genes to explain why 
they were selected are summarised in Table 3.5.1. The MCF7 endocrine sensitive results 
from Section 3.4 have been included in these figures to allow for direct comparison and 
the main results have been summarised in Table 4.3.1. 
E2 treatment significantly increased the expression of the ERα target gene TFF1 
in both MCF7 and MCF7-TAMR cells, 3.4-fold and 2.9-fold respectively, but had no 
significant impact in MCF7-LTED cells (Figures 4.3.1a-c). Co-treatment of MIB with E2 
was unable to compete with the E2-induced TFF1 expression for any of the cell lines 
(Figures 4.3.1a-c), in agreement with earlier reporter assays (Figures 3.4.2 and 4). As 
expected, E2-induced expression of TFF1 was inhibited via both anti-oestrogens in MCF7 
cells (Figure 4.3.1a), however this was unexpectedly also the case for MCF7-TAMR cells 
(Figure 4.3.1b). However, although these patterns also appear to occur in MCF7-LTED 
cells, anti-oestrogen treatments displayed no significant effect on TFF1 expression in this 
cell line (Figure 3.5.2.1c). These results suggest that in TAM-resistant cells (MCF7-
TAMR), some ERα target genes are still regulated by oestrogen, and anti-oestrogens  
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(a) Trefoil Factor 1 (TFF1) 
 Effect of Treatment 
Cell Line E2 MIB TAM FULV 
MCF7 ↑ - ↓ from E2 induction ↓ from E2 induction 
MCF7-TAMR ↑ - ↓ from E2 induction ↓ from E2 induction 
MCF7-LTED - - - - 
(b) Myelocytomatosis Oncogene Cellular Homolog (MYC) 
 Effect of Treatment 
Cell Line E2 MIB TAM FULV 
MCF7 
↑ and ↑ from MIB 
induction 
- 
↓ from E2 induction, 
regardless of MIB 
treatment  
↓ from E2 induction, 
regardless of MIB 
treatment 
MCF7-TAMR - - - 
↓ from E2 induction, 
regardless of MIB 
treatment 
MCF7-LTED - ↓ - 
↓ from E2 induction, 
regardless of MIB 
treatment 
(c) Zinc Finger And BTB Domain Containing 16 (ZBTB16) 
 Effect of Treatment 
Cell Line E2 MIB TAM FULV 
MCF7 
↓ from MIB 
induction 
↑ and ↑ from E2 
induction 
↑ from EM induction ↑ from EM induction 
MCF7-TAMR 
↓ from MIB 
induction 
↑ and ↑ from E2 
induction 
- ↑ from EM induction 
MCF7-LTED - ↑ - - 
(d) N-Myc Downstream-Regulated Gene 1 (NDRG1) 
 Effect of Treatment 
Cell Line E2 MIB TAM FULV 
MCF7 
↓ from MIB 
induction 
- - ↑ from E2 induction 
MCF7-TAMR - - - - 
MCF7-LTED 
↓ from MIB 
induction 
↑ - - 
(e) Gene Regulated in Breast Cancer 1 (GREB1) 
 Effect of Treatment 
Cell Line E2 MIB TAM FULV 
MCF7 
↑ and ↑ from MIB 
induction 
↑ 
↓ from E2 induction, 
regardless of MIB 
treatment 
↓ from E2 induction, 
regardless of MIB 
treatment 
MCF7-TAMR ↑ - ↓ from E2 induction ↓ from E2 induction 
MCF7-LTED 
↑ and ↑ from MIB 
induction 
↑ ↓ from E2 induction 
↓ from E2 induction, 
regardless of MIB 
treatment 
Table 4.3.1: Expression changes in AR and ERα target genes in different Breast 
Cancer cell lines in response to hormone and drug treatments 
↑ and ↓ indicates an increase or decrease in gene expression respectively, in response 
to 17-β -Oestradiol (E2), Mibolerone (MIB), Tamoxifen (TAM) or Fulvestrant (FULV) 
treatments. Two Oestrogen Receptor alpha (ERα) target genes (TFF1, and MYC), two 
Androgen Receptor (AR) target genes (ZBTB16 and NDRG1) and a target gene for both 
(GREB1) were investigated in MCF7 cells and its TAM Resistant (TAMR) and Long Term 
Oestrogen Deprived (LTED) derivatives. 
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Figure 4.3.1 Effect of oestrogen, androgen and anti-oestrogen treatment on the 
expression of the ERα target gene TFF1 in MCF7 cells and its endocrine 
resistant derivatives 
MCF7 cells (a) and their Tamoxifen Resistant (TAMR) (b) and Long Term Oestrogen 
Deprived (LTED) (c) derivatives were incubated in hormone depleted media for 120 
hours, treated with 1 nM of the relevant hormones 17-β-Oestradiol (E2)/Mibolerone 
(M)/both/ ethanol (EtOH) as a control for 8 hours, with or without the presence of 100 
nM Fulvestrant (F)/Tamoxifen (T). RNA was extracted, reverse transcribed into cDNA 
and qPCR was conducted using SYBR green to measure the expression level of the 
Oestrogen Receptor alpha (ERα) target gene Trefoil Factor 1 (TFF1). Mean of 3 
independent experiments are displayed, ±SE. T-Test P<0.05*, P<0.005**. 
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could still have some benefit, but androgen inhibits this effect. However, this may not be 
the case for MCF7-LTED cells, so endocrine resistance could differ between the two cell 
line models. 
For the alternative ERα target gene MYC, E2 treatment significantly increased its 
expression in MCF7 cells (2.1-fold) but not MCF7-TAMR or MCF7-LTED cells (Figures 
4.3.2a-c). Again, co-treatment of MIB with E2 was unable to compete with the E2-induced 
MYC expression in MCF7 cells, and did not decrease or induce its expression in the 
resistant lines (Figures 4.3.2a-c). However, MIB treatment in MCF7-LTED negatively 
regulated MYC expression, but this effect was lost via co-treatment with E2. As expected, 
E2-induced expression of MYC was inhibited via both anti-oestrogens in MCF7 cells 
(Figure 4.3.2a), however MYC expression was significantly reduced via FULV but not 
TAM treatment in MCF7-TAMR and MCF7-LTED cells (Figures 4.3.2b-c). The addition of 
MIB treatment had no effect upon the anti-oestrogen inhibition to E2-induced expression 
of MYC in any of the cell lines (Figures 4.3.2a-c). These results suggest that some ERα 
target genes lose oestrogen responsiveness in endocrine resistance, however FULV 
could still inhibit ERα action and downregulate their expression. 
The expression of an AR target gene, ZBTB16, was induced via MIB treatment 
1,025-fold in MCF7 cells (Figure 4.3.3a). This effect also occurred in the endocrine 
resistant cell lines, however it was more strongly induced in MCF7-TAMR cells (24,442-
fold), and induction was weaker in MCF7-LTED cells (330.6-fold) (Figures 4.3.3b-c). The 
expression of ZBTB16 was not induced via E2 treatment in any of the cell lines, even in 
the presence of anti-oestrogens (Figures 4.3.3a-c), and co-treatment with E2 significantly 
reduced MIB-induced ZBTB16 expression in MCF7 and MCF7-TAMR cells, by 54.9 % 
and 43.2 %, respectively, and abrogated the significant increase produced by MIB   
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Figure 4.3.2 Effect of oestrogen, androgen and anti-oestrogen treatment on the 
expression of the ERα target gene MYC in MCF7 cells and its endocrine resistant 
derivatives 
MCF7 cells (a) and their Tamoxifen Resistant (TAMR) (b) and Long Term Oestrogen 
Deprived (LTED) (c) derivatives were incubated in hormone depleted media for 120 
hours, treated with 1 nM of the relevant hormones 17-β-Oestradiol (E2)/ Mibolerone 
(M)/both/ ethanol (EtOH) as a control for 8 hours, with or without the presence of 100 
nM Fulvestrant (F)/Tamoxifen (T). RNA was extracted, reverse transcribed into cDNA 
and qPCR was conducted using SYBR green to measure the expression level of the 
Oestrogen Receptor alpha (ERα) target gene Myelocytomatosis Oncogene Cellular 
Homolog (MYC). Mean of 3 independent experiments are displayed, ±SE. T-Test 
P<0.05*, P<0.005**. 
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Figure 4.3.3 Effect of oestrogen, androgen and anti-oestrogen treatment on the 
expression of the AR target gene ZBTB16 in MCF7 cells and its endocrine 
resistant derivatives 
MCF7 cells (a) and their Tamoxifen Resistant (TAMR) (b) and Long Term Oestrogen 
Deprived (LTED) (c) derivatives were incubated in hormone depleted media for 120 
hours, treated with 1 nM of the relevant hormones 17-β-Oestradiol (E2)/ Mibolerone 
(M)/both/ ethanol (EtOH) as a control for 8 hours, with or without the presence of 100 
nM Fulvestrant (F)/Tamoxifen (T). RNA was extracted, reverse transcribed into cDNA 
and qPCR was conducted using SYBR green to measure the expression level of the 
Androgen Receptor (AR) target gene Zinc Finger And BTB Domain Containing 16 
(ZBTB16). Mean of 3 independent experiments are displayed, ±SE. T-Test P<0.05*, 
P<0.005**. 
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treatment in MCF7-LTED cells (Figures 4.3.3a-c). Importantly, this inhibitive action of E2 
was significantly reversed via treatment with the anti-oestrogens in MCF7 cells (Figure 
4.3.3a) and FULV treatment in MCF7-TAMR cells (Figure 4.3.3b). This effect was also 
observed in MCF7-LTED cells, however it was not significant (Figure 4.3.3c). Therefore, 
MIB induces expression of this gene in all models. However, in the endocrine resistant 
and sensitive models, oestrogen treatment inhibits androgen induction of this gene, and 
anti-oestrogen treatments could reverse this effect. This indicates that in endocrine 
resistance ERα still demonstrates inhibitory action on AR activity, and that anti-
oestrogens abrogate this effect and make the AR more active.    
The expression of the alternative AR target NDRG1 was not induced following MIB 
treatment in MCF7 or MCF7-TAMR cells, however it could be significantly induced 3.1-
fold by MIB treatment in MCF7-LTED cells (Figures 4.3.4a, c). Co-treatment of E2 with 
MIB inhibited NDRG1 expression in both MCF7 and MCF7-LTED cells by 55.1 % and 
49.0 %, respectively (Figures 4.3.4a, c). Co-treatment with FULV significantly increased 
E2-induced NDRG1 expression in MCF7 cells, and this was lost in MCF7-LTED cells 
(Figures 4.3.4a, c). NDRG1 expression was unaffected by the hormone and drug 
treatments in MCF7-TAMR cells, suggesting that regulation of this gene has been lost in 
this endocrine resistant model (Figure 4.3.4b). These results suggest that the regulation 
of the AR target gene NDRG1 is induced by FULV treatment in endocrine sensitive cells, 
and that androgen regulation of NDRG1 is “switched on” in a model of AI resistance 
(MCF7-LTED), but oestrogen abrogates this regulation. However, the regulation of this 
gene is weaker than that of ZBTB16, and it is not regulated in a model of TAM resistance 
(MCF7-TAMR).  
The expression of GREB1, a target gene for both ERα and AR, was significantly 
induced via E2 treatment in MCF7 (12.5-fold), MCF7-TAMR (10.3-fold) and MCF7-LTED  
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Figure 4.3.4 Effect of oestrogen, androgen and anti-oestrogen treatment on the 
expression of the AR target gene NDRG1 in MCF7 cells and its endocrine 
resistant derivatives 
MCF7 cells (a) and their Tamoxifen Resistant (TAMR) (b) and Long Term Oestrogen 
Deprived (LTED) (c) derivatives were incubated in hormone depleted media for 120 
hours, treated with 1 nM of the relevant hormones 17-β-Oestradiol (E2)/ Mibolerone 
(M)/both/ ethanol (EtOH) as a control for 8 hours, with or without the presence of 100 
nM Fulvestrant (F)/Tamoxifen (T). RNA was extracted, reverse transcribed into cDNA 
and qPCR was conducted using SYBR green to measure the expression level of the 
Androgen Receptor (AR) target gene N-Myc Downstream-Regulated Gene 1 
(NDRG1). Mean of 3 independent experiments are displayed, ±SE. T-Test P<0.05*. 
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Figure 4.3.5 Effect of oestrogen, androgen and anti-oestrogen treatment on the 
expression of an ERα and AR target gene GREB1 in MCF7 cells and its 
endocrine resistant derivatives 
(a) MCF7 cells and their (b) Tamoxifen Resistant (TAMR) and (c) Long Term 
Oestrogen Deprived (LTED) derivatives were incubated in hormone depleted media 
for 120 hours, treated with 1 nM of the relevant hormones 17-β-Oestradiol (E2)/ 
Mibolerone (M)/both/ ethanol (EtOH) as a control for 8 hours, with or without the 
presence of 100 nM Fulvestrant (F)/Tamoxifen (T). RNA was extracted, reverse 
transcribed into cDNA and qPCR was conducted using SYBR green to measure the 
expression level of the Oestrogen Receptor alpha (ERα) and Androgen Receptor (AR) 
target gene Gene Regulated in Breast Cancer 1 (GREB1). Mean of 3 independent 
experiments are displayed, ±SE. T-Test P<0.05*, P<0.005**, P<0.0005***. 
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cells (5.6-fold), and to a lesser degree by MIB in MCF7 (3.8-fold) and MCF7-LTED (3.2-
fold) cells, but not in MCF7-TAMR cells (Figures 4.3.5a-c). In all 3 cell lines, treatment 
with the anti-oestrogens was able to significantly reduce E2-induced GREB1 expression 
(Figures 4.3.5a-c). However, co-treatment of MIB resulted in a partial abrogation of anti-
oestrogen inhibition to E2-induced expression of GREB1 in MCF7-TAMR cells, as these 
differences were no longer significant (Figure 4.3.5b), however E2-induced GREB1 
expression was still significantly reduced via both anti-oestrogens in MCF7 cells and via 
FULV in MCF7-LTED cells in the presence of MIB (Figures 4.3.5a, c). Therefore, GREB1 
appears to be more strongly regulated by ERα than AR in all of our cell line models, and 
anti-oestrogen treatment only slightly increases the androgen-regulation of this gene, 
including in the resistant models. 
In conclusion, the main results from this section have demonstrated that the 
endocrine resistant cell line models have altered hormone-regulated expression of AR 
and ERα regulatory target genes in comparison to their endocrine sensitive parental line. 
Some ERα target genes lose oestrogen responsiveness in endocrine resistance, however 
anti-oestrogen treatment (particularly FULV) can still inhibit ERα action and downregulate 
their expression, suggesting that this receptor is still, in part, promoting BCa growth. 
Androgen treatment can abrogate the effect of this anti-oestrogen inhibition in the 
endocrine resistant and sensitive cells, suggesting that androgen can drive growth and 
endocrine resistance when ERα is inhibited. In conjunction with this, in some cases 
oestrogen treatment was found to downregulate AR target gene expression, and anti-
oestrogen treatment could reverse this effect. The mechanism of resistance alters 
between these TAM-resistance and AI-resistance models as they have differing 
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responses to hormone and anti-oestrogen treatments for the genes, including that not all 
androgen-regulated genes are upregulated. 
4.4 AR and ERα localisation alters in endocrine sensitive and resistant cells  
It is known that AR and ERα cross-talk supresses each other’s transcriptional 
activity (Fioretti et al., 2014) and it has previously been demonstrated that this cross-talk 
is at least in part as a result of a direct interaction of the receptors (Panet-Raymond et al., 
2000). Additionally, AR and ERα are both ligand-dependant transcription factors that 
exert their effects in the nucleus (Sever and Glass, 2013). Confocal microscopy was 
therefore conducted to investigate whether AR and ERα colocalise. 
Initially, ERα-Red Fluorescent Protein (ERα-RFP) and AR-Green Fluorescent 
Protein (AR-GFP) plasmids were transfected into COS-1 cells, which are negative for 
both ERα and AR, and the localisation of the receptors were investigated following 
treatment with Ethanol (EtOH) as a control, ERα ligand (E2), AR ligand (MIB) or both 
(Figure 4.4.1). 4’, 6-diamidino-2-phenylindole (DAPI) was used to stain cell nuclei. In the 
absence of hormone treatment, AR was predominantly cytoplasmic and ERα nuclear. 
However, upon E2 treatment AR nuclear localisation and ERα cytoplasmic localisation 
became more pronounced, although they remained predominantly cytoplasmic and 
nuclear, respectively. Following MIB treatment (+/- E2), ERα localisation remained 
pronounced in the nucleus. AR nuclear co-localisation with ERα was much more 
pronounced with MIB treatment, and following co-treatment with E2 and MIB. Nuclear 
translocation of AR, in response to MIB, was partially blocked by E2, with some 
cytoplasmic localisation evident (Figure 4.4.1). 
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Figure 4.4.1 Exogenous AR and ERα localisation 
COS-1 cells were transiently transfected with plasmids encoding Androgen Receptor 
fused to Green Fluorescent Protein (AR-GFP) and Oestrogen Receptor alpha fused 
to Red Fluorescent Protein (ERα-RFP), cultured in hormone depleted media for 24 
hours and treated with EtOH (vehicle) or 1 nM 17-β-Oestradiol (E2) and/or Mibolerone 
(MIB) for 2 hours. Cells were fixed using 4 % paraformaldehyde. 4’,6-diamidino-2-
phenylindole (DAPI) was used to stain the nucleus (blue). Cells were visualised using 
confocal microscopy. Scale bar = 10 µm. 
 
 
Figure 4.4.1 Exogenous AR and ERα localisation 
COS-1 cells were transiently transfected with plasmids encoding Androgen Receptor 
fused to Green Fluorescent Protein (AR-GFP) and Oestrogen Receptor alpha fused 
to Red Fluorescent Protein (ERα-RFP), cultured in hormone depleted media for 24 
hours and treated with EtOH (vehicle) or 1 nM 17-β-Oestradiol (E2) and/or Mibolerone 
(MIB) for 2 hours. Cells were fixed using 4 % paraformaldehyde. 4’,6-diamidino-2-
phenylindole (DAPI) was used to stain the nucleus (blue). Cells were visualised using 
E
2
 
 175 
 
To identify whether AR and ERα colocalise in endocrine sensitive disease and how 
this changes in endocrine resistance, confocal microscopy was used to identify the 
localisation of these receptors in MCF7 and T47D cells (Figures 4.4.2-3) and how this 
changes in their TAMR and LTED endocrine resistant derivatives (Figures 4.4.4-7). Cells 
were treated with the same hormone treatments as in Figure 4.4.1. Antibodies specific 
for AR and ERα were used followed by secondary antibodies labelled with Alexa Fluor 
488 (green, AR) or 568 (red, ERα) to visualise receptor localisation. DAPI was used to 
stain cell nuclei. The localisation of AR and ERα was noted under all conditions and is 
summarised in Table 4.4.1. 
In the absence of hormone, AR was predominantly cytoplasmic and ERα was 
predominantly nuclear for both MCF7 and T47D cells (Figures 4.4.2-3). Upon E2 
treatment however, AR nuclear localisation and ERα cytoplasmic localisation additionally 
became more pronounced, displaying co-localisation (Figures 4.4.2-3). In T47D cells, AR 
and ERα remained both nuclear and cytoplasmic, following all hormone treatments 
(Figure 4.4.3). In MCF7 cells however, AR nuclear localisation was more pronounced with 
MIB treatment, but mainly cytoplasmic upon co-treatment with E2 (Figure 4.4.2).  
This was then expanded to the endocrine resistant derivatives of MCF7 cells: 
MCF7-TAMR and MCF7-LTED (Figures 4.4.4-5). In both resistant lines, in the absence 
of hormone AR was predominantly cytoplasmic and ERα was predominantly nuclear, as 
previously demonstrated in the parental line. As for MCF7 cells, upon E2 treatment, 
MCF7-LTED AR nuclear localisation and ERα cytoplasmic localisation additionally 
became more pronounced, displaying co-localisation (Figure 4.4.5). By contrast, in 
MCF7-TAMR cells, AR remained predominantly cytoplasmic (Figure 4.4.4). Unlike the 
parental cell line, AR and ERα were both nuclear and cytoplasmic with MIB treatment for 
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Figure 4.4.2 AR and ERα localisation in MCF7 cells 
 
Cells were cultured in hormone depleted media for 24 hours and treated with EtOH 
(vehicle) or 1 nM 17-β-Oestradiol (E2) and/or Mibolerone (MIB) for 2 hours.  Cells were 
fixed using 4 % paraformaldehyde and methanol and probed with anti-Androgen 
Receptor (AR) and/or anti-Oestrogen Receptor alpha (ERα) following with secondary 
antibodies labelled with Alexa Fluor 488 (green, AR) or 568 (red, ERα) to visualise 
receptor localisation. 4’,6-diamidino-2-phenylindole (DAPI) was used to stain the 
nucleus (blue). A secondary antibody only stain (2
o
) is displayed as a control. Cells 
were visualised using confocal microscopy. Scale bar = 10 µm. 
 
anti-Androgen 
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Figure 4.4.3 AR and ERα localisation in T47D cells 
 
Cells were cultured in hormone depleted media for 24 hours and treated with EtOH 
(vehicle) or 1 nM 17-β-Oestradiol (E2) and/or Mibolerone (MIB) for 2 hours.  Cells were 
fixed using 4 % paraformaldehyde and methanol and probed with anti-Androgen 
Receptor (AR) and/or anti-Oestrogen Receptor alpha (ERα) following with secondary 
antibodies labelled with Alexa Fluor 488 (green, AR) or 568 (red, ERα) to visualise 
receptor localisation. 4’,6-diamidino-2-phenylindole (DAPI) was used to stain the 
nucleus (blue). A secondary antibody only stain (2o) is displayed as a control. Cells 
were visualised using confocal microscopy. Scale bar = 10 µm. 
 
Figure 4.4.3 AR and ERα localisation in T47D cells 
 
Cells were cultured in hormone depleted media for 24 hours and treated with EtOH 
(vehicle) or 1 nM 17-β-Oestradiol (E2) and/or Mibolerone (MIB) for 2 hours.  Cells were 
fixed using 4 % paraformaldehyde and methanol and probed with anti-Androgen 
Receptor (AR) and/or anti-Oestrogen Receptor alpha (ERα) following with secondary 
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Figure 4.4.4 AR and ERα localisation in MCF7-Tamoxifen Resistant (TAMR) cells 
Cells were cultured in hormone depleted media for 24 hours and treated with EtOH 
(vehicle) or 1 nM 17-β-Oestradiol (E2) and/or Mibolerone (MIB) for 2 hours.  Cells were 
fixed using 4 % paraformaldehyde and methanol and probed with anti-Androgen 
Receptor (AR) and/or anti-Oestrogen Receptor alpha (ERα) following with secondary 
antibodies labelled with Alexa Fluor 488 (green, AR) or 568 (red, ERα) to visualise 
receptor localisation. 4’,6-diamidino-2-phenylindole (DAPI) was used to stain the 
nucleus (blue). A secondary antibody only stain (2o) is displayed as a control. Cells 
were visualised using confocal microscopy. Scale bar = 10 µm. 
 
Figure 4.4.5 AR and ERα localisation in MCF7-Long Term Oestrogen Deprived 
(LTED) cells 
Figure 4.4.4 AR and ERα localisation in MCF7-Tamoxifen Resistant (TAMR) cells 
Cells were cultured in hormone depleted media for 24 hours and treated with EtOH 
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Figure 4.4.5 AR and ERα localisation in MCF7-Long Term Oestrogen Deprived 
(LTED) cells 
 
Cells were cultured in hormone depleted media for 24 hours and treated with EtOH 
(vehicle) or 1 nM 17-β-Oestradiol (E2) and/or Mibolerone (MIB) for 2 hours.  Cells were 
fixed using 4 % paraformaldehyde and methanol and probed with anti-Androgen 
Receptor (AR) and/or anti-Oestrogen Receptor alpha (ERα) following with secondary 
antibodies labelled with Alexa Fluor 488 (green, AR) or 568 (red, ERα) to visualise 
receptor localisation. 4’,6-diamidino-2-phenylindole (DAPI) was used to stain the 
nucleus (blue). A secondary antibody only stain (2o) is displayed as a control. Cells 
were visualised using confocal microscopy. Scale bar = 10 µm. 
 
 
Figure 4.4.5 AR and ERα localisation in MCF7-Long Term Oestrogen Deprived 
(LTED) cells 
 
Cells were cultured in hormone depleted media for 24 hours and treated with EtOH 
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MCF7-TAMR and MCF7-LTED (Figures 4.4.4-5). Co-treatment with E2 resulted in AR 
shifting to predominantly nuclear localisation in MCF7-LTED cells, but AR remained both 
nuclear and cytoplasmic in MCF7-TAMR cells (Figures 4.4.4-5). 
Finally, this experiment was conducted in the endocrine resistant derivatives of 
T47D cells: T47D-TAMR and T47D-LTED (Figures 4.4.6-7). In contrast to their parental 
line, AR was predominantly nuclear prior to hormone treatment and colocalised with ERα 
in T47D-TAMR and T47D-LTED cells. In accordance with T47D cells, E2 treatment 
resulted in both nuclear and cytoplasmic localisation of AR and ERα in T47D-TAMR cells 
(Figure 4.4.6). By contrast, in T47D-LTED cells E2 treatment resulted in more pronounced 
cytoplasmic localisation of both AR and ERα (Figure 4.4.7). Interestingly, in T47D-TAMR 
cells, both AR and ERα were predominantly cytoplasmic upon treatment with MIB, in the 
presence or absence of E2 (Figure 4.4.6), in contrast to T47D and T47D-LTED cells 
where the receptors were both cytoplasmic and nuclear (Figures 4.4.2,7).  
To conclude, AR and ERα localisation varies between two endocrine sensitive 
models, and differs from these parental lines in their endocrine resistant derivatives, 
however the receptors are commonly found to colocalise upon hormone treatments. The 
results from this section are summarised in Table 4.4.1.  
4.5 The responsiveness of AR and ERα regulatory target genes to hormones differs 
in endocrine resistant cells  
In Section 4.3, the regulation of AR and ERα target genes in response to treatment 
with hormones and anti-oestrogens was analysed to investigate how it changes in 
endocrine resistance. This was conducted using MCF7, MCF7-TAMR and MCF7-LTED  
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Figure 4.4.6 AR and ERα localisation in T47D-Tamoxifen Resistant (TAMR) cells 
 
Cells were cultured in hormone depleted media for 24 hours and treated with EtOH 
(vehicle) or 1 nM 17-β-Oestradiol (E2) and/or Mibolerone (MIB) for 2 hours. Cells were 
fixed using 4 % paraformaldehyde and methanol and probed with anti-Androgen 
Receptor (AR) and/or anti-Oestrogen Receptor alpha (ERα) following with secondary 
antibodies labelled with Alexa Fluor 488 (green, AR) or 568 (red, ERα) to visualise 
receptor localisation. 4’,6-diamidino-2-phenylindole (DAPI) was used to stain the 
nucleus (blue). A secondary antibody only stain (2o) is displayed as a control. Cells 
were visualised using confocal microscopy. Scale bar = 10 µm. 
 
 
Figure 4.4.6 AR and ERα localisation in T47D-Tamoxifen Resistant (TAMR) cells 
 
Cells were cultured in hormone depleted media for 24 hours and treated with EtOH 
(vehicle) or 1 nM 17-β-Oestradiol (E2) and/or Mibolerone (MIB) for 2 hours. Cells were 
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Figure 4.4.7 AR and ERα localisation in T47D-Long Term Oestrogen Deprived 
(LTED) cells 
 
Cells were cultured in hormone depleted media for 24 hours and treated with EtOH 
(vehicle) or 1 nM 17-β-Oestradiol (E2) and/or Mibolerone (MIB) for 2 hours.  Cells 
were fixed using 4 % paraformaldehyde and methanol and probed with anti-Androgen 
Receptor (AR) and/or anti-Oestrogen Receptor alpha (ERα) following with secondary 
antibodies labelled with Alexa Fluor 488 (green, AR) or 568 (red, ERα) to visualise 
receptor localisation. 4’,6-diamidino-2-phenylindole (DAPI) was used to stain the 
nucleus (blue). A secondary antibody only stain (2o) is displayed as a control. Cells 
were visualised using confocal microscopy. Scale bar = 10 µm. 
 
 
Table 4.4.1 Endogenous AR and ERα cellular localisation following androgen or 
oestrogen treatment  
Figure 4.4.7 AR and ERα localisation in T47D-Long Term Oestrogen Deprived 
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(a) AR Localisation 
 EtOH E2 MIB E2 + MIB 
COS-1 
(Exogenous) 
C C N N + C 
MCF7 C N + C N C 
MCF7-TAMR C C N + C N + C 
MCF7-LTED C N + C N + C N 
T47D C N + C N + C N + C 
T47D-TAMR N N + C C C 
T47D-LTED N C N + C N + C 
(b) ERα Localisation 
 EtOH E2 MIB E2 + MIB 
COS-1 
(Exogenous) 
N N N N 
MCF7 N N + C N N + C 
MCF7-TAMR N N N N + C 
MCF7-LTED N N + C N N 
T47D N N + C N + C N + C 
T47D-TAMR N N + C C C 
T47D-LTED N C N + C N + C 
Table 4.4.1 Endogenous AR and ERα cellular localisation following androgen 
or oestrogen treatment  
Table indicates whether (a) AR or (b) ERα were predominantly Nuclear (N), 
Cytoplasmic (C) or both (N + C) following 2 hour treatment with androgen 
(Mibolerone, MIB) or oestrogen (17-β-Oestradiol, E2) in MCF7 and T47D endocrine 
sensitive cell lines and their Tamoxifen Resistant (TAMR) and Long Term Oestrogen 
Deprived (LTED) derivatives. 
 
Figure 4.5.1 Direct comparison of expression of ERα target genes TFF1 and 
MYC in MCF7, MCF7-TAMR and MCF7-LTED cells 
Table 4.4.1 Endogenous AR and ERα cellular localisation following androgen 
or estr gen treatment  
Table indicates whether (a) AR or (b) ERα were predominantly Nuclear (N), 
Cytoplasmic (C) or both (N + C) following 2 hour treatment with androgen 
(Mibolerone, MIB) or oestrogen (17-β-Oestradiol, E2) in MCF7 and T47D endocrine 
sensitive cell lines and their Tamoxifen Resistant (TAMR) and Long Term Oestrogen 
Deprived (LTED) derivatives. 
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cells. The aim of this section was to investigate if the sensitivity to E2 or MIB is altered in 
the endocrine resistant lines as compared to their endocrine sensitive parental line. The 
same target genes were selected as investigated previously (Table 3.5.1), as well as 
three additional AR target genes: Dopa Decarboxylase (DDC), SEC14 Like Lipid Binding 
2 (SEC14L2) and Deiodinase, Iodothyronine Type II (DIO2) (Figures 4.5.1-6). DDC is an 
androgen regulated gene that has been identified as an important AR co-activator in PCa 
(Margiotti et al., 2007, Wafa et al., 2003). SEC14L2 has been identified as an androgen-
regulated gene associated with PCa risk and involved in PCa cellular proliferation (Bolton 
et al., 2007, Chan et al., 2016, Ni et al., 2005). Interestingly, SEC14L2 has been reported 
to have low expression in MCF7 (Wang et al., 2009), but can be upregulated via androgen 
treatment in T47D (Takagi et al., 2010). By contrast, although DIO2 has been reported to 
be rapidly upregulated via DHT treatment in PCa, its function is involved in the regulation 
of Thyroid hormone Receptor (TR) activity through the production of the more potent 
thyroid hormone triiodothyronine from thyroxine, the process of which is upregulated via 
E2 (Detti et al., 2013, Xu et al., 2006).  
As demonstrated in Figure 4.3.1, the ERα target TFF1 was upregulated by E2 
treatment in all 3 cell lines, however this was only significant for MCF7 (Figure 4.5.1a). 
Interestingly, in all 4 treatments, MCF7 cells had a significantly higher TFF1 expression 
than MCF7-TAMR cells, suggesting that this gene is silenced in this model of endocrine 
resistance. Additionally, the expression of the alternative ERα target gene MYC was 
upregulated in MCF7 cells via E2 treatment, and co-treatment of MIB with E2 was unable 
to compete with the E2-induced MYC expression (Figure 4.5.1b). Although significant 
differences between treatments were lost in the endocrine resistant lines, a similar MYC 
expression and no significant differences between the 3 cell lines for each hormone  
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Figure 4.5.1 Direct comparison of expression of ERα target genes TFF1 
and MYC in MCF7, MCF7-TAMR and MCF7-LTED cells 
MCF7 cells, their Tamoxifen Resistant (TAMR) and Long Term Oestrogen 
Deprived (LTED) derivatives were incubated in hormone depleted media for 
120 hours, and treated with 1 nM of the relevant hormones 17-β-Oestradiol 
(E2)/ Mibolerone (M)/both/ ethanol (EtOH) as a control for 8 hours. RNA was 
extracted, reverse transcribed into cDNA and qPCR was conducted using 
SYBR green to measure the expression level of the Oestrogen Receptor alpha 
(ERα) target genes (a) Trefoil Factor 1 (TFF1) and (b) Myelocytomatosis 
Oncogene Cellular Homolog (MYC). Expression was normalised to RPL19 
ribosomal protein, L19, and expression is relative to the MIB-treated MCF7 
sample for each gene. Mean of 5 independent experiments, ±SE. T-Test 
*P<0.05, **P<0.005, ***P<0.0005, ****P<0.00005.  
 
 
Figure 4.5.1 Direct comparison of expression of ERα target genes TFF1 
and MYC in MCF7, MCF7-TAMR and MCF7-LTED cells 
MCF7 cells, their Tamoxifen Resistant (TAMR) and Long Term Oestrogen 
Deprived (LTED) derivatives were incubated in hormone depleted media for 
120 hours, and treated with 1 nM of the relevant hormones 17-β-Oestradiol 
(E2)/ Mibolerone (M)/both/ ethanol (EtOH) as a control for 8 hours. RNA was 
extracted, reverse transcribed into cDNA and qPCR was conducted using 
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treatment were observed. This suggests that an alteration to the regulation of MYC is not 
important for these endocrine resistant lines. 
The expression of 5 AR target genes were subsequently evaluated (Figures 4.5.2-
3). ZBTB16 expression was induced by androgen in all cell lines (although this was not 
significant for MCF7-LTED) (Figure 4.5.2a). Androgen sensitivity (i.e. fold change in 
ZBTB16 expression in response to MIB) was higher in MCF7-TAMR cells (2,621.1-fold) 
than MCF7 cells (1,981.7-fold), but total expression levels were higher in MCF7 (Figure 
4.5.2a). ZBTB16 expression was barely detectable in MCF7-LTED cells compared to the 
other cell lines (Figure 4.5.2a). Co-treatment with E2 reduced MIB-induced ZBTB16 
expression in all cell lines, however this effect was most noticeable in MCF7 cells (48.1 
%) and only significant in this cell line. These results indicate that although ZBTB16 
expression is reduced in our endocrine resistant models, its androgen regulation has 
become stronger in the MCF7-TAMR line, indicating that AR activity has increased in this 
cell line. Additionally, oestrogen significantly reduced the androgen-induced ZBTB16 
expression in MCF7 cells, however this effect was not significant in the resistant lines, 
indicating that ERα inhibition of this expression is decreased in endocrine resistance. 
These results also indicate that the regulation of this gene is more important in MCF7-
TAMR cells than in MCF7-LTED cells.  
On the other hand, NDRG1 expression was weakly induced via MIB treatment (1.8 
- 2.6-fold) and co-treatment with E2 reduced this effect in all cell lines, however this was 
only significant in MCF7 cells (Figure 4.5.2b). Under all treatment conditions, NDRG1 
expression was highest in MCF7 cells, followed by MCF7-LTED then MCF7-TAMR cells 
(Figure 4.5.3b). These results indicate that NDRG1 expression is lost in endocrine 
resistance. 
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Figure 4.5.2 Direct comparison of expression of AR target genes ZBTB16 
and NDRG1 in MCF7, MCF7-TAMR and MCF7-LTED cells 
MCF7 cells, their Tamoxifen Resistant (TAMR) and Long Term Oestrogen 
Deprived (LTED) derivatives were incubated in hormone depleted media for 
120 hours, and treated with 1 nM of the relevant hormones 17-β-Oestradiol 
(E2)/ Mibolerone (M)/both/ ethanol (EtOH) as a control for 8 hours. RNA was 
extracted, reverse transcribed into cDNA and qPCR was conducted using 
SYBR green to measure the expression level of the Androgen Receptor (AR) 
target genes (a) Zinc Finger And BTB Domain Containing 16 (ZBTB16) and 
(b) N-Myc Downstream-Regulated Gene 1 (NDRG1). Expression was 
normalised to RPL19 ribosomal protein, L19, and expression is relative to the 
MIB-treated MCF7 sample for each gene. Mean of at least 5 independent 
experiments, ±SE. T-Test *P<0.05, **P<0.005, ***P<0.0005, ****P<0.00005.  
 
 
Figure 4.5.2 Direct comparison of expression of AR target genes ZBTB16 
and NDRG1 in MCF7, MCF7-TAMR and MCF7-LTED cells 
MCF7 cells, their Tamoxifen Resistant (TAMR) and Long Term Oestrogen 
Deprived (LTED) derivatives were incubated in hormone depleted media for 
120 hours, and treated with 1 nM of the relevant hormones 17-β-Oestradiol 
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By contrast, DDC expression was significantly induced by MIB treatment in all cell 
lines, however this effect was much stronger in MCF7 cells (41.5-fold) than in MCF7-
TAMR (3.4-fold) and MCF7-LTED cells (10.7-fold), and co-treatment with E2 reduced this 
effect, however for MCF7 and MCF7-LTED cells this was not deemed significant (Figure 
4.5.3a). However, DDC expression was significantly higher with MIB treatment in the 
resistant cell lines than MCF7 cells, and MCF7-LTED cells had the highest DDC 
expression of the 3 cell lines, upon treatment with EtOH, MIB or E2 + MIB. The elevated 
expression of this gene in the absence of androgen in the resistant lines indicate that an 
alternative factor or mechanism could be upregulating DDC expression in these cells, and 
therefore this may be an important gene in these resistant cell lines, in particular in MCF7-
LTED cells. Interestingly, in the absence of MIB treatment, DDC expression was also 
significantly upregulated 5.8-fold via E2 treatment in MCF7 cells, but this effect was lost 
in its resistant derivatives (Figure 4.5.3a). Therefore, this could be additionally an ERα 
target gene in endocrine sensitive disease, the regulation of which is lost in endocrine 
resistance, and warrants further investigation. 
DIO2 expression was only significantly induced via MIB treatment in MCF7 cells 
(Figure 4.5.3b). Additionally, MIB-induced DIO2 expression was significantly higher in 
MCF7 cells than the other two cell lines (Figure 4.5.3b). This suggests that DIO2 is an 
AR target gene upregulated by androgen in endocrine sensitive cells, the regulation of 
which is lost in endocrine resistance. 
Lastly, in MCF7 and MCF7-LTED cells, SEC14L2 expression was significantly 
induced via MIB treatment (16.8-fold and 26.8-fold, respectively), and this induction was 
unaffected by co-treatment with E2, with similar expression values observed for both cell 
lines under each treatment (Figure 4.5.3c). However, no significant differences were  
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Figure 4.5.3 Direct comparison of expression of AR target genes DDC, DIO2 and 
SEC14L2 in in MCF7, MCF7-TAMR and MCF7-LTED cells 
MCF7 cells, their Tamoxifen Resistant (TAMR) and Long Term Oestrogen Deprived 
(LTED) derivatives were incubated in hormone depleted media for 120 hours, and 
treated with 1 nM of the relevant hormones 17-β-Oestradiol (E2)/ Mibolerone (M)/both/ 
ethanol (EtOH) as a control for 8 hours. RNA was extracted, reverse transcribed into 
cDNA and qPCR was conducted using SYBR green to measure the expression level 
of the Androgen Receptor (AR) target genes (a) Dopa Decarboxylase (DDC) (b) 
SEC14 Like Lipid Binding 2, (SEC14L2) and (c) Deiodinase, Iodothyronine Type II, 
(DIO2). Expression was normalised to RPL19 ribosomal protein, L19, and expression 
is relative to the MIB-treated MCF7 sample for each gene. Mean of 4 independent 
experiments, ±SE. T-Test *P<0.05, **P<0.005, ***P<0.0005, ****P<0.00005.  
 
 
Figure 4.5.3 Direct comparison of expression of AR target genes DDC, DIO2 and 
SEC14L2 in in MCF7, MCF7-TAMR and MCF7-LTED cells 
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observed for SEC14L2 expression in MCF7-TAMR cells between hormone treatments 
(Figure 4.5.3c). This indicates that SEC14L2 is an AR target gene upregulated in MCF7 
cells, and that this regulation is slightly upregulated through endocrine resistance in 
MCF7-LTED cells, however it is lost in the other resistance model MCF7-TAMR. 
As observed previously (Figure 4.2.5), in all cells lines the expression of the AR 
and ERα target GREB1 was induced via E2 treatment and to a lesser degree in response 
to MIB, however these differences were not always significant in this experiment (Figure 
4.5.2). Interestingly, GREB1 expression was stronger in MCF7 and MCF7-LTED cells 
than for MCF7-TAMR cells with all treatments, although these differences were not 
always significant. This suggests that GREB1 regulation is lost in the MCF7-TAMR cell 
line, but its regulation remains in MCF7-LTED cells. 
To conclude, the regulation of ERα target genes or a target gene for both ERα and 
AR is either unaltered or deceased in the endocrine resistant cell lines, suggesting that 
ERα regulation has become less important for cancer progression in these models of 
resistance. However, the expression of some of the AR targets, including ZBTB16 and 
DDC, have become more sensitive to androgen treatment in at least one of the endocrine 
resistance lines compared to the parental line, demonstrating that AR activity/sensitivity 
has increased in relation to the regulation of these genes in endocrine resistance. 
Additionally, ERα inhibition of AR target gene expression can be lost in endocrine 
resistance. These effects are cell line specific, indicating that the two models of endocrine 
resistance vary. Additionally, the regulation of some AR target genes does not appear to 
be important in either model of endocrine resistance, such as NDRG1 and DIO2, 
indicating that although AR activity increases in these models of resistance, not all AR 
targets are upregulated. 
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Figure 4.5.4 Direct comparison of expression of an ERα and AR target 
gene GREB1 in MCF7, MCF7-TAMR and MCF7-LTED cells 
MCF7 cells, their Tamoxifen Resistant (TAMR) and Long Term Oestrogen 
Deprived (LTED) derivatives were incubated in hormone depleted media for 
120 hours, and treated with 1 nM of the relevant hormones 17-β-Oestradiol 
(E2)/ Mibolerone (M)/both/ ethanol (EtOH) as a control for 8 hours. RNA was 
extracted, reverse transcribed into cDNA and qPCR was conducted using 
SYBR green to measure the expression level of the Oestrogen Receptor alpha 
(ERα) and Androgen Receptor (AR) target gene Gene Regulated in Breast 
Cancer 1, (GREB1). Expression was normalised to RPL19 ribosomal protein, 
L19, and expression is relative to the MIB-treated MCF7 sample for each 
gene. Mean of 6 independent experiments, ±SE. T-Test *P<0.05, **P<0.005, 
***P<0.0005, ****P<0.00005.  
 
 
Figure 4.5.4 Direct comparison of expression of an ERα and AR target 
gene GREB1 in MCF7, MCF7-TAMR and MCF7-LTED cells 
MCF7 cells, their Tamoxifen Resistant (TAMR) and Long Term Oestrogen 
Deprived (LTED) derivatives were incubated in hormone depleted media for 
120 hours, and treated with 1 nM of the relevant hormones 17-β-Oestradiol 
(E2)/ Mibolerone (M)/both/ ethanol (EtOH) as a control for 8 hours. RNA was 
extracted, reverse transcribed into cDNA and qPCR was conducted using 
SYBR green to measure the expression level of the Oestrogen Receptor alpha 
(ERα) and Androgen Receptor (AR) target gene Gene Regulated in Breast 
Cancer 1, (GREB1). Expression was normalised to RPL19 ribosomal protein, 
L19, and expression is relative to the MIB-treated MCF7 sample for each 
gene. Mean of 6 independent experiments, ±SE. T-Test *P<0.05, **P<0.005, 
***P<0.0005, ****P<0.00005.  
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4.6 AR drives endocrine resistant cell growth 
Previously conducted colony formation assays (Figure 3.5.2) suggested that 
androgens may be able to promote endocrine resistance.  Therefore, it was of interest as 
to whether the cell line models of endocrine resistance have lost their oestrogen 
responsiveness and become more sensitive to androgens for growth. Growth assays 
were initially conducted to confirm that in the parental MCF7 endocrine sensitive cell line, 
cellular proliferation was driven through oestrogen and not androgen (Figure 4.6.1a). The 
results demonstrated that MCF7 cell growth was significantly enhanced by E2 treatment 
from the lowest concentration tested (0.1 nM), but only the highest concentration of MIB 
(100 nM) was found to significantly increase its growth (Figure 4.6.1a). However, in the 
endocrine resistant cell line derivatives of MCF7, a reduced (MCF7-TAMR and MCF7-
FULVR) or no (MCF7-LTED) response to E2 treatment was observed, as compared to 
the parental cells (Figures 4.6.1b-d). Additionally, it was demonstrated that these resistant 
cells were more sensitive to MIB for growth compared to E2 (Figures 4.6.1b-d). For 
instance, the proliferation of MCF7-TAMR cells was significantly enhanced from 0.1 nM 
MIB (Figure 4.6.1b).  
To expand upon these results, growth assays were additionally conducted in the 
T47D endocrine sensitive cell line and its endocrine resistant cell line derivatives T47D-
TAMR and T47D-LTED (Figures 4.6.2a-c). T47D cells were more sensitive to MIB for 
growth than MCF7 cells, however the line was still more sensitive to E2 than MIB (Figure 
4.6.2a). Both T47D-TAMR and T47D-LTED cell lines were responsive to E2 for growth, 
but to a lesser extent compared to T47D cells (Figure 4.6.2b-c). Similar to the MCF7 
resistant models, T47D-TAMR were more sensitive to MIB than the parental T47D cells 
at the 100 nM concentration (P=0.04) however its oestrogen and androgen sensitivity  
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Figure 4.6.1: Endocrine Resistant derivatives of MCF7 cells are more sensitive 
to androgen than oestrogen for growth 
(a) MCF7 cells and their endocrine resistant derivatives (b) Tamoxifen Resistant 
(MCF7-TAMR), (c) Long Term Oestrogen Deprived (MCF7-LTED) and (d) Fulvestrant 
Resistant (MCF7-FULVR) cells were treated for 72 hours with different concentrations 
of the synthetic androgen Mibolerone (MIB) and 17-β-Oestradiol (E2). Proliferation 
was assessed using WST-1 assays. Mean of at least 3 replicate experiments are 
displayed, ±SE. T-Test was conducted between 0 nM and the following concentrations, 
*P<0.05, **P<0.005, ***P<0.0005, ****P<0.00005. 
 
Figure 4.6.1: Endocrine Resistant derivatives of MCF7 cells are more sensitive 
to androgen than oestrogen for growth 
(a) MCF7 cells and their endocrine resistant derivatives (b) Tamoxifen Resistant 
(MCF7-TAMR), (c) Long Term Oestrogen Deprived (MCF7-LTED) and (d) Fulvestrant 
Resistant (MCF7-FULVR) cells were treated for 72 hours with different concentrations 
of the synthetic androgen Mibolerone (MIB) and 17-β-Oestradiol (E2). Proliferation 
was assessed using WST-1 assays. Mean of at least 3 replicate experiments are 
displayed, ±SE. T-Test was conducted between 0 nM and the following concentrations, 
*P<0.05, **P<0.005, ***P<0.0005, ****P<0.00005. 
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Figure 4.6.2: Endocrine Resistant derivatives of T47D cells have altered 
sensitivity to androgen and oestrogen for growth 
(a) T47D cells and their endocrine resistant derivatives (b) Tamoxifen Resistant 
(T47D-TAMR) and (c) Long Term Oestrogen Deprived (T47D-LTED) cells were 
treated for 72 hours with different concentrations of the synthetic androgen Mibolerone 
(MIB) and 17-β-Oestradiol (E2). Proliferation was assessed using WST-1 assays. 
Mean of at least 3 replicate experiments are displayed, ±SE. T-Test was conducted 
between 0 nM and the following concentrations, *P<0.05, **P<0.005, ***P< 0.0005, 
****P<0.00005. 
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(a) T47D cells and their endocrine resistant derivatives (b) Tamoxifen Resistant 
(T47D-TAMR) and (c) Long Term Oestrogen Deprived (T47D-LTED) cells were 
treated for 72 hours with different concentrations of the synthetic androgen Mibolerone 
(MIB) and 17-β-Oestradiol (E2). Proliferation was assessed using WST-1 assays. 
Mean of at least 3 replicate experiments are displayed, ±SE. T-Test was conducted 
between 0 nM and the following concentrations, *P<0.05, **P<0.005, ***P< 0.0005, 
****P<0.00005. 
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were similar (Figure 4.6.2b). T47D-LTED cells, by contrast, had a similar sensitivity to 
MIB to the parental line (Figure 4.6.2c). The majority of the endocrine resistant cell lines 
therefore have partially lost their oestrogen responsiveness, and are instead more 
sensitive to androgens for growth.  
To confirm the role of AR in this androgen-induced growth, AR and ESR1 (ERα) 
levels were reduced using siRNA by 98.2 % and 80.7 % respectively in MCF7 cells and 
100 % and 85.3 % respectively in MCF7-TAMR cells (Figure 4.6.3a). Interestingly, AR 
levels decreased by 51.5 % (MCF7) and 86.1 % (MCF7-TAMR) with ERα knockdown 
(Figure 4.6.3a). Proliferation assays were subsequently conducted following MIB and E2 
treatment (Figures 4.6.3b-d). In MCF7 cells, growth was weakly increased by E2 and MIB 
treatment (not significant, Figure 4.6.3b, c). ERα knockdown resulted in a decrease in 
MCF7 cell growth regardless of hormone treatment (Figure 4.6.3b), although this effect 
was not significant. These results are in accordance with proliferation assays conducted 
previously, where it was demonstrated that inhibiting ERα activity with anti-oestrogens 
did not cause a significant induction of androgen-stimulated growth (Figure 3.5.1). In 
MCF7-TAMR cells, growth was significantly stimulated by MIB and this effect was 
abrogated following AR knockdown (Figure 4.6.3d), indicating that androgen-induced 
growth is dependent on the AR in this cell line. These results suggest that androgens are 
driving growth in many cases of endocrine resistance through the action of AR, and 
thereby anti-androgen treatment in these cases could be of benefit. It should be noted 
that the ligand-responsiveness of the cells in this experiment was weaker than for other 
experiments, suggesting that the siRNA transfection protocol was partially inhibitory to 
growth.   
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Figure 4.6.3 ERα knockdown abrogates MCF7 cell growth, and AR knockdown 
abrogates androgen-stimulated growth in MCF7-TAMR cells 
Androgen Receptor (AR) or Oestrogen Receptor alpha (ERα) levels were depleted 
using siRNA in MCF7 or MCF7-Tamoxifen Resistant (TAMR) cells alongside a Non-
Targeting (NT) siRNA control for 72 hours. (a) Cells were collected for Western blotting 
analysis. The percentage expression of ERα or AR following knockdown as compared 
to the NT siRNA control samples were analysed using Fusion X Software with β-
Tubulin as a loading control. MCF7 results were additionally shown in Figure 3.2.2. (b-
d) Cells were treated for a further 72 hours following transfection, with ethanol (EtOH) 
vehicle, 1 nM Mibolerone (MIB) or 1 nM 17-β-Oestradiol (E2). Proliferation was 
assessed using WST-1 assays for (b) MCF7 cells following ERα knockdown and (c) 
AR knockdown, and (d) MCF7-TAMR cells following AR knockdown. Mean of at least 
3 experiments are displayed, ±SE. T-Test *P<0.05. 
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4.6.1 Anti-androgen treatment can successfully inhibit the proliferation of models 
of endocrine resistance 
Following the knockdown growth assays, it was of interest to investigate whether 
targeting AR through therapeutics could be used to inhibit androgen-induced growth in 
endocrine resistant cells. Therefore, further proliferation assays were conducted on 
MCF7 and T47D cells, and their TAMR and LTED derivatives following treatment with 1 
nM MIB +/- the anti-androgens BIC and Hydroxyflutamide (OHF) (Figures 4.6.4-5). 
In MCF7 cells, as also demonstrated previously (Figure 4.6.1a), this concentration 
of MIB (1nM) did not stimulate cellular proliferation, however BIC also significantly 
reduced cell growth in this cell line as compared to the ethanol (EtOH) treated samples 
(Figure 4.6.4a). In MCF7-TAMR and MCF7-LTED cells, as also demonstrated previously, 
MIB significantly induced cellular proliferation, and this effect was reduced via anti-
androgen treatment, although OHF in MCF7-TAMR cells did not reach significance 
(P=0.054) (Figures 4.6.4b-c). BIC treatment additionally resulted in a significant reduction 
in cell growth in the absence of MIB in both MCF7-TAMR and MCF7-LTED cell lines, 
however OHF simulated MCF7-TAMR proliferation in the absence of MIB (Figures 4.6.4b-
c).  
MIB stimulated growth in T47D cells and its T47D-TAMR and T47D-LTED 
derivatives (Figures 4.6.5a-c), as seen previously (Figures 4.6.2a-c). Treatment with both 
anti-androgens reduced this androgen-stimulated growth, including in the endocrine 
sensitive cells, however this effect did not reach significance for OHF treatment in T47D-
TAMR cells (P=0.063) (Figures 4.6.5a-c). Interestingly, OHF simulated T47D-LTED 
proliferation in the absence of MIB (Figure 4.6.5c) as seen in the MCF7-TAMR cell line  
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Figure 4.6.4 Androgen-stimulated growth in endocrine resistant derivatives of 
MCF7 cells is inhibited by treatment with anti-androgens 
(a) MCF7, (b) MCF7-Tamoxifen Resistant (TAMR) and (c) MCF7-Long Term 
Oestrogen Deprived (LTED) cells were treated for 72 hours with 1 nM Mibolerone 
(MIB) or Ethanol (EtOH) as a control, 10 µM anti-androgen Bicalutamide (BIC) / 
Hydroxyflutamide (OHF) in hormone-depleted media. Proliferation was assessed 
using WST-1 assays. Mean of three replicate experiments are displayed, ±SE. T-Test 
*P<0.05, **P<0.005. 
 
 
Figure 4.6.4 Androgen-stimulated growth in endocrine resistant derivatives of 
MCF7 cells is inhibited by treatment with anti-androgens 
(a) MCF7, (b) MCF7-Tamoxifen Resistant (TAMR) and (c) MCF7-Long Term 
Oestrogen Deprived (LTED) cells were treated for 72 hours with 1 nM Mibolerone 
(MIB) or Ethanol (EtOH) as a control, 10 µM anti-androgen Bicalutamide (BIC) / 
Hydroxyflutamide (OHF) in hormone-depleted media. Proliferation was assessed 
using WST-1 assays. Mean of three replicate experiments are displayed, ±SE. T-Test 
*P<0.05, **P<0.005. 
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Figure 4.6.5 Androgen-stimulated growth in T47D cells and its endocrine resistant 
derivatives is inhibited by treatment with anti-androgens 
(a) T47D, (b) T47D-Tamoxifen Resistant (TAMR) and (c) T47D-Long Term Oestrogen 
Deprived (LTED) cells were treated for 72 hours with 1 nM Mibolerone (MIB) or Ethanol 
(EtOH) as a control, 10 µM anti-androgen Bicalutamide (BIC) / Hydroxyflutamide (OHF) 
in hormone-depleted media. Proliferation was assessed using WST-1 assays. Mean of 
three replicate experiments are displayed, ±SE. T-Test *P<0.05, **P<0.005. 
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(Figure 4.6.1.1b). These results suggest that anti-androgen treatment could be beneficial 
in tumours for both endocrine sensitive and endocrine resistant disease that are thought 
to be showing androgen-induced growth. 
4.7 The effect of anti-oestrogen and anti-androgen treatments upon AR and ERα 
expression is altered in endocrine resistance 
It has been demonstrated that the response of AR and ERα target gene expression 
to hormone and anti-oestrogen treatments is different in endocrine resistant cells as 
compared to endocrine sensitive cells (Section 4.2), and that anti-androgen treatment can 
inhibit endocrine resistant cell growth (Section 4.6.1). Therefore, it was investigated how 
anti-oestrogen and anti-androgen treatments affect ligand-induced changes to AR and 
ERα expression in MCF7 cells and its MCF7-TAMR and MCF7-LTED derivatives (Figures 
4.7.1a-c). 
In MCF7, AR levels stabilised in response to MIB and treatment with anti-
androgens (OHF and BIC) abrogated this effect. Interestingly, in the absence of MIB 
treatment, the anti-oestrogen TAM decreased AR levels, yet the alternative anti-
oestrogen FULV produced a slight increase in AR levels (Figure 4.7.1a). Interestingly, co-
treatment with FULV increased MIB-induced AR levels 3.2-fold, however co-treatment of 
MIB with TAM resulted in little variation in AR levels (Figure 4.7.1a). ERα levels, on the 
other hand, decreased following both MIB or anti-androgen treatment, yet the 
combination of MIB with anti-androgens slightly abrogated (BIC) or cancelled out this 
effect (OHF) (Figure 4.7.1a). TAM treatment increased ERα expression 2.4-fold, whereas 
FULV decreased its expression, and the addition of MIB reduced both of these effects 
(Figure 4.7.1a). 
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Figure 4.7.1 AR and ERα expression in MCF7 cells and its endocrine resistant 
derivatives, following different hormone and drug treatments 
 
(a) MCF7 cells and their (b) Tamoxifen Resistant (TAMR) and (c) Long Term 
Oestrogen Deprived (LTED) derivatives were grown in hormone depleted media for 72 
hours, then treated for 24 hours with different combinations of 1 nM Mibolerone (MIB) 
or vehicle (Ethanol, EtOH) and 1 µM anti-androgens Hydroxyflutmatide (OHF) or 
Bicalutamide (BIC), or 100 nM anti-oestrogens Tamoxifen (TAM) and Fulvestrant 
(FULV). Cells were lysed and immunoblotting conducted to examine androgen 
receptor (AR) and oestrogen receptor α (ERα) expression, with β-Actin included as a 
loading control. Densitometry analysis was conducted using the Fusion FX software 
to identify the percentage of AR and ERα expression as compared to vehicle.  
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Figure 4.7.2 AR and ERα expression in MCF7 cells and its endocrine resistant 
derivatives, following different hormone and drug treatments 
 
MCF7 cells and their Tamoxifen Resistant (TAMR) and Long Term Oestrogen Deprived 
(LTED) derivatives were grown in hormone depleted media for 72 hours, then treated 
for 24 hours with different combinations of 1 nM Mibolerone (MIB) or vehicle (Ethanol, 
EtOH) and 1 µM anti-androgens Hydroxyflutmatide (OHF) or Bicalutamide (BIC), or 
100 nM anti-oestrogens Tamoxifen (TAM) and Fulvestrant (FULV). Cells were lysed 
and immunoblotting conducted to examine Androgen receptor (AR) and Oestrogen 
receptor α (ERα) expression, with β-Actin included as a loading control. Densitometry 
analysis was conducted using the Fusion FX software to identify the percentage of (a) 
ERα or (b) AR expression as compared to vehicle for each cell line. 
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In accordance with the endocrine sensitive cells, AR expression stabilised 
following MIB treatment in the endocrine resistant lines, however to a larger extent of 4.8-
fold in MCF7-TAMR and 2.6-fold in MCF7-LTED as compared to 1.7-fold in the parental 
MCF7 line (Figures 4.7.1a-c). As seen in the endocrine sensitive cells, this effect was 
abrogated via anti-androgen treatment in MCF7-LTED cells, and in the absence of MIB 
both OHF and BIC reduced ligand-independent AR expression (Figure 4.7.1c). In MCF7-
TAMR cells, treatment with anti-androgens also reduced MIB-induced AR levels, however 
in the absence of ligand anti-androgen treatment resulted in a 1.9-fold increase in AR 
expression for both OHF and BIC (Figure 4.7.1b). As demonstrated in MCF7 cells, TAM 
reduced the MIB increase in AR levels for MCF7-TAMR or MCF7-LTED (Figures 4.7.1a-
c). In contrast, FULV had little effect upon MIB-induced AR levels in MCF7-TAMR and 
MCF7-LTED (Figures 4.7.1b-c).  
ERα expression, consistent with MCF7 cells, decreased following both MIB or anti-
androgen treatment in MCF7-LTED cells, however unlike in MCF7 cells where the 
combination of MIB with anti-androgen treatment appeared to abrogate this effect, it 
enhanced this effect in MCF7-LTED cells (Figure 4.7.1c). Alternatively, in the MCF7-
TAMR line, ERα expression remained fairly constant following MIB treatment (105.1 %) 
and interestingly increased with anti-androgen treatment regardless of the presence of 
MIB (Figure 4.7.1b). As demonstrated in MCF7 cells, FULV treatment in both MCF7-
TAMR and MCF7-LTED cells reduced ERα expression, however this was not abrogated 
via MIB treatment (Figure 4.2.2b-c). Similar to MCF7 cells, in MCF7-LTED cells TAM 
treatment resulted in a slight increase in ERα expression and this was not affected by 
MIB treatment (Figure 4.2.2c). Alternatively, in MCF7-TAMR cells TAM treatment reduced 
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ERα expression, but upon treatment with both MIB and TAM ERα expression increased 
1.6-fold (Figure 4.2.2b). 
In conclusion, AR expression was more responsive to MIB in the endocrine 
resistant cells than the endocrine sensitive cells, suggesting that the AR has an increased 
sensitivity to androgen in therapy resistance. Treatment with either anti-androgen or the 
anti-oestrogen TAM could at least partially abrogate this ligand-induced effect in all 3 cell 
lines. This indicates that anti-androgen treatment could be beneficial in both endocrine 
sensitive and endocrine resistant BCa. However, when ERα expression was decreased 
through FULV treatment in MCF7 cells, AR levels were enhanced, which could contribute 
to cancer progression. In MCF7 and MCF7-LTED cells, androgen or anti-androgen 
treatment decreased ERα expression, which suggests that AR signalling can also affect 
ERα expression. However, in MCF7-TAMR cells, ERα levels remained fairly constant 
following MIB treatment but increased with anti-androgen treatment. Previous data 
obtained from siRNA knockdown analysis demonstrated that a decrease in ERα levels 
also results in a decrease in AR levels (Figure 4.6.3a), however in this experiment a 
reduction in ERα levels through treatment does not appear to have a significant impact 
on AR expression in any of the cell lines. 
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4.8 AR and ERα display altered DNA binding in endocrine resistance 
It has been previously demonstrated that AR binding to DNA is disrupted by E2 
signalling in MCF7 cells (Figures 3.5.6c-d). To see if this was the case in endocrine 
resistance, ChIP was used to investigate ERα and AR binding in MCF7-TAMR cells. Cells 
were treated with EtOH as a control, 1 nM E2, 1 nM MIB or both (E2 + MIB) and 
crosslinked with formaldehyde prior to DNA shearing via sonication to approximately 200 
bp. ChIP assays were subsequently conducted to pull down AR or ERα. qPCR analysis 
was conducted to amplify a known ERE in the promoter region of the TFF1 gene 340-354 
bp upstream (TFF1 +ve) and a negative control region 685-520 bp upstream (TFF1 –ve) 
for ERα pull down (Figure 4.8.1a) or a known ARE located between exons 3 and 4 of the 
ZBTB16 gene (ZBT +ve) and its relative negative control region 2,443 bp upstream (ZBT 
-ve) for AR pull down (Figure 4.8.1b). 
The results demonstrated that AR was recruited in a ligand-dependent manner to 
the ARE (Figure 4.8.1a) (as previously seen in MCF7 cells, Figures 3.5.6c-d). Co-
treatment with E2 decreased AR recruitment to this site (Figure 4.8.1a). It was also 
demonstrated that ERα appeared to be constitutively bound to the ERE (Figure 4.8.1b), 
which ERα was recruited to in a ligand-dependent manner in MCF7 cells (Figure 3.2.4b). 
Therefore, TAM resistance has impacted the recruitment of ERα and AR to this gene. 
ChIP-Seq will be conducted on these samples in future work to provide more insight into 
where in the genome ERα and AR bind in these TAM resistant cells. 
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Figure 4.8.1 Investigation of ERα and AR recruitment in MCF7-TAMR cells 
Tamoxifen Resistant (TAMR) derivative of MCF7 cells were treated with ethanol 
(EtOH), 1 nM 17-β-Oestradiol (E2), 1 nM Mibolerone (MIB) or both (E2 + MIB) and 
crosslinked with formaldehyde prior to DNA shearing via sonication to approximately 
200 bp. Chromatin Immunopreceipitation (ChIP) assays were then conducted, to pull 
down (a) Androgen Receptor (AR) or (b) Oestrogen Recptor alpha (ERα). Subsequent 
qPCR analysis was conducted to amplify a known ERE in the promoter region 
approximately 400 bp upstream of Trefoil Factor 1, TFF1, (TFF1 +ve) and a negative 
control region approximately 2 kb upstream (TFF1 –ve) or a known androgen 
response element (ARE) upstream of the Zinc Finger And BTB Domain Containing 16 
(ZBTB16) gene (ZBT +ve) and its relative negative control region (ZBT -ve). A 
representative example from two replicate experiments are displayed, ±SE. 
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4.9 Discussion 
4.9.1 AR and ERα expression are generally correlated in endocrine resistance 
It has been previously demonstrated that ERα and AR expression is often 
correlated in BCa (Table 3.2.1 and Figure 3.2.1) as also reported by others (Vera-Badillo 
et al., 2014, Collins et al., 2011, Lin et al., 2015). Therefore, immunoblotting was 
conducted to investigate AR and ERα expression in our cell line models of endocrine 
sensitive and resistant disease (Figure 4.2.1). The results demonstrated here that 
although there are differences in expression between the cell lines, AR and ERα 
expression was observed to be generally correlated across all the cell lines (Figure 
4.2.1b). This suggests that in endocrine resistance the receptors could both be regulated 
by a common factor, or that one receptor regulates the expression of the other. However, 
in contrast to this it was later demonstrated that a reduction in ERα levels through 
treatment does not appear to have a significant impact on AR expression in MCF7, MCF7-
TAMR or MCF7-LTED cells (Figure 4.7.1). 
Previously, it was indicated that ERα regulates AR in endocrine sensitive disease 
(Section 3.6.1). It was demonstrated that ERα knockdown resulted in a reduction in AR 
expression in endocrine sensitive cells (Figure 3.2.2) and experiments suggested that 
ERα could regulate AR expression through an ERE on the AR gene (ERE+151,438-726, 
Figure 3.2.5), and that ERα was recruited ligand-dependently to an alternative ERE 
upstream of AR (ERE-19,247-18,610, Figure 3.2.4). Interestingly, when ERα levels were 
depleted in MCF7-TAMR cells, AR expression decreased by 86.1 %, an even greater 
reduction than the 51.5 % observed in MCF7 cells (Figure 4.6.3a). This demonstrated 
that in this mechanism of TAM resistance, ERα is still regulating AR expression. 
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Therefore, if AR is driving this form of endocrine resistance, the use of an alternative 
endocrine therapy to target the ERα and degrade its expression, such as FULV, could be 
beneficial. This is in line with work published by others, as it has been described that in 
the majority of TAM resistance cases ERα expression is maintained, and some patients 
have responded to alternative endocrine therapies, such as FULV (Osborne, 1998, 
Howell et al., 1995, Howell et al., 1996, Schiff et al., 2003). 
4.9.1.1 ERα and AR colocalise in models of endocrine resistance 
The subcellular localisation of AR and ERα was initially investigated via 
transfecting COS-1 cells with ERα-RFP and AR-GFP (Figure 4.4.1). In the absence of 
hormone, AR was predominantly cytoplasmic and ERα nuclear. These results are in line 
with IHC conducted previously by another group that demonstrated that ERα is more 
commonly localised in the nucleus than the cytoplasm in BCa tumours (Li et al., 2015a) 
and that prior to ligand binding AR is often cytoplasmic in PCa cells (Leung and Sadar, 
2017, Brooke, 2005). However, upon oestrogen or androgen treatment the receptors 
became more colocalised in the nucleus (Figure 4.4.1), as these receptors are both 
ligand-dependant transcription factors that exert their effects in the nucleus (Sever and 
Glass, 2013). Subsequent investigation of endogenous AR and ERα in the endocrine 
sensitive cell lines (MCF7 and T47D) and their TAMR and LTED derivatives, 
demonstrated that AR and ERα localisation varies between the endocrine resistant 
models and the parental lines, however the receptors are commonly found to colocalise 
with hormone treatments (Figures 4.4.2-7). For instance, unlike in the other cell lines, in 
T47D-TAMR cells both AR and ERα were predominantly cytoplasmic upon treatment with 
MIB, in the presence or absence of E2 (Figure 4.4.6). This result could indicate an usual 
mechanism of regulation in this cell line, such as non-genomic AR signalling, which has 
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been demonstrated by others to occur in advanced, therapy-resistant PCa cell line 
models (Liao et al., 2013, Leung and Sadar, 2017). ChIP assays in future work could 
therefore indicate whether AR is binding to DNA in this cell line. 
4.9.2 Endocrine resistant cells have enhanced sensitivity to androgen and 
increased AR activity 
Our resulted indicate that the resistant cell lines have an enhanced sensitivity to 
androgen. AR expression was stabilised via MIB treatment more strongly in MCF7-TAMR 
(4.8-fold) and MCF7-LTED cells (2.6-fold) than their parental line (1.7-fold) (Figures 
4.7.1a-c), and the endocrine resistant lines have an increased sensitivity to MIB for growth 
(with the exception of T47D-LTED) (Figures 4.6.1-2). The role of AR in facilitating 
endocrine resistance has been investigated by others (De Amicis et al., 2010, Rechoum 
et al., 2014, Ciupek et al., 2015). For instance, an elevated AR expression has been 
associated with TAM resistant tumours and the exogenous overexpression of AR has 
been demonstrated to promote TAM resistance in vitro (De Amicis et al., 2010). 
Additionally, an increase in the AR activator PSAP has been demonstrated to promote AI 
resistance through promoting AR recruitment to HREs (Ali et al., 2015). Therefore, there 
could be an increased importance of androgens and the AR in endocrine resistance. 
4.9.2.1 AR and ERα signalling is altered in endocrine resistance 
The regulation of ERα target genes TFF1 and MYC (Table 3.5.1) was investigated 
in MCF7 cells and their endocrine resistant derivatives MCF7-LTED and MCF7-TAMR. 
TFF1 was significantly induced via E2 treatment in MCF7 cells, however this induction 
was decreased in both models of endocrine resistance and hence not always significant 
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(Figures 4.3.1 and 4.5.1a). Additionally, it was demonstrated that total TFF1 levels were 
higher in MCF7 cells than the resistant lines, in particular MCF7-TAMR cells (Figure 
4.5.1a). ChIP assays additionally demonstrated that ERα recruitment to a known ERE in 
the promoter region of the TFF1 gene was significantly induced via E2 treatment in MCF7 
cells (Figure 3.2.4b), however in MCF7-TAMR cells ERα appeared to be constitutively 
bound to this ERE and was unaffected by E2 treatment (Figure 4.8.1b). So, TAM 
resistance has impacted ERα recruitment to this gene. In accordance with these results, 
E2 treatment significantly increased MYC expression in MCF7 cells, but not in the 
resistant lines (Figures 4.3.2a-c and 4.5.1b). Taken together, these results suggest that 
some ERα target genes lose oestrogen responsiveness in endocrine resistance.  
As expected, E2-induced expression of MYC and TFF1 was inhibited via both anti-
oestrogens in MCF7 cells (Figures 4.3.1a and 4.3.2a). It was further demonstrated that 
FULV treatment could also significantly reduce MYC expression in both MCF7-TAMR and 
MCF7-LTED cells (Figures 4.3.2b-c) and TFF1 expression in MCF7-TAMR cells (Figure 
4.3.1b). These results demonstrate that ERα has remained at least partially active in 
these cells, and therefore treatment with an alternative anti-oestrogen such as FULV, 
which inhibits ERα activity via an alternative mechanism of action to TAM, could still be 
of benefit in these resistance models. This is in accordance with work conducted by 
others, where it has been demonstrated that ERα expression is commonly maintained in 
TAM resistance and that some patients have responded to alternative endocrine 
therapies, including FULV (Osborne, 1998, Howell et al., 1995, Howell et al., 1996, Schiff 
et al., 2003). However, it is surprising that TAM was still able to significantly inhibit TFF1 
expression in MCF7-TAMR cells (Figure 4.3.1b). In order to see if this result is true for 
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more E2-regulated genes, global gene analysis for instance through RNA-Sequencing 
(RNA-Seq), is required. 
GREB1 is both an AR and ERα target gene (Table 3.5.1), however in all cells lines 
the expression GREB1 was induced via E2 treatment and to a lesser degree by MIB 
(Figures 4.3.5 and 4.5.2). In all 3 cell lines, treatment with anti-oestrogens was able to 
significantly reduce E2-induced GREB1 expression, and MIB was only able to partially 
abrogate this effect in MCF7-TAMR cells (Figures 4.3.5a-c). This suggests that genes 
where it appears that AR and ERα are not competing are inhibited by anti-oestrogen 
treatment. 
Interestingly, the patterns of expression observed for 5 AR target genes varied 
greatly between the genes and the cell lines. Two AR target genes become more 
sensitive to androgen treatment in one model of endocrine resistance but not the other 
(ZBTB16 in MCF7-TAMR and SEC14L2 in MCF7-LTED); one gene demonstrated a 
smaller induction from androgen treatment in the endocrine resistant cells than the 
endocrine sensitive cells, but increased total levels of expression in endocrine resistance 
(DDC); one gene demonstrated a decreased expression and responsiveness to androgen 
in endocrine resistance (DIO2); and the expression of another gene appeared to be 
unaffected in endocrine resistance (NDRG1) (Figures 4.3.3-4 and 4.5.3-4).  
It appears that the endocrine resistant cells have a unique androgen signalling 
pathway to endocrine sensitive cells, differing to that observed in PCa (Farmer et al., 
2005, Need et al., 2012). DDC is an androgen regulated gene that has been identified as 
an important AR co-activator in PCa (Margiotti et al., 2007, Wafa et al., 2003); SEC14L2 
is as an androgen-regulated gene associated involved in PCa cellular proliferation (Bolton 
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et al., 2007, Chan et al., 2016, Ni et al., 2005); DIO2 has been reported to be rapidly 
upregulated via DHT treatment in PCa (Xu et al., 2006); ZBTB16 has been demonstrated 
as an AR target gene in PCa cells (van de Wijngaart et al., 2009); and NDRG1 is an AR 
target gene identified to be positively regulated by androgen treatment in PCa cells 
(Masuda et al., 2005, Nelson et al., 2002, Ngan et al., 2009). However, it was not 
observed in all endocrine resistant lines that the expression of these genes became more 
sensitive in response to androgen, and the total expression levels of the genes did not 
increase in all endocrine resistant models. MABC (ERα-negative, AR positive) tumours 
have been demonstrated to have increased androgen-signalling with a distinct gene 
expression profile (Farmer et al., 2005). Therefore it was expected that the regulation of 
AR targets would not follow patterns demonstrated in PCa, and it was hypothesised that 
androgen signalling in endocrine resistance could appear more like that observed in 
MABC. 
ERα activity, however, could influence the results for DIO2 and DDC target gene 
analysis. DIO2 has been demonstrated to function in the regulation of TR activity through 
the production of the more potent thyroid hormone triiodothyronine from thyroxine, the 
process of which is upregulated via E2 (Detti et al., 2013, Xu et al., 2006). Therefore there 
is a possibility that this gene is also regulated by ERα. Additionally, in the absence of MIB 
treatment, DDC expression was also significantly increased via E2 treatment in MCF7 
cells, but this effect was lost in its resistant derivatives (Figure 4.5.4a). Therefore, this 
gene could be additionally an ERα target gene in endocrine sensitive disease, or part of 
the mechanism via which ERα is regulating AR could be through the regulation of DDC, 
the effect of which is lost in endocrine resistance. These results would therefore be worth 
exploring further. 
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Alternatively, lack of an increase in androgen induction of DDC in the resistant 
lines as compared to MCF7 cells was because the total DDC levels were significantly 
higher in the absence of hormone treatments in the resistant cell lines than MCF7 cells 
(Figure 4.5.4a). These results indicate that DDC expression could be being additionally 
regulated by an alternative factor or mechanism in these cells. DDC has been identified 
by others as an important AR co-activator in PCa (Margiotti et al., 2007, Wafa et al., 
2003), therefore an alternative factor could be increasing its expression in order to 
promote AR activity in endocrine resistance, which warrants further investigation. 
Interestingly, it also appears that AR signalling in endocrine resistance may differ 
to that in MABC. ZBTB16 has been identified as an androgen-regulated AR target gene 
in MABC (Robinson et al., 2011), and therefore this was hypothesised to be the case in 
endocrine resistant BCa. However, androgen induced expression of this target gene was 
increased in MCF7-TAMR cells but not MCF7-LTED cells. Additionally, the differences in 
regulation observed between the different resistance models could be from variations in 
the mechanism via which AR is driving endocrine resistance in these different models. 
For instance, alternative co-factors or pioneer factors could be influencing AR activity in 
these lines. Additionally, differing DNA modifications to AR could be present in these 
lines. Therefore, further analysis using ChIP-Seq and RNA-Seq experiments would give 
further insight into the differences in AR signalling between these resistant lines, and how 
androgen signalling differs in endocrine resistance to endocrine sensitive disease and 
PCa. 
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4.9.2.1.1 AR and ERα cross-talk in gene expression 
Co-treatment of MIB was unable to compete with the E2-induced TFF1 or MYC 
expression for any of the cell lines (Figures 4.3.1a-c and 4.3.2a-c), as also demonstrated 
in earlier reporter assays (Figures 3.4.2 and 4). However, co-treatment with E2 
significantly reduced MIB-induced expression of ZBTB16, NDRG1 and DIO2 in MCF7 
cells, and for ZBTB16 and NDRG1 this effect additionally occurred in at least one of the 
resistant lines (Figures 4.3.3, 4.3.4, and 4.5.4b). This was also observed for DDC in all 
cell lines, however it was not always significant (Figure 4.5.4a). Importantly, anti-
oestrogen treatment could significantly reverse this inhibitive action of E2 on ZBTB16 
expression in some cases: via TAM or FULV treatment in MCF7 cells (Figure 4.3.3a) and 
by FULV treatment in MCF7-TAMR cells (Figure 4.3.3b). This effect was also observed 
in MCF7-LTED cells, however it was not significant (Figure 4.3.3c). This indicates that 
ERα cross-talk is having an inhibitory effect on AR activity, in endocrine resistant as well 
as endocrine sensitive cells, and that treatment with anti-oestrogens could abrogate these 
effects. This crosstalk was supported by confocal microscopy where it was demonstrated 
that when AR and ERα were exogenously transfected into COS-1 cells, nuclear 
translocation of AR in response to MIB was partially blocked by E2, with some 
cytoplasmic localisation evident (Figure 4.4.1). However, in the case of NDRG1, a gene 
much more weakly induced by androgen than ZBTB16 in MCF7 cells, co-treatment with 
FULV significantly its increased E2-induced expression in MCF7 cells, and this was lost 
in MCF7-LTED cells (Figures 4.3.4a, c). This indicates that genes which are not strong 
AR targets in endocrine sensitive cells can be induced via endocrine therapy.  
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4.9.3 Changes to AR and ERα expression in endocrine resistance 
4.9.3.1 An upregulation of AR expression is not essential for endocrine resistance 
An elevated expression of AR has been reported in some TAM-resistant tumours, 
and it has been demonstrated that a ratio of AR:ERα higher than 2.0 increases the 
possibility of development of TAM resistance more than 4-fold (Cochrane et al., 2014, 
Carreno et al., 2007, De Amicis et al., 2010). Additionally, exogenous overexpression of 
AR in MCF7 cells has been demonstrated to promote TAM resistance in vitro (De Amicis 
et al., 2010, Ciupek et al., 2015). Therefore, it was investigated as to whether AR 
expression was altered in our cell line models of endocrine resistance (Figure 4.2.1a). 
The results demonstrated that AR expression was 2.6-fold higher in MCF7-LTED cells 
and 3.9-fold in T47D-TAMR cells as compared to the relevant parental lines, which 
indicates that its elevated expression could help facilitate resistance in these lines (Figure 
4.2.1a). 
However, AR expression remained relatively constant in MCF7-TAMR cells as 
compared its parental line (Figure 4.2.1a), but these cells displayed an enhanced 
sensitivity to androgen for growth (Figure 4.6.1b) and siRNA knockdown growth 
experiments confirmed that this effect was produced through AR (Figure 4.6.3d). 
Additionally, it was demonstrated that AR expression is more responsive to MIB treatment 
in MCF7-TAMR cells and the expression of the AR target gene ZBTB16 was more 
responsive to androgen treatment in this resistant line than demonstrated in the parental 
line (Figures 4.3.3 and 4.7.1). Therefore, an alternative mechanism to AR overexpression 
must be important in the development of this endocrine resistant line. Interestingly, both 
AR and ERα expression were strongly decreased in T74D-LTED cells (Figure 4.2.1a), 
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which additionally were later demonstrated to have a similar sensitivity to MIB to the 
parental line (Figure 4.6.2c). This suggestis that these cells retained androgen sensitivity 
despite these low AR levels, indicating that AR could drive growth in tumours which have 
developed this resistance mechanism. However, MCF7-FULVR was also displayed to 
have strongly decreased AR and ERα expression (Figure 4.2.1a), but was sensitive to 
androgen for growth (Figure 4.6.1d), which suggests that low levels of AR are sufficient 
to drive proliferation in these resistant cells.  
4.9.3.2 ERα expression varies in endocrine resistant models 
It has been demonstrated that the endocrine resistant cells have developed a 
reduced sensitivity or lost their response to oestrogen for growth, as compared to their 
parental lines (Figures 4.6.1-2). Therefore, it could be expected that ERα expression is 
downregulated or lost in these lines. Although ERα expression was decreased in all but 
one resistant cell line (T47D-TAMR, where it increased by 1.8-fold), this reduction was 
only slight in MCF7-TAMR and MCF7-LTED cells (16.2 and 24.9 %, respectively) (Figure 
4.2.1a). This suggests that a loss of ERα expression is not required for the alternative 
signalling driving these resistance mechanisms to occur. It has been reported that ERα 
expression is often maintained in TAM resistance, and therefore these results are in line 
with work previously conducted (Osborne, 1998, Howell et al., 1995, Howell et al., 1996, 
Schiff et al., 2003).  
However, a more noticeable decrease in ERα expression was observed in two of 
the resistant lines: MCF7-FULVR (4.1 %) and T47D-LTED (29.4 %). A downregulation or 
loss of ERα expression has been estimated from published work to arise in approximately 
15-20 % of endocrine resistant tumours, and this resistance mechanism has been linked 
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to promoting the activity of HDAC1 and the PI3K/AkT/mTOR signalling pathway (Citro et 
al., 2015). Therefore, this could be an important factor in these endocrine resistant lines, 
and warrants further investigation. On the other hand, FULV treatment advances the 
degradation of ERα expression (Kaklamani and Gradishar, 2017, Lumachi et al., 2015, 
Lanvin et al., 2007, Osborne et al., 2004), so this effect in MCF7-FULVR could be due to 
the constant exposure to FULV treatment in the maintenance of this resistant line. 
4.9.4 AR drives endocrine resistant cell growth 
It is well established that BCa proliferation is driven through oestrogens via the 
action of ERα in endocrine sensitive disease, for example through its regulation of the 
PI3K/AKT/mTOR signalling pathway (Beatson, 1896, Pan et al., 2017, Chuffa et al., 2017, 
Ali and Coombes, 2002). Studies have suggested that the AR, by contrast, has an 
inhibitory effect on ERα-driven cancer progression (Rahim and O'Regan, 2017, Fioretti et 
al., 2014, Tarulli et al., 2014) and it has been demonstrated that AR overexpression or 
androgen treatment abrogates E2-stimulated cellular proliferation in endocrine sensitive 
cells (Cops et al., 2008, Szelei et al., 1997). In support of this, our proliferation assays 
conducted on MCF7 and T47D cells demonstrated that endocrine sensitive cells respond 
with an elevated sensitivity to oestrogens over androgens for growth (Figure 4.6.1a and 
4.6.2a), demonstrating the importance of the ERα pathway in driving cancer growth. 
Unlike MCF7 cells, however, whose growth was only significantly increased by the 
highest concentration of MIB (100 nM), T47D cells were sensitive to MIB for growth. As 
MIB is a synthetic analogue of DHT that cannot be metabolised to E2, this was not 
produced by oestrogenic effects. Additionally, AR was demonstrated to be more highly 
expressed in T47D cells than MCF7 cells (Figure 4.2.1a). This suggests that for endocrine 
sensitive tumours that have a high AR expression, AR signalling could produce a 
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sensitivity to androgen for growth, and therefore targeting this axis in treatment could be 
beneficial.  
It has been reported that androgens are secreted in significantly higher quantities 
than oestrogens in women (Burger, 2002) and two of the main androgens that are 
produced in women are precursors for E2: androstenedione and testosterone (Figure 
1.7.3.1). Several studies have indicated that treatment with different endocrine therapies 
can cause an increase in androgen levels (Takagi et al., 2010, Rossi et al., 2009), and 
that increased androgen levels are associated with endocrine resistance (Berrino et al., 
2005, Hanamura et al., 2013, Baumgart et al., 2014). In addition to this, in MABC (ERα-
negative, AR-positive BCa) it has been demonstrated that AR has an oncogenic effect 
and its expression is associated with aggressive tumours (Doane et al., 2006; Robinson 
et al., 2011; Lehmann-Che et al., 2013). Therefore, it can be assumed that as androgens 
are readily available, in the absence of an active ERα the AR would be able to function 
more highly and drive endocrine resistant cell growth. In support of this, previously 
conducted colony formation assays (Figure 3.5.2) suggested that androgens may be able 
to promote the onset of endocrine resistance. Figures 4.6.1b-d demonstrated that the 
MCF7 endocrine resistant derivatives have a reduced (MCF7-TAMR and MCF7-FULVR) 
or no (MCF7-LTED) response to E2 and have become more sensitive to MIB for growth 
(Figures 4.6.1b-d). Therefore, AR signalling could be a common mechanism in resistance 
to different endocrine therapies.  
Additionally, the T47D endocrine resistant derivatives have a reduced response to 
E2 for growth (Figures 4.6.2b-c). Although T47D-TAMR cells were more sensitive to MIB 
than the parental T47D cells, its oestrogen and androgen sensitivity were similar (Figure 
4.6.2.b), and T47D-LTED cells displayed a similar sensitivity to MIB to the parental line 
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(Figure 4.6.2c). siRNA knockdown of AR abrogated MIB-stimulated growth in MCF7-
TAMR cells, which demonstrated that androgen-induced growth is dependent on the AR 
in this cell line (Figure 4.6.3). It was expected that androgen-stimulated growth would be 
induced by ERα knockdown, as in the absence of functioning ERα we have demonstrated 
previously that the AR can become activated (Chapter 3). However, ERα knockdown 
resulted in a decrease in MCF7 cell growth regardless of hormone treatment (Figure 
4.6.3a). This lack of AR-induced growth could be the result of the reduction in AR levels 
as a side effect of siRNA knockdown.  
These results demonstrate that all of the endocrine resistant cell lines have a 
reduced sensitivity to oestrogen, and the majority an enhanced sensitivity to androgen for 
proliferation. There were variations between how the endocrine resistant models behaved 
in response to androgen or oestrogen treatment, however this was expected as work 
previously conducted has indicated that multiple alternative resistance mechanisms can 
develop using a resistance model developed in the same way (Hayashi and Kimura, 
2015). Additionally, qPCR analysis of MCF7-TAMR and MCF7-LTED cells have 
demonstrated different androgen and oestrogen induced regulation of AR and ERα target 
genes within these endocrine resistance models (Section 4.9.2). However, these results 
indicate that androgens are a potential common driver of endocrine resistant growth 
through the action of AR in resistance pathways.  
4.9.4.1 Anti-androgen treatment can successfully inhibit the proliferation of models 
of endocrine resistance 
Growth assays have indicated that AR drives endocrine resistant cell growth. 
Therefore, it was hypothesised that anti-androgens which are currently used in the 
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treatment of PCa could be repurposed for use in endocrine resistant BCa. To explore this, 
proliferation assays were conducted to investigate the effects of the anti-androgens BIC 
and OHF on MIB-stimulated growth in MCF7 and T47D cells, and their TAMR and LTED 
endocrine resistant derivatives (Figures 4.6.1.1-2). The results demonstrated that BIC 
and OHF inhibited MIB-stimulated growth in all the resistant cell lines tested (Figures 
4.6.1.1b-c and 4.6.1.2b-c). Interestingly, this included the T47D-LTED line (Figure 
4.6.1.2c) which was demonstrated to have a much lower AR expression than the other 
lines (Figure 4.2.1a) as well as no enhanced sensitivity to MIB than its parental line 
(Figure 4.6.2c), suggesting that AR is still important for cancer progression in this line. 
BIC treatment additionally resulted in a significant reduction in cell growth in the absence 
of MIB in both MCF7-TAMR and MCF7-LTED (Figures 4.6.1.1b-c). Interestingly, both BIC 
and OHF treatment significantly reduced MIB-stimulated growth in T47D cells (Figure 
4.6.1.2a), and BIC treatment significantly decreased MCF7 proliferation in the absence 
of MIB treatment (Figure 4.6.1.1a). As these results suggest that AR is a common factor 
in driving endocrine resistance in our cell line models (Figures 4.6.1, 4.6.2, 4.6.1.1 and 
4.6.1.2), it could be hypothesised that anti-androgens could be used as a therapeutic to 
treat endocrine resistance. 
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Chapter 5: Conclusions 
5.1 Targeting AR to prevent the development of endocrine resistance 
The majority of BCa patients are post-menopausal women with ERα-positive, 
luminal tumours (Rakha and Green, 2016, Ali and Coombes, 2002). Treatment for these 
patients usually involves the administration of endocrine therapy which aims to block ERα 
activity. This includes anti-oestrogens (SERMs such as TAM and SERDs such as FULV), 
which aim to target ERα directly to block its action. Additionally, AIs such as Anastrozole 
are commonly administered which block aromatase activity to reduce E2 synthesis, thus 
decreasing circulating oestrogen levels and E2 synthesised within the tumour (Patani and 
Martin, 2014, Kaklamani and Gradishar, 2017). Endocrine therapy has been largely 
successful, however the development of endocrine resistance in patients with ERα-
positive disease is a major issue in BCa treatment. It is currently estimated that 20-30 % 
of BCa patients will experience endocrine resistance, and many mechanisms by which 
this may occur have been described (Vorobiof, 2016). 
Endocrine resistance development has been reported to occur by multiple 
mechanisms, including mutations to the gene encoding ERα, ESR1, resulting in 
constitutive activation of ERα (Fanning et al., 2016, Reinert et al., 2017), increased co-
factor expression hyperactivating the ERα pathway (Osborne et al., 2003, Jin et al., 2015, 
Hiken et al., 2016), phosphorylation of ERα resulting in its ligand-independent activity 
(Hayashi and Kimura, 2015), the stimulation of ERα via activation of growth factor 
signalling pathways (Abdel-Hafiz, 2017) and miRNA-mediated alterations to ERα 
expression or to the levels of proteins functioning in cell cycle regulation (Miller et al., 
2008, Wei et al., 2014, Zhao et al., 2008). Many of these mechanisms have been found 
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to overlap, with one group describing how their development of AI-resistance cell line 
models using the same method resulted in multiple resistance mechanisms, sometimes 
within the same model (Hayashi and Kimura, 2015).  
The AR has been demonstrated to promote cancer progression in a subclass of 
ERα-negative AR-positive tumours (MABC disease) (Fioretti et al., 2014, Badve et al., 
2011, Rakha and Green, 2017, Vranic et al., 2017, Farmer et al., 2005, Doane et al., 
2006), and the AR has fairly recently been implicated in promoting the onset of endocrine 
resistance (Ali et al., 2015, Fujii et al., 2014, Rechoum et al., 2014, Ciupek et al., 2015, 
De Amicis et al., 2010). To develop further understanding of this resistance mechanism, 
the initial aim of this thesis was to explore how AR signalling is altered in endocrine 
sensitive disease following treatment with endocrine therapies, from its previously 
demonstrated tumour suppressive action (Cops et al., 2008, Kampa et al., 2005, Wang 
et al., 2013, Lanzino et al., 2013), to drive the development of endocrine resistance. 
The key results presented here demonstrated that ERα inhibits AR activity and 
through anti-oestrogen treatment this inhibition could be abrogated (TAM) and even 
promote a hyperactivated AR (FULV) (Figures 3.4.2d and 3.4.4d); colony formation 
assays indicated that long term androgen treatment could abrogate the growth inhibitory 
effects of anti-oestrogens on oestrogen-treated endocrine sensitive cells (Figure 3.5.2); 
anti-oestrogen treatment decreases the hormone-induced expression of ERα regulatory 
target genes, yet increases that of AR targets in endocrine sensitive cells (Figure 3.5.3-
4); and that in endocrine sensitive cells, oestrogen treatment abrogates androgen-
induced AR enrichment at an ARE, but anti-oestrogens can partially rescue this effect 
(Figure 3.5.6). Therefore, anti-oestrogen treatment could, in addition to inhibiting ERα 
activity, lead to a more active AR and so select for this mechanism of resistance. In 
 223 
 
addition to these results, in Chapter 4 it was demonstrated that anti-androgens could 
significantly reduce androgen-stimulated growth in some endocrine sensitive cells (Figure 
4.6.5a). Taken together, these results provide strong evidence to suggest that resistance 
to endocrine therapy can be promoted via enhanced AR activity. It is likely that this effect, 
which is produced through the inhibition of ERα signalling, is due to the removal of 
ERα/AR crosstalk that has been demonstrated here (Figure 3.4.1) and by others (Peters 
et al., 2009, Need et al., 2012, Fioretti et al., 2014, Lanzino et al., 2005).  
Importantly, the development of this resistance mechanism could be prevented via 
co-treatment with anti-androgens, since treatment with the anti-androgen BIC enhanced 
the abrogation of growth in both TAM and FULV treated samples (Figure 3.5.1) and 
prevented androgen-induced FULV/TAM resistance in the colony formation assays 
(Figure 3.5.2). This work therefore indicates that the administration of anti-androgens as 
a combination therapy with endocrine therapies could help to prevent activation of AR 
signalling and potentially halt this resistance mechanism from occurring in endocrine 
sensitive patients. This model is summarised in Figure 5.1.1. 
Clinical trials investigating the use of the anti-androgen Enzalutamide in 
combination with various endocrine therapies (including the AI Exemestane and the anti-
oestrogen FULV) in ERα-positive patients expressing AR are currently underway (Table 
1.9.4.1). Enzalutamide is a second generation anti-androgen that, in addition to 
competing with ligands to block AR action, stops AR nuclear translocation and AR 
interaction with DNA and co-factors (Nadal and Bellmunt, 2016, Rahim and O'Regan, 
2017, Pelekanou and Castanas, 2016). These clinical trials are following recently 
published work whereby the authors established the pharmacokinetic interactions, safety, 
tolerability and correct dosage for the use of Enzalutamide combination with endocrine 
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Figure 5.1.1 Targeting the Androgen Receptor therapeutically could abrogate 
the development of therapy resistance in endocrine sensitive patients 
 (a) In patients that are positive for Oestrogen Receptor alpha (ERα), ERα drives 
cancer growth via interactions with Oestrogen Response Elements (EREs), and 
anti-oestrogen treatment can inhibit this growth. (b) ERα inhibits the Androgen 
Receptor (AR), and anti-oestrogen treatment reverses this repression, so AR can 
promote endocrine resistance via interactions with Androgen Response 
Elements (AREs) to promote cancer progression. (c) Therefore, the combination 
of endocrine therapy with anti-androgens to inhibit AR action could prevent the 
onset of endocrine resistance. 
 
Figure 5.1.1 Targeting the Androgen Receptor therapeutically could abrogate 
the development of therapy resistance in endocrine sensitive patients 
 (a) In patients that are positive for Oestrogen Receptor alpha (ERα), ERα drives 
cancer growth via interactions with Oestrogen Response Elements (EREs), and 
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therapy in ERα-positive BCa patients (Schwartzberg et al., 2017). An additional benefit 
to using Enzalutamide in this co-therapy is that in addition to targeting AR to prevent 
resistance onset, Enzalutamide could enhance endocrine therapy action via the induction 
of Cytochrome P450 3A4 (CYP3A4), as Enzalutamide has been previously demonstrated 
to be a strong CYP3A4 inducer (Gibbons et al., 2015). CYP3A4 is a protein which often 
metabolises endocrine therapies, for instance it produces the primary active metabolite 
for TAM, N- dimethyltamoxifen (Yiannakopoulou, 2012). The results of this clinical trial, 
comparing antiandrogens and antioestrogens as monotherapies or combination 
therapies, will therefore confirm whether my hypothesis for the use of anti-androgens in 
these patients is correct.   
The use of the novel Selective Androgen Receptor Modulator (SARM) Enobosarm 
is currently being investigated in many BCa clinical trials, including as the sole treatment 
for patients with ERα-positive AR-positive tumours (Table 1.9.1). It has been 
demonstrated that Enobosarm cannot be metabolised by aromatase or 5α-reductase, and 
therefore as well as acting as an anti-androgen, Vontela et al. suggested in 
postmenopausal patients with ERα-positive BCa, it could potentially decrease E2 
synthesis via directly competing with oestrogen-precursors (Vontela et al., 2017). 
Therefore, colony formation assays to assess the effect of Enobosarm on endocrine 
sensitive cells could provide interesting results, and the combination of Enobosarm with 
endocrine therapy in patients with ERα- and AR-positive disease could be beneficial.  
We are yet to see how effective anti-androgens will be in endocrine sensitive 
disease, but data from MABC suggests that these therapies will not be effective in all 
patients. Clinical trials conducted so far have indicated that targeting androgen signalling 
can have a good response in some patients. For instance, a recently published case study 
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described how one patient with metastatic MABC who had been undergoing palliative 
chemotherapy had a complete clinical response to BIC following 4 months of treatment, 
and remained in remission for at least 12 months (Arce-Salinas et al., 2016). However, a 
Phase II clinical trial investigating the use of BIC in MABC patients, observed a 
complete/partial response or stable disease in just 19% of the patients enlisted after 6 
months of treatment (Gucalp et al., 2013). Furthermore, a Phase II clinical trial in MABC 
of  Abiraterone Acetate (AA), a 17α-hydroxylase and CYP17 inhibitor (and thereby an 
androgen synthesis inhibitor, often used for treatment in castrate-resistant PCa patients) 
administered in combination with Prednisone (known to decrease androgen production 
in PCa patients) demonstrated a clinical benefit within 6 months in 20 % of patients 
(Bonnefoi et al., 2016). Therefore, there is a need to better understand why some patients 
respond better to treatments that target the AR than others, to identify which patients are 
likely to benefit from this therapeutic strategy.  
Due to the complexity of endocrine resistance and the various mechanisms of 
resistance described, as well as the mixed response observed to anti-androgen therapy 
in MABC patients, it would be beneficial to identify endocrine sensitive patients likely to 
have a positive clinical response to anti-androgen and anti-oestrogen combination 
therapy. One group demonstrated a significant increase in levels of Prosaposin (PSAP), 
a proposed AR activator, in the serum of BCa patients prior to surgery who experienced 
subsequent recurrence (Ali et al., 2015). The authors suggested its use as a biomarker 
to potentially identify patients likely to develop endocrine resistance as a result of AR 
signalling. Therefore, this could also be a potential biomarker to indicate patients who 
would benefit from this combination therapy and this requires further investigation. Future 
research into identifying additional potential biomarkers would also be of interest, for 
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instance via obtaining tissue samples from ERα-positive patients during biopsy prior to 
treatment initiation. Comparison of samples from patients that are responsive and non-
responsive to this combination of therapeutics could be used to identify such prognostic 
biomarkers.  
To conclude, rather than the use of anti-oestrogens or AIs as monotherapies in 
endocrine sensitive BCa patients, I propose that to prevent the onset of endocrine 
resistance it may be of clinical benefit to combine these therapies with anti-androgens. 
Ongoing clinical trials to investigate the use of Enzalutamide in combination with 
endocrine therapies such as AI and FULV will provide further insight into this hypothesis. 
However, due to the variability of endocrine resistant mechanisms in BCa, I propose that 
the development of a biomarker(/s) that can stratify patient according to their predicted 
response would be essential in order to identify patients likely to benefit from this 
combination therapy. 
5.2 Mechanisms via which AR could drive endocrine resistance 
The initial aim of this thesis was to explore how AR can promote the onset of 
endocrine resistance, and our results proposed a potential clinical benefit to combine 
endocrine therapy with anti-androgen treatment (Chapter 3). However, in some cases 
patients experience de novo rather than acquired resistance, whereby patients have an 
innate resistance or are prone to develop resistance to endocrine therapy quickly (Reinert 
et al., 2017). Therefore, the second aim of this thesis was to investigate the mechanism 
by which AR drives endocrine resistant cell growth in multiple resistance models, and to 
evaluate whether anti-androgens can block this form of cancer progression (Chapter 4).  
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Accumulating research has implicated the role of AR in endocrine resistance (Ali 
et al., 2015, Fujii et al., 2014, Rechoum et al., 2014, Ciupek et al., 2015, De Amicis et al., 
2010). However, how AR promotes endocrine resistance remains unclear, with research 
describing alternative mechanisms, for example: elevated AR expression has been 
shown to drive TAM resistance through activation of EGFR signalling, which results in 
TAM becoming agonistic and therefore stimulates ERα activity (De Amicis et al., 2010, 
Ciupek et al., 2015); overexpression of AR and aromatase causes an activation in ERα 
activity and differentially expressed ERα target genes as well as AR target genes, which 
promotes resistance to the AI Anastrazole (Rechoum et al., 2014); increased AR and 
PSA expression, alongside a loss of ERα expression, promotes AI resistance through an 
enhanced sensitivity to androgen for growth and a differential expression of androgen-
induced genes (Fujii et al., 2014); and PSAP activates AR and can promote AR 
recruitment to HREs to drive AI resistance (Ali et al., 2015). These results suggest that, 
as described previously, endocrine resistance mechanisms are complex and can vary 
greatly, therefore the role of AR in endocrine resistance is likely to vary between patients.  
Therefore, a better understanding of the role of the AR in BCa and its role in 
endocrine resistance is important in order to identify how to better use therapeutics. To 
do this, we used cell line models of resistance to TAM, FULV and AI endocrine treatments, 
derived from two alternative endocrine sensitive cell lines. Our results demonstrated that 
AR signalling promoted proliferation in all of the models of endocrine resistance tested. 
All but one (T47D-LTED) of the endocrine resistant cell lines displayed an enhanced 
sensitivity to androgen for growth (Figures 4.6.1-2) and siRNA knockdown in MCF7-
TAMR cells confirmed the role of the AR in this enhanced proliferation (4.6.3d). 
Additionally, AR levels were more responsive to androgen treatment in the resistant lines  
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tested (MCF7-TAMR and MCF7-LTED) than their parental line (Figures 4.7.1a-c). The 
alternative proposed mechanisms via which AR could potentially drive endocrine 
resistance across these cell line models are summarised in Figure 5.2.1. 
ChIP and microarray analyses of the ZR-75-1 ERα-positive cell line have 
demonstrated that the regulation of several E2 and DHT target genes could be 
antagonised via their co-treatment, suggesting an overlap of the ERα and AR signalling 
pathways (Need et al., 2012). Need et al. further demonstrated that AR and ERα binding 
sites were often closely located, overlapped or shared for a common gene, which 
indicates that the binding of one receptor could potentially block the other from interacting 
with a HRE, or antagonise its desired regulatory effect (Need et al., 2012) (Figure 5.2.1a). 
Our results have demonstrated that E2 reduces MIB-induced AR enrichment at an ARE, 
and this effect can be partially rescued via TAM or FULV (Figure 3.5.6). Additionally, we 
have demonstrated that E2 can significantly reduce MIB-induced expression of AR target 
genes such as ZBTB16 in MCF7 and MCF7-TAMR cells (Figures 4.3.3a-c) and that 
nuclear translocation of AR in response to MIB could be partially blocked by E2 (Figure 
4.4.1). Therefore, AR could be competing with ERα for common binding sites in endocrine 
sensitive disease, so inhibition of ERα increases AR binding, promoting endocrine 
resistance (Figure 5.2.1a).  
It has been previously demonstrated that AR can supress ERα signalling via 
interacting with EREs (Peters et al., 2009). Therefore, in the absence of functioning ERα, 
it could be hypothesised that AR could interact with EREs and take over ERα signalling 
to drive endocrine resistance (Figure 5.2.1d). However, gene expression analysis 
indicated that AR is not regulating ERα target genes in the endocrine resistant cells 
(Figures 4.3.1-2), as in MABC cells it has been demonstrated that androgen treatment   
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Figure 5.2.1 Proposed mechanisms via which the Androgen Receptor could 
drive endocrine resistant growth, which could be blocked via targeting it  
(a) Androgen Receptor (AR) is competing with Oestrogen Receptor alpha (ERα) for 
common binding sites in endocrine sensitive disease, so inhibition of ERα increases 
AR binding, promoting endocrine resistance. (b) ERα is inhibiting AR action via a 
protein-protein interaction in endocrine sensitive disease, so inhibition of ERα 
increases AR signalling, promoting endocrine resistance. (c) ERα and AR are 
competing for shared co-activators in endocrine sensitive disease, and so inhibition of 
ERα increases AR activity. (d) In the absence of functioning ERα, AR interacts with 
Oestrogen Response Elements (EREs) and takes over ERα signalling to drive 
endocrine resistance. (e) In endocrine-sensitive disease, ERα is inhibiting AR from 
interacting with Androgen Response Elements (AREs) to act as a physical barrier, so 
when ERα is inhibited AR signalling increases to drive endocrine resistance. 
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results in the activation of oestrogen-associated genes (Doane et al., 2006). It could be 
that alternative ERα target genes to those explored here are being regulated by AR in 
these resistant lines, and future ChIP-Seq and RNA-Seq analysis on AR binding in MCF7-
TAMR cells would provide insight on this. Alternatively, it could be that in endocrine-
sensitive disease, ERα could be inhibiting AR from interacting with AREs to act as a 
physical barrier, so that when ERα is inhibited AR signalling increases to drive endocrine 
resistance (Figure 5.2.1e). AR and ERα target gene expression demonstrated that the 
transcriptome is altered in endocrine resistance compared to the parental lines, and there 
were differences between the models of therapy resistance (Figures 4.3.1-5 and 4.5.1-
4). Therefore, as seen in MABC (Farmer et al., 2005, Need et al., 2012), endocrine 
resistant cells appear to have a unique androgen signalling pathway, differing to that 
observed in PCa (for which AR signalling is also important), but additionally unique 
between the different types of endocrine resistance. Again, future analyses (through 
NGS) on these resistant lines could provide insight into this mechanism. 
Yeast and mammalian two-hybrid systems have been used previously to 
demonstrate that ERα and AR can heterodimerise, resulting in suppression of the 
transcriptional activity of both receptors (Panet-Raymond et al., 2000). Confocal imaging 
demonstrated that, in conjunction with this, AR and ERα localisation were commonly 
found to colocalise with hormone treatments (Figures 4.4.2-7). Therefore, there is a 
possibility that ERα is inhibiting AR action via a protein-protein interaction in endocrine 
sensitive disease, so inhibition of ERα increases AR signalling, promoting endocrine 
resistance (Figure 5.2.1b). In order to investigate this further, these imaging and 2-hybird 
assays would need to be performed in the presence of an anti-oestrogen to see if this 
blocks colocalisation or interaction between the receptors. The loss of this interaction 
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would be predicted to increase receptor activity. Co-Immunoprecipitation (co-IP) could 
additionally be used in future work in order to demonstrate whether AR and ERα interact 
in our endocrine sensitive models, and whether this is altered in the resistance models, 
in order to support this theory.  
Previous studies have demonstrated that a ratio of AR:ERα higher than 2.0 
increases the development of TAM resistance more than 4-fold (Cochrane et al., 2014, 
Carreno et al., 2007, De Amicis et al., 2010). By contrast to this, immunoblotting 
demonstrated that the highest AR:ERα ratio observed in these endocrine resistance 
models was for MCF7-LTED (3.5), however MCF7-TAMR cells (which had an AR:ERα 
ratio of 1.1) were subsequently found to be more responsive to androgen for growth than 
this cell line derivative (Figures 4.2.1b and 4.6.1). 
AR and ERα cross-talk is also influenced by shared co-factors and pioneer factors 
such as ARA70 (Fioretti et al., 2014, Lanzino et al., 2005). Competition for these limiting 
factors could also result in inhibitory cross-talk between the receptors, and therefore 
inhibition of ERα through endocrine therapies could produce an increase in AR activity 
(Figure 5.2.1c). This could explain the lack of AR overexpression as a mechanism for the 
increase in AR sensitivity for all resistance models with the exception of MCF7-LTED and 
T47D-TAMR (Figure 4.2.1a). Alternatively, inhibiting ERα with treatment could result in 
an increase in the availability of a common pioneer factor such as FOXA1 (Hurtado et al., 
2011, Robinson et al., 2011) to the AR.  
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5.3 Targeting AR as a treatment option for endocrine resistance 
Our results demonstrated that androgen-stimulated growth of both our models of 
TAM and AI resistance derived from two alternative endocrine sensitive cell lines could 
be successfully inhibited via anti-androgen (OHF/BIC) treatment (Figures 4.6.4b-c and 
4.6.5b-c). These results are supported by work by others, who have demonstrated that 
Enzalutamide and BIC treatment are effective in inhibiting AR-driven endocrine 
resistance (De Amicis et al., 2010, Ali et al., 2015). Importantly, AR appears to be able to 
promote therapy resistance to different anti-oestrogens and AIs, and although our cell 
line models behave differently, and the mechanisms via which AR drives endocrine 
resistance in them appears to differ, they all responded to anti-androgen treatment. 
Therefore, targeting AR could be a viable option to treat resistance to various agents 
targeting ERα signalling.  
Published research on endocrine resistance has demonstrated that the 
mechanisms by which endocrine resistance can occur can vary greatly. Therefore, as 
growth might not always be driven via AR in endocrine resistance, the response to anti-
androgen treatment for endocrine resistant AR-positive disease could vary between 
patients (as found in MABC). Therefore, the identification of tumours that are dependent 
on AR for growth could aid in patient stratification. In order to do this, I propose that the 
development of a panel of biomarkers in order to indicate a positive response to this 
therapy would be highly beneficial, such as PSAP (as discussed in Section 5.1). 
Additionally, the proposed future ChIP-Seq and RNA-Seq analyses in MCF7-TAMR cells, 
the preparation of which is presented in Figure 4.8.1, will indicate genes regulated in 
response to androgen signalling in this cell line, and these studies can be expanded to 
the other resistant models to identify similarities. 
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5.4 Final Conclusion 
In conclusion, I propose that there could be a clinical benefit from the 
administration of anti-androgen therapies for a subset of patients with tumours that 
express the AR in order to prevent the development of endocrine resistance or for the 
treatment of endocrine resistant disease. This is supported by a recent case study 
whereby the first incidence of a positive clinical response from a patient with ERα, PR 
and AR-positive BCa to a SARM following failure and developed resistance to a vast 
number of ERα-targeted endocrine therapies was recorded (Vontela et al., 2017). 
However, clinical trials have indicated that therapeutics targeting AR may not always be 
beneficial to patients with AR-positive endocrine sensitive or resistant BCa. Ongoing 
clinical trials to investigate the use of Enzalutamide and Enobosarm in advanced patients 
with ERα-positive and AR-positive disease who have not responded or developed 
resistance to endocrine therapies will provide further insight into this hypothesis (Table 
1.9.1). Due to the variability of endocrine resistance mechanisms in BCa, I propose that 
the development of a panel of prognostic biomarkers perhaps including PSAP to predict 
clinical response to these therapies would be highly beneficial. 
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